Top

Gautam Borthakur, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Borthakur

::Dr. Borthakur is a Professor in the Department of Leukemia since 2018. His clinical and research work is focused on improving therapies for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). His primary commitment is to bring new agents/combinations to the clinic for improving outcome in patients with these diseases. He has particular interest in core binding factor leukemia. He has opened more than thirty investigator-initiated or industry-sponsored clinical trials in his area of interest and has an active translational research program on autophagy , mitochondrial dynamics, kinase inhibition (ERK 1/2) and epigenetic targets, for example BRD4 in AML.

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

My translational research interests are in autophagy, mitochondrial dynamics, epigenetic modulators and MAPK inhibition in AML

Education & Training

Degree-Granting Education

1984	Assam Medical College, Dibrugarh, IN, Medicine, MBBS
1979	Cotton College, Guwahati University, Assam, IN, Biology, BS

Postgraduate Training

2004-2005	Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
2001-2004	Clinical Fellowship, Hematology-Oncology, The University of Texas Health Science Center Houston and The University of Texas MD Anderson Cancer Center, Houston, Texas
1993-1996	Clinical Residency, Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New York
1987-1990	Clinical Residency, Pathology, Post-Graduate Institute of Medical Education and Research, Chandigarh
1985-1987	House Officer, Internal Medicine, RML Hospital and GB Pant Hospital, New Delhi
1985-1985	Clinical Internship, Medicine, Assam Medical College, Dibrugarh

Board Certifications

2005	American Board of Internal Medicine--Medical Oncology
2004	American Board of Internal Medicine-Hematology
1996	American Board of Internal Medicine
1990	National Academy of Medical Sciences (India)-Patho

Experience & Service

Academic Appointments

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2012

Research Associate, Department of Thrombosis Research Section, Baylor College of Medicine, Houston, TX, 2000 - 2001

Instructor, Post-Graduate Institute of Medical Education and Research, Chandigarh, 1990 - 1993

Administrative Appointments/Responsibilities

Director, Department of Special Care Unit, Memorial Medical Center, Livingston, TX, 1996 - 2000

Institutional Committee Activities

Member, Clinical Research Billing Subcommittee, 2023 - Present

Member, Executive Committee of Faculty Senate, 2022 - Present

Nomination and Selection Committee, Samuel J. Hassenbusch, MD, PhD PRS Leadership & Institutional Service Award, 2022 - Present

Senator, Faculty Senate, 2020 - Present

Vice-Chair, Institutional Review Board, 2019 - Present

Member, CME Advisory Committee, 2018 - 2019

Member- Division of Cancer Medicine, PRS Clinical Revenue Cycle Committee, 2017 - Present

Senator, Faculty Senate, 2015 - 2017

Member, Institutional Review Board 5, 2013 - Present

Member, Institutional Research Grant Study Section Review Committee for Clinical Translational and Population-based Research Projects, 2012 - Present

Associate Member, Institutional Review Board 5, 2012 - 2013

Member, Clinical Research Committee 1, 2012 - 2014

Member, Institutional Review Board 5, 2011 - 2012

Committee Chair, Institutional Research Grant Study Section Review Committee for Clinical Translational and Population-based Research Projects, 2011 - 2012

Vice Chairman, Institutional Research Grant Study Section Review Committee for Clinical Translational and Population-based Research Projects, 2010 - 2011

Member, Institutional Research Grant Study Section Review Committee for Clinical Translational and Population-based Research Projects, 2009 - 2010

Member, Clinical Research Committee 4, 2007 - 2010

Member, Sepsis Order Committee, 2006 - 2007

Member, Anemia Guidelines Committee, 2006 - 2007

Honors & Awards

	Silver Medal for First and Third Professional (M.D.) examinations, Dibrugarh University Assam, India
	Angelica B. Mioti Award for Outstanding Clinician, The Brooklyn Hospital Center, New York
	2008 ASCO Cancer Foundation Career Development Award, American Society of Clinical Oncology
	The Shirley Stein Scientific Endowment Research Award, Chief Academic Office, The University of Texas MD Anderson Cancer Center

Professional Memberships

Society of Hematologic Oncology

Active Member, 2013 - Present

Indo-American Cancer Association

Member, 2011 - Present

Harris County Medical Society

Member, 2007 - Present

Texas Medical Society

Member, 2007 - Present

American Association for Cancer Research

Member, 2006 - Present

American Society of Hematology

Member, 2001 - Present

American Society of Clinical Oncology

Member, 2001 - Present

Selected Publications

Peer-Reviewed Articles

Haddad, FG, Sasaki, K, Senapati, J, Xiao, L, Park, GS, Abuasab, T, Venugopal, S, Rivera, D, Bazinet, A, Babakhanlou, R, Kim, K, Ong, F, Desikan, SP, Pemmaraju, N, Loghavi, S, Borthakur, G, DiNardo, C, Abbas, HA, Short, NJ, Daver, N, Jabbour, EJ, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Kadia, TM. Outcomes of Patients with Newly Diagnosed AML and Hyperleukocytosis. JCO Oncology Practice 20(12):1637-1644, 2024. PMID: 39013130.
Urrutia, S, Kantarjian, H, Ravandi-Kashani, F, Bueso-Ramos, CE, Kanagal-Shamanna, R, Jabbour, EJ, Montalban-Bravo, G, Short, NJ, Daver, N, Borthakur, G, DiNardo, CD, Kadia, TM, Masarova, L, Bose, P, Pemmaraju, N, Garcia-Manero, G, Sasaki, K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. Journal of Hematology and Oncology 17(1), 2024. PMID: 39548557.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. PMID: 38695144.
Marques-Piubelli ML, Kumar B, Basar R, Panowski S, Srinivasan S, Norwood K, Prashad S, Szenes V, Balakumaran A, Arandhya A, Lu W, Khan K, Duenas D, McAllen S, Gomez JA, Burks JK, Acharyal S, Borthakur G, Wang WL, Wang W, Wang S, Solis LM, Marin D, Rezvani K, Daher M, Vega F. Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents. Virchows Arch 485(5):937-941, 2024. PMID: 38388965.
Gener-Ricos, G, Bataller, A, Rodriguez-Sevilla, JJ, Chien, KS, Quesada, AE, Almanza-Huante, E, Hammond, DE, Sasaki, K, DiNardo, C, Kadia, TM, Daver, N, Borthakur, G, Issa, GC, Short, NJ, Kanagal Shamanna, R, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. PMID: 38896064.
Senapati, J, Kantarjian, HM, Bazinet, A, Reville, PK, Short, NJ, Daver, N, Borthakur, G, Bataller, A, Jabbour, EJ, DiNardo, C, Haddad, FG, Sasaki, K, Popat, UR, Oran, B, Alousi, AM, Loghavi, S, Shpall, E, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. PMID: 38809547.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109(8):2660-2664, 2024. e-Pub 2024. PMID: 38572554.
Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
Montalban-Bravo G, Jabbour E, Chien K, Hammond D, Short N, Ravandi F, Konopleva M, Borthakur G, Daver N, Kanagal-Shammana R, Loghavi S, Qiao W, Huang X, Schneider H, Meyer M, Kantarjian H, Garcia-Manero G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res 142:107518, 2024. e-Pub 2024. PMID: 38744144.
Bataller A, Gener-Ricos G, Almanza E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
Jen WY, Sasaki K, Loghavi S, Wang SA, Qiao W, Borthakur G, Ravandi F, Kadia TM, Issa GC, Short NJ, Yilmaz M, Daver NG, DiNardo CD. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol 204(6):2259-2263, 2024. e-Pub 2024. PMID: 38603594.
Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian H. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 24(6):375-381, 2024. e-Pub 2024. PMID: 38431521.
Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38(5):1178-1181, 2024. e-Pub 2024. PMID: 38418609.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. Journal of Clinical Oncology 42(13):1499-1508, 2024. e-Pub 2024. PMID: 38277619.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma:1-6. e-Pub 2024. PMID: 38696743.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. The Lancet Haematology 11(4):e287-e298, 2024. PMID: 38548404.
Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clinical Cancer Research 30(7):1319-1326, 2024. PMID: 38300723.
Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, Khoury JD, Kantarjian H, Bhalla KN. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38(3):545-556, 2024. e-Pub 2023. PMID: 38086946.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. British Journal of Haematology 204(3):898-909, 2024. e-Pub 2023. PMID: 37946611.
Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Advances 8(4):909-915, 2024. PMID: 38207208.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Advances 8(4):927-935, 2024. e-Pub 2023. PMID: 38113472.
Jen WY, Sasaki K, Rausch CR, DiNardo CD, Kadia TM, Yilmaz M, Borthakur G, Alvarado Y, McCue D, McCue D, Kantarjian HM, Ravandi F. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. Leukemia and Lymphoma 65(3):1-5, 2024. e-Pub 2023. PMID: 38054837.
Tyagi A, Jaggupilli A, Ly S, Yuan B, El-Dana F, Hegde VL, Anand V, Kumar B, Puppala M, Yin Z, Wong STC, Mollard A, Vankayalapati H, Foulks JM, Warner SL, Daver N, Borthakur G, Battula VL. TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia 38(1):82-95, 2024. e-Pub 2023. PMID: 38007585.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of Hematology and Oncology 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer Journal 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
Krug B, Hu B, Chen H, Ptack A, Chen X, Gretarsson KH, Deshmukh S, Kabir N, Andrade AF, Jabbour E, Harutyunyan AS, Lee JJY, Hulswit M, Faury D, Russo C, Xu X, Johnston MJ, Baguette A, Dahl NA, Weil AG, Ellezam B, Dali R, Blanchette M, Wilson K, Garcia BA, Soni RK, Gallo M, Taylor MD, Kleinman CL, Majewski J, Jabado N, Lu C. H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs. bioRxiv, 2023. e-Pub 2023. PMID: 38116029.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. PMID: 37441846.
Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades. Clinical Lymphoma Myeloma and Leukemia 23(11):e369-e378, 2023. e-Pub 2023. PMID: 37690903.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. American Journal of Hematology 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. American Journal of Hematology 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clinical Cancer Research 29(21):4352-4360, 2023. PMID: 37585491.
Klink AJ, Keating SJ, Brokars J, Feinberg B, Jabbour E. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2023. PMID: 38135632.
Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 23(10):742-748, 2023. e-Pub 2023. PMID: 37308342.
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. American Journal of Hematology 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat U. Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation. Blood Advances 7(14):3573-3581, 2023. e-Pub 2023. PMID: 37104058.
Pouleau B, Estoppey C, Suere P, Nallet E, Laurendon A, Monney T, Pais Ferreira D, Drake A, Carretero-Iglesia L, Macoin J, Berret J, Pihlgren M, Doucey MA, Gudi GS, Menon V, Udupa V, Maiti A, Borthakur G, Srivastava A, Blein S, Mbow ML, Matthes T, Kaya Z, Edwards CM, Edwards JR, Menoret E, Kervoëlen C, Pellat-Deceunynck C, Moreau P, Zhukovsky E, Perro M, Chimen M. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma. Blood 142(3):260-273, 2023. PMID: 37192303.
Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Advances 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
Zhu HH, Qin YZ, Zhang ZL, Liu YJ, Wen LJ, You MJ, Zhang C, Such E, Luo H, Yuan HJ, Zhou HS, Liu HX, Xu R, Li J, Li JH, Hao JP, Jin J, Yu L, Zhang JY, Liu LP, Zhang LP, Huang RB, Shen SH, Gao SJ, Wang W, Yan XJ, Zhang XY, Du X, Chu XX, Yu YF, Wang Y, Mi YC, Lu Y, Cai Z, Su Z, Taussig DC, MacMahon S, Ball ED, Wang HY, Welch JS, Yin CC, Borthakur G, Sanz MA, Kantarjian HM, Huang JY, Hu J, Chen SN. A global study for acute myeloid leukemia with RARG rearrangement. Blood Advances 7(13):2972-2982, 2023. PMID: 36799929.
Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discovery 4(4):276-293, 2023. e-Pub 2023. PMID: 37102976.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Advances 7(11):2378-2387, 2023. e-Pub 2022. PMID: 35973199.
Bhattacharya S, Piya S, Ma H, Sharma P, Zhang Q, Baran N, Ruvolo VR, McQueen T, Davis RE, Pourebrahim R, Konopleva M, Kantarjian H, Cosford NDP, Andreeff M, Borthakur G. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) overcomes adaptive drug resistance in acute myelogenous leukemia. Molecular Cancer Research 21(6):548-563, 2023. PMID: 36787422.
Zhang W, Yu G, Zhang H, Basyal M, Ly C, Yuan B, Ruvolo V, Piya S, Bhattacharya S, Zhang Q, Borthakur G, Battula V, Konopleva M, Rice WG, Andreeff M. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through inhibition of autophagy. Haematologica 108(6):1500-1514, 2023. e-Pub 2023. PMID: 36226489.
Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37(6):1397-1400, 2023. e-Pub 2023. PMID: 37185307.
Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol 98(6):E142-E144, 2023. e-Pub 2023. PMID: 36877196.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Advances 7(10):1958-1966, 2023. PMID: 36287248.
Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Advances 7(6):933-942, 2023. PMID: 36322818.
Bataller A, Haddad F, Ghayas C Issa G, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short N. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):746-749, 2023. PMID: 36657414.
Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):746-749, 2023. e-Pub 2023. PMID: 36657414.
Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Komblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq, 2023. e-Pub 2023. PMID: 36865338.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2022. PMID: 36458426.
Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. Clinical Cancer Research 29(4):711-722, 2023. PMID: 36350312.
Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq, 2023. PMID: 36865338.
Dawson M, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea D, Davies F, Morgan G, Glass J, Kamdar M, Mateos M, Tovar N, Yeh P, García Delgado R, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry A, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich N, McCabe M, Foley S, Horner T, Dhar A, Kremer B, Dickinson M. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res 16(29):711-722, 2023. PMID: None.
Bhattacharya S, Piya S, Ma H, Sharma P, Zhang Q, Baran N, Ruvolo V, McQueen T, Davis E, Pourebrahim R, Konopleva M, Kantarjian H, Cosford N, Andreeff A, Borthakur G. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) overcomes adaptive drug resistance in acute myelogenous leukemia. Mol Cancer Res, 2023. PMID: 36787422.
Zhu H, Qin Y, Zhang Z, Liu Y, Wen L, You J, Zhang C, Such E, Luo H, Yuan H, Zhou H, Liu H, Xu R, Li J, Li J, Hao J, Jin J, Yu L, Zhang J, Liu L, Zhang L, Huang R, Shen S, Gao S, Wang W, Yan X, Zhang X, Du X, Chu X, Yu Y, Wang Y, Mi Y, Lu Y, Cai Z, Su Z, Taussig D, MacMahon S, Ball E, Wang H, Welch J, Yin C, Borthakur G, Sanz M, Kantarjian H, Huang J, Hu J, Chen S. A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv, 2023. PMID: 36799929.
Ye MT, Wang Y, Zuo Z, Calin S, He H, Tang Z, Jabbour EJ, Borthakur G, Zhang Y, Yang Y, You MJ. Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia. Cancer 129(1):49-59, 2023. e-Pub 2022. PMID: 36281717.
Siddiqui M, Borthakur G. What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome?. Expert Opinion on Pharmacotherapy 24(7):775-778, 2023. e-Pub 2023. PMID: 37070468.
Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. PMID: 37196217.
Wang Y, Quesada AE, Zuo Z, Medeiros LJ, Yin CC, Li S, Xu J, Borthakur G, Li Y, Yang C, Abaza Y, Gao J, Lu X, You MJ, Zhang Y, Lin P. The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. Cancers (Basel) 15(1), 2022. e-Pub 2022. PMID: 36612194.
Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. American Journal of Hematology 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Jo Hematol Oncol 15(1):12, 2022. e-Pub 2022. PMID: 35093134.
Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes. American Journal of Hematology 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia. Am J Hematol 97(11):1427-1434, 2022. e-Pub 2022. PMID: 36053747.
Lachowiez C, Lachowiez P, Kantarjian H Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T Pierce S, Tang G, Patel K, Medeiros J, Abbas H, Haddad F, Hammond D, Short N, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia T, Loghavi S, DiNardo C. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. PMID: None.
Issa G, Bidikin A, Venugopal S, Konopleva M, DiNardo C, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short N, Maiti A, Sasaki K, Masarova L, Pierce S, Takashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv, 2022. PMID: 36322818.
Dawson M, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A Vogl D, Polleya D, Davies F, Morgan G, Glass J, Kamdar M, Mateos Manteca NV, Tovar N, Yeh P, Garcia Delgado R, Basheer F, Marando L, Gallipoli P, Wyce A, Shilpa Krishnatry A, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich N, McCabe M, Foley S, Horner T, Dhar A, Kremer B, Dickinson M. A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. Clin Cancer Res, 2022. PMID: 36350312.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour E, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol 97(11):1427-1434, 2022. PMID: 36053747.
Jabbour E, Sasaki K, Haddad F, Issa G, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. PMID: 36054032.
Lachowiez C, Borthakur G, Loghavi S, Zeng Z, Kadia T, Masarova L, Takahashi K, Tippett G, Garcia J, Bose P, Jabbour E, Ravandi F, Daver N, Manero GG, Vyas P, Kantarjian H, Konopleva M, DiNardo C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clin Lymphoma Myeloma Leuk 22:S240-S241, 2022. PMID: 36163821.
Abuasab T, Senapati J, Kadia T, Ravandi F, DiNardo C, Pemmaraju N, Ohanion M, Alvarado Y, Kantarjian H, Borthakur G. AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)- Based Regimen. Clin Lymphoma Myeloma Leuk 22:S235-S236, 2022. PMID: 36163808.
Haddad FG, Kantarjian H, Short NJ, Konopleva M, Jain N, Huang X, Ravandi F, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S204, 2022. PMID: 36163747.
Kambhampati S, Eghtedar A, McMahon C, de Botton S, Pigneux A, Ball B, Borthakur G, Volkert A, Gausman JA, Baker K, Hodgson G, Warlick E, Roth D, Kelly M, Pollyea D, Stein E. AML-108 SELECT-AML-1 Trial in Progress. Clin Lymphoma Myeloma Leuk 22:S213, 2022. PMID: 36163766.
Bidikian A, Kantarjian H, Dabaja B, Ravandi F, Jabbour E, DiNardo C, Borthakur G, Daver N, Garcia-Manero G, Kadia T, Sasaki K, Issa G. AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Clin Lymphoma Myeloma Leuk 22:S233-S234, 2022. PMID: 36163805.
Venugopal S, Kantarjian H, Maiti A, Short NJ, Montalban-Bravo G, Alvarado Y, Chien K, Kanagal-Shamanna R, Pemmaraju N, Daver N, Kadia T, Borthakur G, Jabbour E, Garcia-Manero G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clin Lymphoma Myeloma Leuk 22:S321, 2022. PMID: 36163977.
Ong F, Kadia T, Short NJ, Yilmaz M, Alvarado Y, Sasaki K, Pierce SA, Garcia-Manero G, DiNardo C, Borthakur G, Konopleva M, Daver N, Kantarjian H, Ravandi F. AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clin Lymphoma Myeloma Leuk 22:S258, 2022. PMID: 36163855.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short N, Daver N, Issa G, Jain N, Bull-Linderman D, DiNardo C, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia T. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 22:S239-S240, 2022. PMID: 36163817.
Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid 1(10):EVIDoa2200034, 2022. e-Pub 2022. PMID: 38319837.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
Wang L, Wang W, Beird HC, Cheng X, Fang H, Tang G, Toruner GA, Yin CC, You MJ, Issa GC, Borthakur G, Peng G, Khoury JD, Medeiros LJ, Tang Z. PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia. Genes (Basel) 13(8), 2022. e-Pub 2022. PMID: 36011278.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol 97(7):865-876, 2022. e-Pub 2022. PMID: 35384048.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
Albert DH, Goodwin NC, Davies AM, Rowe J, Feuer G, Boyiadzis M, Dorritie KA, Mancini M, Gandour-Edwards R, Jonas BA, Borthakur G, Aldoss I, Rizzieri DA, Odenike O, Prebet T, Singh S, Popovic R, Shen YU, McDaniel KF, Kati WM, Modi DA, Motwani M, Wolff JE, Frost DJ. Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo 36(4):1615-1627, 2022. PMID: 35738590.
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 374(33):3848-3857, 2022. e-Pub 2022. PMID: 35704787.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv 6(10):3027-3035, 2022. PMID: 35061885.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. PMID: 35483396.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
Piya S, Yang Y, Bhattacharya S, Sharma P, Ma H, Mu H, He H, Ruvolo V, Baran N, Davis RE, Jain AK, Konopleava M, Kantarjian H, Andreeff M, You MJ, Borthakur G. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia 36(5):1261-1273, 2022. e-Pub 2022. PMID: 35173274.
Tang G, Zou Y, Wang SA, Borthakur G, Toruner G, Hu S, Li S, Xu J, Medeiros LJ, Tang Z. 3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. Ann Hematol 101(4):847-854, 2022. e-Pub 2022. PMID: 35184217.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2021. PMID: 34601571.
Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol 97(1):68-78, 2022. e-Pub 2021. PMID: 34716921.
Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel) 14(1), 2022. e-Pub 2021. PMID: 35008312.
Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):672-675, 2022. e-Pub 2021. PMID: 34668451.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):1-9, 2021. e-Pub 2021. PMID: 34380367.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia. Cancer 127(22):4213-4220, 2021. e-Pub 2021. PMID: 34343352.
Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica 106(11):2853-2858, 2021. e-Pub 2021. PMID: 33054123.
Yang RK, Toruner GA, Wang W, Fang H, Issa GC, Wang L, Quesada AE, Thakral B, Patel KP, Peng G, Liu S, Yin CC, Borthakur G, Tang Z, Wang SA, Miranda RN, Khoury JD, Medeiros LJ, Tang G. CBFB Break-Apart FISH Testing. Cancers (Basel) 13(21), 2021. e-Pub 2021. PMID: 34771519.
Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. e-Pub 2021. PMID: 34171128.
Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127(19):3552-3565, 2021. e-Pub 2021. PMID: 34161603.
Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. PMID: 34424319.
Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, Popovic R, Modi DA, Joshi RH, Wolff JE, Jonas BA. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer 127(16):2943-2953, 2021. e-Pub 2021. PMID: 33934351.
Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome. Lancet Haematol 8(8):e552-e561, 2021. PMID: 34329576.
Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia. Cancer 127(12):2049-2061, 2021. e-Pub 2021. PMID: 33818756.
Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127(11):1894-1900, 2021. e-Pub 2021. PMID: 33449377.
Han SY, Mrózek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Møller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv 5(10):2481-2489, 2021. PMID: 34003250.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2020. PMID: 32236406.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. PMID: 33885751.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. PMID: 33885753.
Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia. Cancer 127(8):1246-1259, 2021. e-Pub 2020. PMID: 33270904.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2020. PMID: 33681815.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2020. PMID: 32561839.
Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase. Am J Hematol 96(2):241-250, 2021. e-Pub 2020. PMID: 33180322.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2020. PMID: 33119202.
Borthakur G, Martinelli G, Raffoux E, Chevallier P, Chromik J, Lithio A, Smith CL, Yuen E, Oakley GJ, Benhadji KA, DeAngelo DJ. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer 127(3):372-380, 2021. e-Pub 2020. PMID: 33107983.
Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Frontiers in Oncology 10:582213, 2021. PMID: 33585199.
Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International journal of hematology 113(1):92-99, 2021. PMID: 32951163.
Siddiqui MT, Price A, Ferrajoli A, Borthakur G. Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax. Leukemia Research Reports 16:100266, 2021. PMID: 34692401.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Advances 5(7):1876-1883, 2021. PMID: 33792630.
Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor. Leukemia and Lymphoma 62(4):1-14, 2021. PMID: 33283580.
DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA, Borthakur G, Jabbour E, Gumbs C, Khoury JD, Routbort M, Gong T, Kondo K, Kantarjian H, Garcia-Manero G, Chen T, Futreal PA. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics 16(5):1-10, 2021. PMID: 32856987.
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, Alaoui-Jamali MA, Alberti S, Alcocer-Gómez E, Alessandri C, Ali M, Alim Al-Bari MA, Aliwaini S, Alizadeh J, Almacellas E, Almasan A, Alonso A, Alonso GD, Altan-Bonnet N, Altieri DC, ÉMC Á, Alves S, Alves da Costa C, Alzaharna MM, Amadio M, Amantini C, Amaral C, Ambrosio S, Amer AO, Ammanathan V, An Z, Andersen SU, Andrabi SA, Andrade-Silva M, Andres AM, Angelini S, Ann D, Anozie UC, Ansari MY, Antas P, Antebi A, Antón Z, Anwar T, Apetoh L, Apostolova N, Araki T, Araki Y, Arasaki K, Araújo WL, Araya J, Arden C, Arévalo MA, Arguelles S, Arias E, Arikkath J, Arimoto H, Ariosa AR, Armstrong-James D, Arnauné-Pelloquin L, Aroca A, Arroyo DS, Arsov I, Artero R, Asaro DML, Aschner M, Ashrafizadeh M, Ashur-Fabian O, Atanasov AG, Au AK, Auberger P, Auner HW, Aurelian L, Autelli R, Avagliano L, Ávalos Y, Aveic S, Aveleira CA, Avin-Wittenberg T, Aydin Y, Ayton S, Ayyadevara S, Azzopardi M, Baba M, Backer JM, Backues SK, Bae DH, Bae ON, Bae SH, Baehrecke EH, Baek A, Baek SH, Baek SH, Bagetta G, Bagniewska-Zadworna A, Bai H, Bai J, Bai X, Bai Y, Bairagi N, Baksi S, Balbi T, Baldari CT, Balduini W, Ballabio A, Ballester M, Balazadeh S, Balzan R, Bandopadhyay R, Banerjee S, Banerjee S, Á B, Bao Y, Baptista MS, Baracca A, Barbati C, Bargiela A, Barilà D, Barlow PG, Barmada SJ, Barreiro E, Barreto GE, Bartek J, Bartel B, Bartolome A, Barve GR, Basagoudanavar SH, Bassham DC, Bast RC, Basu A, Batoko H, Batten I, Baulieu EE, Baumgarner BL, Bayry J, Beale R, Beau I, Beaumatin F, Bechara LRG, Beck GR, Beers MF, Begun J, Behrends C, Behrens GMN, Bei R, Bejarano E, Bel S, B. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 17(1):1-382, 2021. e-Pub 2021. PMID: 33634751.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma 61(13):1-8, 2020. e-Pub 2020. PMID: 32755333.
Ball S, Borthakur G. Apoptosis targeted therapies in acute myeloid leukemia: an update. Expert Rev Hematol 13(12):1373-1386, 2020. e-Pub 2020. PMID: 33205684.
Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol 95(12):E326-E329, 2020. e-Pub 2020. PMID: 32886803.
Khoury JD, Tashakori M, Yang H, Loghavi S, Wang Y, Wang J, Piya S, Borthakur G. Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. Cancers (Basel) 12(12), 2020. e-Pub 2020. PMID: 33255818.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
Borthakur G. Evolving strategies for the management of core-binding factor acute myeloid leukemia. Clin Adv Hematol Oncol 18(11):691-694, 2020. PMID: 33406060.
Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol 95(11):E313-E315, 2020. e-Pub 2020. PMID: 32804409.
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. Am J Hematol 95(11):1288-1295, 2020. e-Pub 2020. PMID: 32681739.
Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol 95(11):1296-1303, 2020. e-Pub 2020. PMID: 32697348.
Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871-e882, 2020. e-Pub 2020. PMID: 32792304.
Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. Br J Cancer 123(10):1496-1501, 2020. e-Pub 2020. PMID: 32868897.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia. Am J Hematol 95(10):1127-1134, 2020. e-Pub 2020. PMID: 32557828.
Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 191(1):e10-e13, 2020. e-Pub 2020. PMID: 32686139.
Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol 95(9):E225-E228, 2020. e-Pub 2020. PMID: 32356320.
Rogers HJ, Wang X, Xie Y, Davis AR, Thakral B, Wang SA, Borthakur G, Cantu MD, Margolskee EM, Philip JKS, Sukhanova M, Bagg A, Bueso-Ramos CE, Orazi A, Arber DA, Hsi ED, Hasserjian RP. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a Bone Marrow Pathology Group study. Am J Hematol 95(7):799-808, 2020. e-Pub 2020. PMID: 32249963.
Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, Pudipeddi M, Nidarmarthy S, Vaddi K, Kantarjian H. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica 105(6):1567-1574, 2020. e-Pub 2019. PMID: 31558670.
Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD, Issa GC, Bose P, Konopleva MY, Yilmaz M, Ohanian M, Borthakur G, Garcia-Manero G, Pierce S, Cortes JE, Kantarjian H, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47, 2020. e-Pub 2020. PMID: 32366832.
Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. PMID: 32330243.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. PMID: 32251497.
Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. e-Pub 2020. PMID: 32068780.
Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer 126(7):1502-1511, 2020. e-Pub 2020. PMID: 31999839.
Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer 126(7):1448-1459, 2020. e-Pub 2020. PMID: 31999850.
Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2019. PMID: 32035785.
Zhang Z, Jiang M, Borthakur G, Luan S, Huang X, Tang G, Xu Q, Ji D, Boyer AD, Li F, Huang R, You MJ. Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy. Am J Hematol 95(2):E48-E51, 2020. e-Pub 2019. PMID: 31769058.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. PMID: 32027746.
Ball S, Das A, Vutthikraivit W, Edwards PJ, Hardwicke F, Short NJ, Borthakur G, Maiti A. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Lymphoma Myeloma Leuk 20(2):87-97.e5, 2020. e-Pub 2019. PMID: 31787589.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2019. PMID: 31553487.
Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol 11(1):19-23, 2020. e-Pub 2019. PMID: 31005650.
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol 143(6):1-7, 2020. e-Pub 2020. PMID: 32289808.
Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma 60(13):1-9, 2019. e-Pub 2019. PMID: 31125272.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med 8(15):6559-6565, 2019. e-Pub 2019. PMID: 31502383.
Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N. Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma 60(11):1-3, 2019. e-Pub 2019. PMID: 31012358.
Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer 125(18):3219-3224, 2019. e-Pub 2019. PMID: 31150121.
Economides MP, McCue D, Borthakur G, Pemmaraju N. Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother 20(13):1-8, 2019. e-Pub 2019. PMID: 31136213.
Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma 60(9):2207-2213, 2019. e-Pub 2019. PMID: 30773968.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
Tallis E, Borthakur G. Novel treatments for relapsed/refractory acute myeloid leukemia with FLT3 mutations. Expert Rev Hematol 12(8):621-640, 2019. e-Pub 2019. PMID: 31232619.
Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk 19(7):431-440.e13, 2019. e-Pub 2019. PMID: 31056348.
Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol 94(6):E158-E160, 2019. e-Pub 2019. PMID: 30838674.
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia 33(6):1373-1386, 2019. e-Pub 2018. PMID: 30575820.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer 125(10):1665-1673, 2019. e-Pub 2019. PMID: 30668890.
Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell 35(5):721-737.e9, 2019. e-Pub 2019. PMID: 31056398.
Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest 129(5):1878-1894, 2019. e-Pub 2019. PMID: 30829648.
Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian HM, Ravandi F. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 125(7):1091-1100, 2019. e-Pub 2018. PMID: 30521114.
Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 3(6):851-861, 2019. PMID: 30885996.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2018. PMID: 30635233.
Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun 10(1):244, 2019. e-Pub 2019. PMID: 30651561.
Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes J. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol 27(1):33-39, 2019. e-Pub 2017. PMID: 28682832.
Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):1-12, 2019. e-Pub 2018. PMID: 29741984.
Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, Kadia T, Brandt M, Maduike R, Kantarjian H, Borthakur G. Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia 32(12):2698-2701, 2018. e-Pub 2018. PMID: 29884905.
Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med 7(11):5457-5469, 2018. e-Pub 2018. PMID: 30318751.
Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
Abaza Y, Cortes J, Ravandi F, Kadia T, Garcia-Manero G, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G. Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93(11):E357-E360, 2018. e-Pub 2018. PMID: 30074261.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol 93(10):1245-1253, 2018. e-Pub 2018. PMID: 30051599.
Yalniz FF, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, DiNardo CD, Konopleva M, Burger J, Gasior Y, Pierce S, Kantarjian H, Garcia-Manero G. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 18(10):658-663.e2, 2018. e-Pub 2018. PMID: 30001986.
Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85, 2018. e-Pub 2018. PMID: 30245189.
Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G. Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). Cancer Med 7(9):4447-4455, 2018. e-Pub 2018. PMID: 30117318.
Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leuk Lymphoma 59(9):1-4, 2018. e-Pub 2018. PMID: 29338567.
Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML). Am J Hematol 93(9):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
Chamoun K, Borthakur G. Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia. Expert Opin Investig Drugs 27(8):1-6, 2018. e-Pub 2018. PMID: 30084282.
Borthakur G. Prognosis interfered with by clonal interference. Blood 132(2):118-119, 2018. PMID: 30002046.
Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124(13):2758-2765, 2018. e-Pub 2018. PMID: 29660836.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
Bhattacharya S, Piya S, Borthakur G. Bromodomain inhibitors: what does the future hold?. Clin Adv Hematol Oncol 16(7):504-515, 2018. PMID: 30067623.
Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59(6):1-11, 2018. e-Pub 2017. PMID: 28972430.
Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol 107(6):689-695, 2018. e-Pub 2018. PMID: 29464484.
Alfayez M, Borthakur G. Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges. Expert Rev Hematol 11(5):373-389, 2018. PMID: 29589969.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28718728.
Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma 59(4):1-4, 2018. e-Pub 2017. PMID: 28838278.
Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol 5(4):e136-e146, 2018. e-Pub 2018. PMID: 29550383.
Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124(6):1160-1168, 2018. e-Pub 2017. PMID: 29266206.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2017. PMID: 29134664.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol 5(2):e63-e72, 2018. e-Pub 2018. PMID: 29331635.
Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
Khan M, Cortes J, Qiao W, Alzubaidi MA, Pierce SA, Ravandi F, Kantarjian HM, Borthakur G. Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 18(1):e19-e25, 2018. e-Pub 2017. PMID: 29107583.
Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93(1):84-90, 2018. e-Pub 2017. PMID: 29027261.
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39, 2018. e-Pub 2018. PMID: 30071517.
Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer 123(24):4851-4859, 2017. e-Pub 2017. PMID: 28841236.
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol 92(12):1295-1302, 2017. e-Pub 2017. PMID: 28850699.
Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123(22):4391-4402, 2017. e-Pub 2017. PMID: 28743165.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
Simkins A, Bannon SA, Khoury JD, Kanagal-Shamanna R, Foglesong JS, Alvarado Y, Borthakur G, DiNardo CD. Diamond-Blackfan Anemia Predisposing to Myelodysplastic Syndrome in Early Adulthood. JCO Precis Oncol 1:1-5, 2017. PMID: 35172515.
Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica 102(10):1709-1717, 2017. e-Pub 2017. PMID: 28729302.
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. Blood 130(13):1514-1522, 2017. e-Pub 2017. PMID: 28774880.
Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, Jabbour E, Bomalaski JS, Chen YP, Hsiao HH, Wang MC, Kuo CY, Chang H, Yeh SP, Cortes J, Chen LT, Chen TY. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Sci Rep 7(1):11253, 2017. e-Pub 2017. PMID: 28900115.
Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol 92(9):845-850, 2017. e-Pub 2017. PMID: 28494506.
Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma 58(9):1-6, 2017. e-Pub 2017. PMID: 28278723.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. e-Pub 2017. PMID: 28919634.
Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv 1(19):1546-1550, 2017. e-Pub 2017. PMID: 29296796.
Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci 18(8), 2017. e-Pub 2017. PMID: 28933735.
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv 1(17):1312-1323, 2017. e-Pub 2017. PMID: 29296774.
Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol 92(7):674-682, 2017. e-Pub 2017. PMID: 28370157.
Malik IA, Cardenas-Turanzas M, Gaeta S, Borthakur G, Price K, Cortes J, Nates JL. Sepsis and Acute Myeloid Leukemia: A Population-Level Study of Comparative Outcomes of Patients Discharged From Texas Hospitals. Clin Lymphoma Myeloma Leuk. e-Pub 2017. PMID: 28844403.
Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol 92(7):599-606, 2017. e-Pub 2017. PMID: 28370097.
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584-2587, 2017. e-Pub 2017. PMID: 28246192.
Boddu P, Borthakur G. Therapeutic targeting of isocitrate dehydrogenase mutant AML. Expert Opin Investig Drugs 26(5):525-530, 2017. e-Pub 2017. PMID: 28388242.
Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol 4(4):e165-e175, 2017. e-Pub 2017. PMID: 28291640.
Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2016. PMID: 28003274.
Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. e-Pub 2017. PMID: 28338082.
Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer 123(4):609-616, 2017. e-Pub 2016. PMID: 27763690.
Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123(4):629-637, 2017. e-Pub 2016. PMID: 27741352.
Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2016. PMID: 27696391.
Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 123(3):426-435, 2017. e-Pub 2016. PMID: 27657543.
Piya S, Andreeff M, Borthakur G. Targeting autophagy to overcome chemo-resistance in Acute Myleogenous leukemia. Autophagy 13(1):0, 2017. e-Pub 2016. PMID: 27797294.
Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2016. PMID: 27673440.
Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias - (de novo and blast phase CML). Am J Hematol 92(1):E3-E4, 2017. e-Pub 2016. PMID: 27727470.
Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol 6:30, 2017. e-Pub 2017. PMID: 29152412.
Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer 122(22):3484-3491, 2016. e-Pub 2016. PMID: 27463065.
Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer 122(21):3336-3343, 2016. e-Pub 2016. PMID: 27509035.
Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk 16(11):616-624, 2016. e-Pub 2016. PMID: 27601000.
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7(45):74380-74392, 2016. e-Pub 2016. PMID: 27602582.
Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. e-Pub 2016. PMID: 27795561.
Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood 128(9):1260-9, 2016. e-Pub 2016. PMID: 27268264.
Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. Haematologica 101(8):e324-7, 2016. e-Pub 2016. PMID: 27175025.
Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol 91(8):800-5, 2016. e-Pub 2016. PMID: 27169385.
Rizzieri DA, Cooley S, Odenike O, Moonan L, Chow KH, Jackson K, Wang X, Brail L, Borthakur G. An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma 57(8):1-7, 2016. e-Pub 2016. PMID: 26735141.
Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol 91(8):819-23, 2016. e-Pub 2016. PMID: 27178680.
Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant 22(7):1218-26, 2016. e-Pub 2016. PMID: 27058617.
Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer 122(12):1871-9, 2016. e-Pub 2016. PMID: 26990290.
Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
Ouyang J, Goswami M, Peng J, Zuo Z, Daver N, Borthakur G, Tang G, Medeiros LJ, Jorgensen JL, Ravandi F, Wang SA. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. Am J Clin Pathol 145(6):769-77, 2016. e-Pub 2016. PMID: 27298396.
Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol. e-Pub 2016. PMID: 26846160.
Jain N, Lamb AE, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. e-Pub 2016. PMID: 26747249.
Jain P, Kantarjian H, Patel KP, Nogueras Gonzalez G, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Guillermo Romo C, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. e-Pub 2016. PMID: 26729897.
Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero G, Thomas D, Pierce S, Verstovsek S, Borthakur G, Cortes J. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk. e-Pub 2016. PMID: 26838606.
Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M. The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations. Cancer Res. e-Pub 2016. PMID: 26822154.
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2016. e-Pub 2016. PMID: 26884599.
Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clin 4:59-68, 2015. e-Pub 2015. PMID: 26674329.
Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 26796981.
Yilmaz M, Lahoti A, O'Brien S, Nogueras-González GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894-904, 2015. e-Pub 2015. PMID: 26217876.
Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 26752456.
Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. e-Pub 2015. PMID: 26492205.
Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. e-Pub 2015. PMID: 26547258.
Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. e-Pub 2015. PMID: 26479889.
Mattiuzzi G, Yilmaz M, Kantarjian H, Borthakur G, Konopleva M, Jabbour E, Brown Y, Pierce S, Cortes J. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. J Infect Chemother 21(9):663-7, 2015. e-Pub 2015. PMID: 26141814.
Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol 90(9):769-73, 2015. e-Pub 2015. PMID: 26017166.
Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26343946.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res 39(9):950-6, 2015. e-Pub 2015. PMID: 26183878.
Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. PMID: 26436130.
Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. e-Pub 2015. PMID: 26365212.
Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-63, 2015. e-Pub 2015. PMID: 26088933.
Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-1412, 2015. e-Pub 2015. PMID: 25840338.
Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer 121(14):2375-82, 2015. e-Pub 2015. PMID: 25809968.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE. A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica 100(7):898-904, 2015. e-Pub 2015. PMID: 25887498.
Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies. Clin Lymphoma Myeloma Leuk 15(7):433-438.e2, 2015. e-Pub 2015. PMID: 25795639.
Owusu-Agyemang P, Borthakur G, Rebello E, Arunkumar R, Wang SA, Rytting M, Jorgensen JL, Hernandez M, Ruiz JR, Cata JP. The Association Between Opioid Administration and Response to Therapy in Patients with Acute Lymphoblastic Leukemia. Leuk Lymphoma 56(6):1-9, 2015. e-Pub 2015. PMID: 25363399.
Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(6):358-63, 2015. e-Pub 2014. PMID: 25630528.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186-93, 2015. e-Pub 2015. PMID: 26688093.
Estécio MR, Maddipoti S, Bueso-Ramos C, DiNardo CD, Yang H, Wei Y, Kondo K, Fang Z, Stevenson W, Chang KS, Pierce SA, Bohannan Z, Borthakur G, Kantarjian H, Garcia-Manero G. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol 169(3):344-51, 2015. e-Pub 2015. PMID: 25612675.
Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica 100(5):653-61, 2015. e-Pub 2015. PMID: 25682595.
Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90(4):276-81, 2015. e-Pub 2015. PMID: 25530214.
Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma 56(4):1-8, 2015. e-Pub 2014. PMID: 25048874.
Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(3):171-6, 2015. e-Pub 2014. PMID: 25441108.
Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol 2(3):e118-28, 2015. e-Pub 2015. PMID: 26687797.
Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 168(5):646-53, 2015. e-Pub 2014. PMID: 25312977.
Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II Study of Methotrexate, Vincristine, Pegylated-Asparaginase, and Dexamethasone (MOpAD) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Am J Hematol 90(2):120-4, 2015. e-Pub 2014. PMID: 25368968.
DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2014. PMID: 26687423.
Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine. Biomed Res Int 2015:497597, 2015. e-Pub 2015. PMID: 25654108.
Pemmaraju N, Sasaki K, Johnson D, Daver N, Afshar-Kharghan V, Chen M, Ahmed S, Colen RR, Kwon M, Huh Y, Borthakur G. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. Front Oncol 5:29, 2015. e-Pub 2015. PMID: 25717439.
Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation. PLoS One 10(10):e0139254, 2015. e-Pub 2015. PMID: 26440941.
Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors - single institution experience. Leuk Lymphoma 55(12):2879-86, 2014. e-Pub 2013. PMID: 23927391.
Arellano ML, Borthakur G, Berger M, Luer J, Raza A. A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia. Clin Lymphoma Myeloma Leuk 14(6):534-9, 2014. e-Pub 2014. PMID: 25052051.
Pemmaraju N, Shetty AV, Prieto VG, Jain N, Kontoyiannis DP, Borthakur G. Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum, and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia. Eur J Haematol 93(6):543-4, 2014. e-Pub 2014. PMID: 24592915.
Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 167(3):356-65, 2014. e-Pub 2014. PMID: 25066676.
Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. e-Pub 2014. PMID: 25403830.
Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. e-Pub 2014. PMID: 25336333.
Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):395-400.e1, 2014. e-Pub 2014. PMID: 24637132.
Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia. Am J Hematol 89(10):964-8, 2014. e-Pub 2014. PMID: 24990142.
Shah DR, Daver N, Borthakur G, Hirsch-Ginsberg C, Oo TH. Pernicious Anemia With Spuriously Normal Vitamin B12 Level Might Be Misdiagnosed As Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 14(4):e141-3, 2014. e-Pub 2014. PMID: 24630920.
DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents. Leuk Lymphoma 55(8):1925-9, 2014. e-Pub 2014. PMID: 24138309.
Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer 120(14):2142-9, 2014. e-Pub 2014. PMID: 24737502.
Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 28(7):1543-5, 2014. e-Pub 2014. PMID: 24487412.
Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. e-Pub 2014. PMID: 25042398.
Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 14(3):231-8, 2014. e-Pub 2013. PMID: 24440659.
Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis. Clin Lymphoma Myeloma Leuk 14(3):223-30, 2014. e-Pub 2013. PMID: 24355079.
Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma 55(6):1337-44, 2014. e-Pub 2013. PMID: 24004182.
Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M. Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies. Clin Cancer Res 20(9):2363-74, 2014. e-Pub 2014. PMID: 24619500.
Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res 20(8):2226-35, 2014. e-Pub 2014. PMID: 24583795.
Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase. Clin Lymphoma Myeloma Leuk 14(2):155-162.e1, 2014. e-Pub 2013. PMID: 24332214.
Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4):973-5, 2014. e-Pub 2013. PMID: 24157581.
Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics. Clin Lymphoma Myeloma Leuk 14(2):163-71, 2014. e-Pub 2014. PMID: 24461514.
Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia. Cancer Discov 4(3):362-75, 2014. e-Pub 2013. PMID: 24346116.
Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373-80, 2014. e-Pub 2013. PMID: 24151050.
Pemmaraju N, Chang E, Daver N, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol 4:130, 2014. e-Pub 2014. PMID: 24918086.
Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G. A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia. PLoS One 9(10):e108694, 2014. e-Pub 2014. PMID: 25285531.
Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver N, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol 4:297, 2014. e-Pub 2014. PMID: 25401088.
Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clin Lymphoma Myeloma Leuk 13(6):693-9, 2013. e-Pub 2013. PMID: 24060289.
Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88(12):1024-9, 2013. e-Pub 2013. PMID: 23913852.
Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 98(11):1686-8, 2013. e-Pub 2013. PMID: 23812943.
Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status. J Clin Oncol 31(29):3681-7, 2013. e-Pub 2013. PMID: 24002496.
Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831-7, 2013. e-Pub 2013. PMID: 23760779.
Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 13 Suppl 2(0 2):S289-94, 2013. e-Pub 2013. PMID: 23969308.
Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2(0 2):S276-81, 2013. e-Pub 2013. PMID: 23969309.
Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy. Clin Lymphoma Myeloma Leuk 13(4):435-40, 2013. e-Pub 2013. PMID: 23763915.
Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(4):477-84, 2013. e-Pub 2013. PMID: 23770156.
Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. J Clin Oncol 31(20):2548-53, 2013. e-Pub 2013. PMID: 23733767.
Pierce A, Whetton AD, Meyer S, Ravandi-Kashani F, Borthakur G, Coombes KR, Zhang N, Kornblau S. Transglutaminase2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility. Proteomics 13(14):2216-24, 2013. e-Pub 2013. PMID: 23576428.
Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121(24):4867-74, 2013. e-Pub 2013. PMID: 23620574.
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase II study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-62, 2013. e-Pub 2013. PMID: 23613521.
Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 161(5):659-66, 2013. e-Pub 2013. PMID: 23530930.
Katragadda L, Carter BZ, Borthakur G. XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opin Investig Drugs 22(5):663-70, 2013. PMID: 23586880.
Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 88(5):365-9, 2013. e-Pub 2013. PMID: 23512829.
Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintás-Cardama A. Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 13(2):139-43, 2013. e-Pub 2012. PMID: 23276886.
Bhatt VR, Kantarjian H, Cortes JE, Ravandi F, Borthakur G. Therapy of Core-binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long Term Results. Clin Lymphoma Myeloma Leuk 13(2):153-8, 2013. e-Pub 2012. PMID: 23266036.
Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE. Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia. Protein Pept Lett 20(4):392-402, 2013. e-Pub 2012. PMID: 23016580.
Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett 329(1):45-58, 2013. e-Pub 2012. PMID: 23036488.
Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE. Phase 1 Study of Anti-CD33 Immunotoxin HUM-195/rGEL in Patients with Advanced Myeloid Malignancies. Haematologica 98(2):217-21, 2013. e-Pub 2012. PMID: 22875630.
Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortés JE, Estrov Z, Pemmaraju N. Ocular Granulocytic Sarcoma: A Case Report and Literature Review of Ocular Extramedullary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(1):93-6, 2013. e-Pub 2012. PMID: 23017332.
Quintás-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 120(24):4840-5, 2012. e-Pub 2012. PMID: 23071272.
Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 118(23):5819-22, 2012. e-Pub 2012. PMID: 22605576.
Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 118(22):5550-9, 2012. e-Pub 2012. PMID: 22569880.
Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 26(11):2428-31, 2012. e-Pub 2012. PMID: 22665218.
Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur G. A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities. Clin Lymphoma Myeloma Leuk 12(5):341-4, 2012. e-Pub 2012. PMID: 22579233.
Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 2012. e-Pub 2012. PMID: 22282348.
Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-70, 2012. e-Pub 2012. PMID: 22252728.
Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res 36(9):1124-7, 2012. e-Pub 2012. PMID: 22475363.
Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 2012. e-Pub 2012. PMID: 22718840.
Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating mutations of the FMS-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica 97(8):1242-5, 2012. e-Pub 2012. PMID: 22532519.
Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 2012. e-Pub 2012. PMID: 22534616.
Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 118(14):3556-64, 2012. e-Pub 2011. PMID: 22139909.
Giles FJ, Vey N, Rizzieri D, Ravandi F, Prebet T, Borthakur G, Jacobsen TF, Hagen S, Nilsson B, O'Brien S. Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia 26(7):1686-9, 2012. e-Pub 2012. PMID: 22222600.
Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, Kantarjian HM. Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. J Clin Oncol 30(18):2204-10, 2012. e-Pub 2012. PMID: 22585696.
Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian H. Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High Risk Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 12(3):197-200, 2012. PMID: 22578814.
Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 2012. e-Pub 2012. PMID: 22422826.
Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, cyclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 2012. e-Pub 2012. PMID: 22360602.
Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 2012. e-Pub 2012. PMID: 22228624.
Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol 87(3):317-8, 2012. e-Pub 2012. PMID: 22228403.
Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-8, 2012. e-Pub 2011. PMID: 21751197.
Al-Kali A, Konoplev S, Lin E, Kadia T, Faderl S, Ravandi F, Ayoubi M, Brandt M, Cortes JE, Kantarjian H, Borthakur G. Hypocellular acute myeloid leukemia in adults: clinical outcome analysis of 123 patients. Haematologica 97(2):235-40, 2012. e-Pub 2011. PMID: 22058194.
Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 118(2):418-27, 2012. e-Pub 2011. PMID: 21717444.
Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 2012. e-Pub 2011. PMID: 22072492.
Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 117(21):4869-77, 2011. e-Pub 2011. PMID: 21480207.
Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118(17):4690-3, 2011. e-Pub 2011. PMID: 21868570.
Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?. Clin Lymphoma Myeloma Leuk 11(5):421-426, 2011. e-Pub 2011. PMID: 21831744.
Schimmer AD, Herr W, Hänel M, Borthakur G, Frankel A, Horst HA, Martin S, Kassis J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C, Jolivet J, Tallman MS, Koschmieder S. Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study. Clin Lymphoma Myeloma Leuk 11(5):433-438, 2011. e-Pub 2011. PMID: 21729686.
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH. Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. J Clin Oncol. e-Pub 2011. PMID: 21969499.
Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 29(23):3173-8, 2011. e-Pub 2011. PMID: 21747082.
Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk 11(4):355-60, 2011. e-Pub 2011. PMID: 21816374.
Stock W, Douer D, Deangelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. e-Pub 2011. PMID: 21827361.
Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Low expression of PP2A regulatory subunit B55a is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia. e-Pub 2011. PMID: 21660042.
Quintás-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica 96(6):918-24, 2011. e-Pub 2011. PMID: 21357704.
Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 117(10):2145-55, 2011. e-Pub 2010. PMID: 21523727.
Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 117(5):982-91, 2011. e-Pub 2010. PMID: 20960502.
Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6):1822-7, 2011. e-Pub 2010. PMID: 21030554.
Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy. Clin Lymphoma Myeloma Leuk 11(1):54-9, 2011. e-Pub 2011. PMID: 21454191.
Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117(2):327-35, 2011. e-Pub 2010. PMID: 20845478.
Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase 1 Study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96(1):62-8, 2011. e-Pub 2010. PMID: 20952518.
Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34(+)38 (-) cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16(1):67-74, 2011. e-Pub 2010. PMID: 20938744.
Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS One 6(8):e23108, 2011. e-Pub 2011. PMID: 21853076.
Bryan J, Borthakur G. Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag 7:1-11, 2010. e-Pub 2010. PMID: 21339937.
Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 116(24):5659-66, 2010. e-Pub 2010. PMID: 21218459.
Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-7, 2010. e-Pub 2010. PMID: 20466853.
Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 116(15):3631-7, 2010. e-Pub 2010. PMID: 20564073.
Apostolidou E, Kantarjian H, Thomas D, Burger I, Borthakur G, Verstovsek S. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clin Lymphoma Myeloma Leuk 10(4):281-4, 2010. PMID: 20709665.
Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 116(13):3152-9, 2010. PMID: 20564631.
Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. J Clin Oncol 28(16):2755-60, 2010. e-Pub 2010. PMID: 20421540.
Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116(11):2673-81, 2010. PMID: 20499401.
Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 116(9):2174-9, 2010. e-Pub 2010. PMID: 20162709.
Samudio IJ, Duvvuri S, Clise-Dwyer K, Watt JC, Mak D, Kantarjian H, Yang D, Ruvolo V, Borthakur G. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leuk Lymphoma 51(5):911-9, 2010. PMID: 20423286.
Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. J Clin Oncol 28(11):1856-62, 2010. e-Pub 2010. PMID: 20212254.
Jones D, Yao H, Romans A, Dando C, Pierce S, Borthakur G, Hamilton A, Bueso-Ramos C, Ravandi F, Garcia-Manero G, Kantarjian H. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 49(2):182-91, 2010. PMID: 19908318.
Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. J Clin Oncol 28(3):398-404, 2010. e-Pub 2009. PMID: 20008620.
Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. J Clin Oncol 28(3):392-7, 2010. e-Pub 2009. PMID: 20008621.
Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 116(1):93-7, 2010. e-Pub 2009. PMID: 19862814.
Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51(1):73-8, 2010. PMID: 20017599.
Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 115(24):5746-51, 2009. e-Pub 2009. PMID: 19795507.
Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 23(12):2275-80, 2009. e-Pub 2009. PMID: 19741728.
Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. Cancer 115(22):5202-9, 2009. e-Pub 2009. PMID: 19691096.
Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. J Clin Oncol 27(32):5418-24, 2009. e-Pub 2009. PMID: 19826111.
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia. J Clin Oncol 27(28):4741-6, 2009. e-Pub 2009. PMID: 19652057.
Sampat K, Kantarjian H, Borthakur G. Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs 18(10):1559-64, 2009. PMID: 19715446.
Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J. Chronic myeloid leukemia (CML) with P190BCR-ABL - analysis of characteristics, outcomes and prognostic significance. Blood 114(11):2232-5, 2009. e-Pub 2009. PMID: 19531657.
Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 2009. e-Pub 2009. PMID: 19567878.
Quintás-Cardama A, De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G, Cortes J. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 115(17):3935-43, 2009. e-Pub 2009. PMID: 19517473.
Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 2009. PMID: 19517462.
Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core binding factor acute myelogenous leukemia compared with de novo core binding factor leukemia. Cancer 115(14):3217-21, 2009. e-Pub 2009. PMID: 19441109.
Quintás-Cardama A, Cortes JE, O'Brien S, Ravandi F, Borthakur G, Liu D, Bleickardt E, Chen TT, Kantarjian HM. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115(13):2912-21, 2009. e-Pub 2009. PMID: 19402171.
Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-302, 2009. e-Pub 2009. PMID: 19242494.
Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113(25):6315-21, 2009. e-Pub 2009. PMID: 19369233.
Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-63, 2009. e-Pub 2009. PMID: 19282457.
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E. Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. J Clin Oncol 26(35):5684-8, 2008. e-Pub 2008. PMID: 18955453.
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core binding factor acute myelogenous leukemia with fludarabine, cytarabine and granulocyte colony stimulating factor results in improved event-free survival. Cancer 113(11):3181-5, 2008. PMID: 18932257.
O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186-91, 2008. PMID: 18846563.
Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14(24):8295-301, 2008. PMID: 19088047.
Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):1995-8, 2008. e-Pub 2008. PMID: 18756533.
Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res 32(10):1505-9, 2008. e-Pub 2008. PMID: 18405972.
Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients age >= 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-45, 2008. e-Pub 2008. PMID: 18565853.
Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3):516-518, 2008. e-Pub 2008. PMID: 18492956.
Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs 26(4):331-8, 2008. e-Pub 2008. PMID: 18425419.
Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 113(2):360-6, 2008. PMID: 18473351.
Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53-5, 2008. e-Pub 2008. PMID: 18403620.
Badgwell BD, Cormier JN, Wray CJ, Borthakur G, Qiao W, Rolston KV, Pollock RE. Challenges in surgical management of abdominal pain in the neutropenic cancer patient. Ann Surg 248(1):104-109, 2008. PMID: 18580213.
Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49(4):690-695, 2008. PMID: 18398735.
Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538-543, 2008. e-Pub 2007. PMID: 18079733.
Borthakur G, Lin E, Faderl S, Ferrajoli A, Wierda W, Giles F, Browning ML, Kantarjian H, Keating M, O'Brien S. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath -1H) based therapies. Cancer 110(11):2478-83, 2007. PMID: 17960607.
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia. Cancer 110(12):2756-2760, 2007. PMID: None.
Quintás-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908-3914, 2007. PMID: 17761974.
Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 109(8):1556-60, 2007. PMID: 17342766.
Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol 136(6):800-5, 2007. PMID: 17341265.
Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109(4):713-7, 2007. PMID: 17219444.
Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624-7, 2007. PMID: 17223919.
Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106(2):346-52, 2006. PMID: 16342165.
Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, Pruthi RK, Tefferi A. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 15(1):21-4, 2004. PMID: 15166939.
Borthakur G, Cruz MA, Dong JF, McIntire L, Li F, Lopez JA, Thiagarajan P. Sulfatides inhibit platelet adhesion to von Willebrand factor in flowing blood. J Thromb Haemost 1(6):1288-95, 2003. PMID: 12871332.
Shrimpton CN, Borthakur G, Larrucea S, Cruz MA, Dong JF, Lopez JA. Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation. J Exp Med 196:1057-66, 2002. PMID: 12391017.
Das A, Borthakur G, Basu A, Mann SB, Banerjee CK. Nasopharyngeal teratoma with a difference. Indian J Pathol Microbiol 37 Suppl:S15-16, 1994. PMID: None.
Borthakur G, Rao SN, Radotra BD, Datta BN, Joshi K. Immunohistochemistry of pleomorphic soft-tissue sarcomas- an alternate view. Bull PGI 27:66-73, 1993. PMID: None.
Borthakur G, Banerjee CK, Rao KL, Radhika S, Samujh R. Malignant rhabdoid tumour of kidney. Indian J Cancer 29(1):27-30, 1992. PMID: None.
Gulati S, Borthakur G, Banerjee CK, Singh S. Zygomycosis of colon. Indian Pediatrics 28:941-943, 1991. PMID: None.

Invited Articles

Borthakur G. Precision 're'arming of CD33 antibodies. Blood 122(8):1334, 2013. PMID: 23970353.
Chen Y, Borthakur G. Lenalidomide as a novel treatment of acute myeloid leukemia. Expert Opin Investig Drugs 22(3):389-97, 2013. e-Pub 2013. PMID: 23316859.
Borthakur G, O'Brien S. Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia. Blood and Lymphatic Cancer: Targets and Therapy 2:137-143, 2012. PMID: None.

Editorials

Borthakur G. Stressing the stem cell in acute myeloid leukemia. Haematologica 109(3):715, 2024. PMID: 37794806.

Abstracts

Jain P, Kantarjian HM, Ravandi F, Kanagal-Shamanna R, Khoury JD, Patel KP, Garcia-Manero G, Konopleva M, Jain N, Sasaki K, Kadia TM, Borthakur G, Garris R, Pierce S, Estrov Z, Wierda WG, Cortes JE, O'Brien SM, Jabbour EJ. Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. Blood 128(22), 2016. PMID: None.
Sasaki K, Jabbour EJ, O'Brien SM, Ravandi F, Thomas DA, Garcia-Manero G, Daver N, Borthakur G, Jain N, Konopleva M, Short NJ, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson PA, Cortes JE, Kantarjian HM. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128(22), 2016. PMID: None.
Abaza Y, Jabbour EJ, Verstovsek S, Estrov Z, Ravandi F, Borthakur G, Kadia TM, Daver N, DiNardo CD, Bueso-Ramos CE, Hidalgo JE, Schneider H, Montalban Bravo G, Alfonso A, Wei Y, Kantarjian HM, Garcia-Manero G. Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. Blood 128(22), 2016. PMID: None.
Jain P, Casteel K, Allen CE, McClain KL, Wang S, Konoplev S, Jabbour EJ, Nogueras Gonzalez G, Huang X, Miller S, Abdelall W, Tamamyan G, Kadia TM, Borthakur G, Estrov Z, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM, Daver N. Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation. Blood 128(22), 2016. PMID: None.
Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Zhang C, Ravandi F, Plunkett W. Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study. Blood 128(22), 2016. PMID: None.
Chihara D, Kantarjian HM, Newberry KJ, Ravandi F, Daver NG, Bose P, DiNardo CD, Pemmaraju N, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Popat UR, Cortes JE, Verstovsek S. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood 128(22), 2016. PMID: None.
Kanagal-Shamanna R, Jain P, Luthra R, Patel KP, Garcia-Manero G, Takahashi K, Ravandi F, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Estrov Z, Wierda WG, O'Brien SM, Cortes JE, Kantarjian HM, Jabbour EJ. Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. Blood 128(22), 2016. PMID: None.
Assi R, Kantarjian HM, Verstovsek S, Garcia-Manero G, Konopleva M, Ravandi F, DiNardo CD, Kadia TM, Daver N, Jabbour EJ, Gborogen RA, Chamoun K, Wierda WG, Borthakur G, Cortes JE. CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. Blood 128(22), 2016. PMID: None.
Ohanian M, Kantarjian HM, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt JR, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood 128(22), 2016. PMID: None.
Sam PY, Ahaneku H, Nogueras-Gonzalez GM, Jabbour E, Garcia-Manero G, Borthakur G, Wierda WG, Daver N, Kadia T, Burger J, Pierce S, DiNardo CD, Ravandi F, Kantarjian HM, Cortes JE. Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood 128(22), 2016. PMID: None.
Montalban-Bravo G, Pierola AA, Takahashi K, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Pierce S, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero G. Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood 128(22), 2016. PMID: None.
Pierola AA, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Pierce S, Kantarjian HM, Garcia-Manero G. Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia. Blood 128(22), 2016. PMID: None.
Pierola AA, Montalban-Bravo G, Takahashi K, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome. Blood 128(22), 2016. PMID: None.
Thompson PA, Strati P, Keating M, O'Brien SM, Ferrajoli A, Burger JA, Jorgensen JL, Faderl S, Estrov Z, Jain N, Kadia T, Borthakur G, DiNardo CD, Daver N, Jabbour EJ, Wierda WG. Early Achievement of MRD-Negativity in IGHV-Mutated (IGHV-M) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse. Blood 128(22), 2016. PMID: None.
Borthakur G, Dawson MA, Stein EM, Karadimitris A, Huntly BJP, Dickinson MJ, Chaidos A, Horner T, Brennan J, Baron J, Kremer BE, Dhar A. A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies. Blood 128(22), 2016. PMID: None.
Abaza Y, Kantarjian HM, Borthakur G, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger JA, Estrov Z, Ohanian M, Lim M, Assi R, Jabbour EJ, Cortes JE. An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). Blood 128(22), 2016. PMID: None.
Jain P, Kantarjian HM, Jabbour EJ, Kanagal-Shamanna R, Patel KP, DellaSala SE, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien SM, Cortes JE. Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML). Blood 128(22), 2016. PMID: None.
Ohanian M, Garcia-Manero G, Jabbour EJ, Daver N, Borthakur G, Kadia TM, Brandt M, Pierce S, Burger J, Richie MA, Patel K, Cortes JE, Kantarjian KM, Ravandi F. Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation. Blood 128(22), 2016. PMID: None.
Alhuraiji A, Kantarjian HM, Jabbour EJ, Boddu PC, Ravandi F, Borthakur G, DiNardo CD, Daver N, Kadia TM, Pemmaraju N, Pierce S, Garcia-Manero G, Cortes JE. Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors. Blood 128(22), 2016. PMID: None.
Chamoun K, Kantarjian HM, Rios MB, Assi R, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia TM, Pemmaraju N, Jabbour EJ, Cortes JE. CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. Blood 128(22), 2016. PMID: None.
Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour EJ, Cortes JE. Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 128(22), 2016. PMID: None.
Abdelall W, Kantarjian HM, Borthakur G, Garcia-Manero G, Patel KP, Jabbour EJ, Daver NG, Kadia T, Gborogen RA, Konopleva M, Ravandi F, Andreeff M, Cortes JE. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 128(22), 2016. PMID: None.
Sasaki K, Kantarjian HM, Jabbour EJ, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Jain P, Skinner J, Rios MB, Pierce S, Garcia-Manero G, Cortes JE. Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood 128(22), 2016. PMID: None.
Daver NG, Cortes JE, Pemmaraju N, Jabbour EJ, Bose P, Zhou L, Pierce S, Van Derbur S, Tuttle CK, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood 128(22), 2016. PMID: None.
Piya S, Bhattacharya S, Mu H, Lorenzi PL, McQueen T, Davis ER, Ruvolo V, Baran N, Qian Y, Crews C, Kantarjian HM, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects. Blood 128(22), 2016. PMID: None.
Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological Responses after Therapy with Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Blood 128(22), 2016. PMID: None.
Borthakur G, Ishizawa J, DiNardo CD, Kadia TM, Weise K, Allen JE, Oster W, Cortes JE, Kantarjian HM, l Andreeff M. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias. Blood 128(22), 2016. PMID: None.
Daver N, Cortes JE, Pemmaraju N, Jabbour EJ, Bose P, Zhou L, Pierce S, Van Derbur S, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S. Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF). Blood 128(22), 2016. PMID: None.
Zahr AA, Cortes JE, Verstovsek S, Matthews J, Jain N, Jabbour EJ, Garcia-Manero G, Andreef M, Naqvi K, Kantarjian HM, Borthakur G. Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis. Blood 128(22), 2016. PMID: None.
Maiti A, Kantarjian HM, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour EJ, Ravandi F, O'Brien SM, Cortes JE. Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML). Blood 128(22), 2016. PMID: None.
Sasaki K, Jabbour EJ, O'Brien SM, Thomas DA, Ravandi F, Garcia-Manero G, Cortes JE, Short NJ, Verstovsek S, Yilmaz M, Wierda WG, Borthakur G, Kadia TM, Konopleva M, Khouri MR, Ferrajoli A, Daver NG, Pemmaraju N, DiNardo CD, Jain N, Benton CB, Takahashi K, Naqvi K, Bose P, Kornblau SM, Andreeff M, Keating MJ, Freireich EJ, Kantarjian HM. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood 128(22), 2016. PMID: None.
Jabbour EJ, Short NJ, Huang X, Maiti A, Kadia TM, Daver N, Borthakur G, DiNardo CD, Pemmaraju N, Sasaki K, Estrov Z, Verstovsek S, Ravandi F, Alvarado Y, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Miller D, Dong X, Kantarjian HM, Garcia-Manero G. A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood 128(22), 2016. PMID: None.
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia TM, Cortes JE, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Patel KP, Kornblau SM, Kantarjian HM, Young KH, Garcia-Manero G, Andreeff M. Pure Erythroid Leukemia Is Characterized By TP53mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. Blood 128(22), 2016. PMID: None.
Borthakur G, Tallman MS, Ofran Y, Foran JM, Uy GL, DiPersio JF, Nagler A, Rowe JM, Showel MM, Altman J, Al-Rawi A, R-Y W, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, Lustig T, Aharon A, Bueso-Ramos CE, Cortes JE, Andreeff M. The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. Blood 128(22), 2016. PMID: None.
Benton CB, Takahashi K, Bose P, Wang F, H-C C, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa GC, Daver N, Jabbour EJ, DiNardo CD, Bueso-Ramos CE, Patel K, Kornblau SM, Konopleva M, Borthakur G, Kadia TM, Cortes JE, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian HM. Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. Blood 128(22), 2016. PMID: None.
Montalban-Bravo G, Takahashi K, Alfonso Pierola A, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Futreal A, Kantarjian HM, Garcia-Manero G. Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System. Blood 128(22), 2016. PMID: None.
Montalban-Bravo G, Alfonso Pierola A, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Patel K, Futreal A, Kantarjian HM, Takahashi K, Garcia-Manero G. Increased Number of Driver Mutations Is a Predictor of Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes. Blood 128(22), 2016. PMID: None.
Montalban-Bravo G, Takahashi K, Alfonso Pierola A, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver N, Borthakur G, Pemmaraju N, Konopleva M, Nogueras-Gonzalez GM, Huang X, Bueso-Ramos CE, Futreal A, Kantarjian HM, Garcia-Manero G. STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes. Blood 128(22), 2016. PMID: None.
Montalban-Bravo G, Takahashi K, Wang F, Konopleva M, Xingzhi S, Nogueras-Gonzalez GM, Huang X, Pierola AA, Jabbour EJ, Colla S, Borthakur G, Daver N, DiNardo CD, Estrov Z, Kadia TM, Pemmaraju N, Ravandi F, Bueso-Ramos CE, Chamseddine AN, Zhang J, Kantarjian HM, Patel K, Chin L, Futreal A, Garcia-Manero G. Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Blood 128(22), 2016. PMID: None.
Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour EJ, Kadia TM, Kornblau SM, Ohanian M, Alfonso Pierola A, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos CE, Kantarjian HM, Garcia-Manero G. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 128(22), 2016. PMID: None.
Jabbour EJ, Kantarjian HM, Sasaki K, Kadia TM, Ravandi F, Cortes JE, Khoury JD, Patel KP, Bueso-Ramos CE, Daver NG, Borthakur G, Jain N, DiNardo CD, Konopleva M, Verstovsek S, Pemmaraju N, Estrov Z, Miller D, Maduike R, Faderl S, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. Blood 128(22), 2016. PMID: None.
Khan M, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia TM, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood 128(22), 2016. PMID: None.
Short NJ, Ravandi F, Huang X, Cortes JE, Pemmaraju N, Daver N, Khouri RB, Borthakur G, Jain N, Konopleva M, Estrov Z, Garcia-Manero G, Kadia TM, Wierda WG, DiNardo CD, O'Brien SM, Shah S, Pike A, Brandt M, Kantarjian HM, Jabbour EJ. Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood 128(22), 2016. PMID: None.
Abaza Y, Kantarjian HM, Jabbour EJ, Thomas DA, Kadia TM, Borthakur G, Burger J, Wierda WG, Jain N, Faderl S, O'Brien SM, Konopleva M, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Kelly MA, Garris R, Garcia-Manero G, Cortes JE, Ravandi F. Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood 128(22), 2016. PMID: None.
Jain P, Kantarjian HM, Jabbour EJ, Nogueras Gonzalez G, Garcia-Manero G, Kanagal-Shamanna R, Patel KP, Hu S, Emogene DellaSala S, Pierce S, Sasaki K, Konopleva M, Wierda WG, Daver N, Kadia TM, Borthakur G, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. Blood 128(22), 2016. PMID: None.
Alfonso Pierola A, Montalban-Bravo G, Chamseddine AN, Takahashi K, Wang F, Xingzhi S, Jabbour EJ, Kadia TM, Ravandi F, Cortes JE, DiNardo CD, Daver NG, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos CE, Patel K, Futreal A, Pierce S, Kantarjian HM, Garcia-Manero G. Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome. Blood 128(22), 2016. PMID: None.
Garcia-Manero G, Daver NG, Montalban-Bravo G, Jabbour EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, Kantarjian HM. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood 128(22), 2016. PMID: None.
Montalban-Bravo G, Huang X, Jabbour EJ, Borthakur G, DiNardo CD, Pemmaraju N, Cortes JE, Verstovsek S, Kadia TM, Daver NG, Wierda WG, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Pierola AA, Brandt M, Sneed T, H-C C, Yang H, Bueso-Ramos CE, Pierce S, Estey EH, Bohannan ZS, Kantarjian HM, Garcia-Manero G. A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials. Blood 128(22), 2016. PMID: None.
Jain N, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, Jabbour EJ, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Alvarado Y, Takahashi K, Benton CB, Pike A, Pierce S, Cortes JE, Kantarjian HM. Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood 128(22), 2016. PMID: None.
Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Pemmaraju N, Borthakur G, Kadia TM, Konopleva M, Kantarjian HM, Cortes JE, Hearn KP, Reyes SR, Bueso-Ramos CE, Garcia-Manero G. Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation. Blood 128(22), 2016. PMID: None.
Jain P, Kantarjian HM, Ravandi F, Jabbour E, Daver N, Pemmaraju N, DiNardo CD, Alvarado Y, Jain N, Borthakur G, Verstovsek S, Ferrajoli A, Ohanian M, Konopleva M, Naqvi K, Fitch T, Garcia-Manero G, Cortes JE, Estrov Z, Kadia TM. Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood 128(22), 2016. PMID: None.
Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Borthakur G, Pemmaraju N, Bueso-Ramos CE, Hidalgo Lopez JE, Blando J, Allison J, Kantarjian HM, Sharma P. Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood 128(22), 2016. PMID: None.
Navada SC, Garcia-Manero G, Hearn KP, Odchimar-Reissig R, Demakos EP, Alvarado Y, Daver N, DiNardo CD, Konopleva M, Borthakur G, Fenaux P, Petrone ME, Zbyszewski PS, Fruchtman SM, Silverman LR. Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study. Blood 128(22), 2016. PMID: None.
Boddu RC, Kantarjian HM, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau SM, Dellasala SE, Pierce S, Jabbour EJ, Cortes JE. Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. Blood 128(22), 2016. PMID: None.
Patel YP, Voit KN, Sasaki K, Ravandi F, Thomas DA, O'Brien SM, Borthakur G, Garcia-Manero G, Cortes JE, Konopleva M, Jain N, Ohanian M, Garris R, Jacob J, Kantarjian HM, Jabbour EJ. Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. Blood 128(22), 2016. PMID: None.
Yilmaz M, Kantarjian H, Thomas D, Kadia T, Garcia-Manero G, Khouri R, Ravandi F, Borthakur G, Cortes J, Ferrajoli A, Sasaki K, Autry J, Garris R, Voit K, O’Brien S, Jabbour E. Outcomes after Blinatumomab Failure in Patients with Relapsed/Refractory (R/R) B-cell ALL (ALL). Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Issa G, Kantarjian H, Yin CC, Qiao W, Ravandi F, Khouri R, Thomas D, Short N, Sasaki K, Garcia-Manero G, Kadia T, Cortes J, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin R, Pierce S, O’Brien S, Jabbour E. Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL (ALL) Independent of MRD Status. Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Sasaki K, Jabbour E, O'Brien S, Khouri M, Thomas D, Garcia-Manero G, Ravandi F, Borthakur G, Short N, Issa G, Gachimova E, Garris R, Cortes J, Kantarjian H. Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL). Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Short N, Jabbour E, O'Brien S, Khouri R, Ravandi F, Thomas D, Garcia-Manero G, Sasaki K, Borthakur G, Jain N, Konopleva M, Jacob J, Garris R, Cortes J, Kantarjian H. A Phase I/II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy as Frontline Therapy for Older Patients with ALL. Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Khan M, Cortes J, Qiao W, Alzubaidi M, Pierce S, Slack R, Ravandi F, Kantarjian H, Borthakur G. Outcomes of Relapsed Core Binding Factor Acute Myeloid Leukemia: an MD Anderson Experience. Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Short N, Jabbour E, O'Brien S, Sasaki K, Thomas D, Garcia-Manero G, Ravandi F, Borthakur, Jain N, Konopleva M, Jacob J, Garris R, Cortes J, Kantarjian H. A Phase II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Patients with Relapsed/Refractory ALL. Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Falchi L, Vitale C, Ciccone M, Hinojosa C, Keating M, Pemmaraju N, Wierda W, Borthakur G, Burger J, Ferrajoli A. Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-morbidities and/or Other Malignancies. Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Short, Garcia-Manero G, Montalban-Bravo G, Sasaki K, Sekeres M, Komrokji R, Steensma D, DeZern A, Roboz G, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian H, Jabbour E. A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS. Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Sasaki K, Kantarjian H, Thomas D, Ravandi F, Khouri M, Cortes J, Pemmaraju N, Kadia T, Short N, Issa G, Garris R, Moore G, Jeanis V, Garcia-Manero G, Borthakur G, Wierda W, O'Brien S, Jabbour E. Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study. Clinical Lymphoma, Myeloma and Leukemia 16(2), 2016. PMID: None.
Sanford D, Cortes JE, Ravandi F, Qiao W, Patel KP, Hoang T, Kadia T, Kantarjian HM, Borthakur G. Prognostic Impact of Kinase Mutations and Minimal Residual Disease in Core-Binding Factor Leukemia. Blood 126(23), 2015. PMID: None.
Abaza Y, Kantarjian HM, Borthakur G, Daver N, Ravandi F, Chihara D, Verstovsek S, Burger JA, Estrov Z, Ohanian M, Jabbour E, Cortes JE. An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). Blood 126(23), 2015. PMID: None.
Khan M, Kristy B, Kadia T, Ferrajoli A, Alvarado Y, Borthakur G, Pemmaraju N, Konopleva M, Garcia-Manero G, DiNardo C. Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial. Blood 126(23), 2015. PMID: None.
Short NJ, Kantarjian HM, Jabbour E, O'Brien S, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia T, Daver N, Borthakur G, Cortes JE, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission Is Not Prognostic for Relapse-Free or Overall Survival in Adult Patients with Acute Lymphoblastic Leukemia. Blood 126(23), 2015. PMID: None.
Ravandi R, Cortes JE, Garcia-Manero G, Estey E, Borthakur G, Jabbour EJ, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, Kornblau SM, Kadia T, Daver N, DiNardo C, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, Kantarjian HM. Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. Blood 126(23), 2015. PMID: None.
Dahl J, Kantarjian HM, Yilmaz M, Kadia T, Garcia-Manero G, Ravandi F, Borthakur G, Cortes JE, Ferrajoli A, Sasaki K, Chahoud J, Autry J, Garris R, Jabbour E. Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure. Blood 126(23), 2015. PMID: None.
Sasaki K, Jabbour E, Thomas DA, Khouri MR, Yilmaz M, Garcia-Manero G, Ravandi F, Borthakur G, Garris R, Gachimova E, Chahoud J, DiNardo C, Pemmaraju N, Cortes JE, Kantarjian HM, O'Brien S. Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. Blood 126(23), 2015. PMID: None.
Masarova L, Verstovsek S, Patel KP, Newberry KJ, Cortes JE, Borthakur G, Konopleva M, Estrov Z, Kantarjian HM. Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia and Polycythemia Vera: Results after a Median 7-Year Follow-up of a Phase 2 Study. Blood 126(23), 2015. PMID: None.
Navada SC, Silverman LR, Hearn KP, Odchimar-Reissig R, Demakos EP, Alvarado Y, Daver N, DiNardo C, Konopleva M, Borthakur G, Pemmaraju N, Kadia T, Fenaux P, Fruchtman S, Azarnia N, Garcia-Manero G. A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS). Blood 126(23), 2015. PMID: None.
Kadia T, Cortes JE, Jabbour EJ, Daver N, Pemmaraju N, Ravandi F, Jain N, Verstovsek S, DiNardo C, Alvarado Y, Ferrajoli A, Burger JA, Garcia-Manero G, Ohanian M, Konopleva M, Estrov Z, Wierda W, Brandt M, Fitch T, Borthakur G, Kantarjian HM. Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood 126(23), 2015. PMID: None.
Montalban-Bravo G, Kantarjian HM, Cortes JE, Ravandi F, Garcia-Manero G, Punit J, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Pierce S, O'Brien S, Jabbour E. Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL). Blood 126(23), 2015. PMID: None.
Jain P, Kantarjian HM, Jabbour E, Estrov Z, Borthakur G, Pemmaraju N, Kadia T, Daver N, Ravandi F, Verstovsek S, O'Brien S, Cortes JE. Outcomes of Patients with Chronic Phase CML Who Discontinued Ponatinib in the Frontline Setting. Blood 126(23), 2015. PMID: None.
Sasaki K, Kantarjian HM, Luthra R, Patel KP, Garcia-Manero G, Verstovsek S, Estey EH, Kadia T, Brandt M, Pierce S, Estrov Z, Ferrajoli A, Borthakur G, Cortes JE, Ravandi F. Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia. Blood 126(23), 2015. PMID: None.
Williams LA, Garcia-Gonzalez A, Ahaneku HO, Cortes JE, Garcia-Manero G, Kantarjian HM, Mendoza TR, Shi Q, Borthakur G, Burger JA, Jabbour EJ, Takahashi K, Lin HK, Limaye A, Cleeland CS. A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 126(23), 2015. PMID: None.
Kongtim P, Popat UR, Jimenez AM, Gabella S, El Fakih RO, Rondon G, Chen J, Bueso-Ramos CE, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian HM, Alousi AM, Hosing CM, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. Blood 126(23), 2015. PMID: None.
George BS, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Jain N, Pierce S, Takahashi K, Jabbour E, Cortes JE. Seven Year Follow up of Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib 400 Mg Twice Daily - a Single Center Study at MDACC. Blood 126(23), 2015. PMID: None.
Zhang H, Watanabe-Smith KM, Bottomly D, Wilmot B, McWeeney SK, Kantarjian HM, Ho J, Davis J, Pond B, Borthakur G, Ramachandran A, Cortes JE, Collins R, Tyner JW. Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib. Blood 126(23), 2015. PMID: None.
Birendra KC, Kantarjian HM, Garcia-Manero G, Daver N, Borthakur G, Konopleva M, Andreeff M, Chihara D, Kadia T, Bose P, Estrov Z, Pemmaraju N, Ravandi F, Cortes JE. Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood 126(23), 2015. PMID: None.
Tamamyan G, Borthakur G, Cortes JE, Ravandi F, Jabbour E, Daver N, Pemmaraju N, Ohanian, Kolomansky A, Todisco G, Shi C, Pierce S, Peng SA, Konopleva M, Kantarjian HM, Kadia T. Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission. Blood 126(23), 2015. PMID: None.
Kantarjian H, Jabbour E, Garcia-Manero G, Kadia T, DiNardo C, Daver N, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Plunkett W. Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia. Blood 126(23), 2015. PMID: None.
Akosile M, Pierce S, Brandt M, Verstovsek S, Borthakur G, Kantarjian H, Ravandi F, Wierda W, Garcia-Manero G, Daver N, Kadia T, Burger JA, Pemmaraju N, Jabbour E, Cortes JE. Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI). Blood 126(23), 2015. PMID: None.
Jain P, Kantarjian HM, Luthra R, Gonzalez GN, Jabbour E, Sasaki K, Guillermo Romo C, Patel KP, Kadia T, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes JE. Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities. Blood 126(23), 2015. PMID: None.
Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, Kantarjian HM. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood 126(23), 2015. PMID: None.
Borthakur G, Foran JM, Wang ES, Rakkar A, Minderman H, Burns J, Andreeff M, Tibes R. A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-Azacitadine. Blood 126(23), 2015. PMID: None.
Ohanian M, Kantarjian HM, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Lim M, Pierce S, O'Brien S, Somer BG, Tari A, Wierda W, Verstovsek S, Cortes JE. Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood 126(23), 2015. PMID: None.
Sasak K, O'Brien S, Ravandi F, Thomas DA, Moore HG, Cortes JE, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jeanis TV, Chahoud J, Borthakur G, Wierda W, Ferrajoli A, Kantarjian HM, Jabbour E. Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. Blood 126(23), 2015. PMID: None.
Montalban-Bravo G, Garcia-Manero G, Short NJ, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Konopleva M, Cortes JE, Kantarjian HM, Jabbour E. Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). Blood 126(23), 2015. PMID: None.
Jabbour E, O'Brien S, Sasaki K, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, Jain N, Konopleva M, Jacob J, Garris R, Cortes JE, Kantarjian HM. Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). Blood 126(23), 2015. PMID: None.
Koller PB, Sasaki K, Ravandi F, Garcia-Manero G, O'Brien S, Cortes JE, Kadia T, Borthakur G, Pemmaraju N, Daver N, Chahoud J, Pike A, Brandt M, Pierce S, Kantarjian HM, Jabbour E. Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. Blood 126(23), 2015. PMID: None.
Issa GC, Kantarjian HM, Jabbour E, Borthakur G, Verstovsek S, Pierce S, Wierda W, Ferrajoli A, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Ravandi F, DellaSala SE, Cortes JE. Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Blood 126(23), 2015. PMID: None.
Jain N, Lamb A, O'Brien SM, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen JL, Lin P, Pierce S, Thomas DA, Rytting M, Borthakur G, Kadia T, Cortes JE, Kantarjian HM, Khoury JD. Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults. Blood 126(23), 2015. PMID: None.
Daver N, Kantarjian HM, Garcia-Manero G, Jabbour E, Pemmaraju N, Vaughan K, Pierce S, Konopleva M, Kadia T, DiNardo C, Borthakur G, Cortes JE, Craig AR, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 126(23), 2015. PMID: None.
Vitale C, Ciccone M, Hinojosa C, Keating M, Pemmaraju N, O'Brien S, Wierda W, Thomas DA, Borthakur G, Ohanian M, Burger JA, Ferrajoli A. Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia. Blood 126(23), 2015. PMID: None.
Daver N, Garcia-Manero G, Cortes JE, Zhou L, Pierce S, Pemmaraju N, Jabbour E, DiNardo C, Kadia T, Borthakur G, Ravandi R, Konopleva M, Wynn F, Van Derbur S, Estrov Z, Kantarjian HM, Verstovsek S. 5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood 126(23), 2015. PMID: None.
Short NJ, Garcia-Manero G, Bravo GM, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian HM, Jabbour E. Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. Blood 126(23), 2015. PMID: None.
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen J, Wang Z, Ma W, Lee H, Orlowski R, Sarbassov DD, Neelapu SS, McDonnell TJ, Miranda RN, Wang M, Kantarjian HM, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response. Blood 126(23), 2015. PMID: None.
Ragon BK, Daver N, Garcia-Manero G, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents. Blood 126(23), 2015. PMID: None.
Ravandi F, Jeffrey JL, Jabbour EJ, Borthakur G, Kadia T, Faderl S, Pierce S, Brandt M, Wang SA, Konoplev S, Daver N, Pemmaraju N, Garcia-Manero G, Andreeff M, Konopleva M, Cortes JE, Kantarjian HM. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia. Blood 126(23), 2015. PMID: None.
Piya S, McQueen T, Mak D, Konopleva M, Zweidler-McKay P, Lu J, Qian Y, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Leukemias and Overcomes Stroma Mediated Resistance By Modulating Surface Expression of CXCR4. Blood 126(23), 2015. PMID: None.
Kadia T, Ravandi F, Daver N, Borthakur G, Cortes JE, Jabbour E, Kornblau SM, Verstovsek S, Wierda W, Burger JA, Estrov Z, DiNardo C, Dong XQ, Pemmaraju N, Ohanian M, Takahashi K, Hendrickson S, Kantarjian H, Garcia-Manero G. Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia. Blood 126(23), 2015. PMID: None.
Johnson A, Bailey AM, Shaw K, Cortes JE, Kadia T, Jabbour EJ, Ravandi F, Meric-Bernstam F, Kantarjian HM, Mills G, Borthakur G. Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib. Blood 126(23), 2015. PMID: None.
Borthakur G, Ofran Y, Nagler A, Rowe JM, Foran JM, Uy GL, DiPersio JF, Altman JK, Frankfurt O, Tallman MS, Peled A, Pereg Y, Vainstein A, Aharon A, Al Rawi A, McQueen T, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. Blood 126(23), 2015. PMID: None.
Jain N, Lamb A, O'Brien S, Konopleva M, Jabbour E, Ravandi F, Zhuang Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian H, Khoury J. Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) in Adults: A High-Risk Subtype. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Sasaki K, Kantarjian H, Luthra R, Patel K, Garcia-Manero G, Verstovsek S, Estey E, Kadia T, Brandt M, Pierce S, Estrov Z, Ferrajoli A, Borthakur G, Cortes J, Ravandi F. Correlation between peripheral blood and bone marrow samples for detection of PML-RARA fusion transcripts by quantitative PCR in patients with acute promyelocytic leukemia. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Abraham M, Al-Rawi A, Pereg Y, Klein S, Wald H, Eizenberg O, Bulvik B, Russovsky L, Vainstein A, Aharon A, McQueen T, Pemmaraju N, Cortes J, Peled A, Borthakur G, Andreeff M. BL-8040, a novel CXCR4 inhibitor, affects AML blasts survival and induces their terminal differentiation. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Yilmaz M, Sasaki K, Ravandi F, Cortes J, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Borthakur G, DiNardo C, Takahashi K, O'Brien S, Estrov Z, Pike A, Brandt M, Kantarjian H. Randomized Phase II Study of Clofarabine or Fludarabine Combined with Idarubicin and Cytarabine for the Treatment of Newly Diagnosed AML. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Tamamyan G, Dohner K, Borthakur G, Paschka P, Ravandi F, Gaidzik VI, Cortes J, Dohner H, Garcia-Manero G, Thol F, Jabbour E, Heuser M, Daver N, Pierce S, Ohanian M, Kolomansky A, Todisco G, Peng SA, Konopleva M, Kantarjian H, Ganser A, Kadia T, Schlenk RF. Updated definition of cure in adult patients with non-APL acute myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Vitale C, Ciccone M, Hinojosa C, Keating MJ, Pemmaraju N, O'Brien S, Wierda WG, Thomas DA, Borthakur G, Ohanian M, Burger JA, Ferrajoli A. Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Daver N, Cortes J, Zhou L, Pierce S, Pemmaraju N, Jabbour E, Borthakur G, Estrov Z, Wynn F, Van Derbur S, Garcia-Manero G, Kantarjian H, Verstovsek S. Combination Approach with Ruxolitinib and Azacytidine in Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Sasaki K, O'Brien S, Ravandi F, Thomas D, Moore HG, Cortes J, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jeanis V, Borthakur G, Wierda W, Ferrajoli A, Kantarjian H, Jabbour E. Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL). Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Sasaki K, O'Brien S, Thomas D, Khouri M, Yilmaz M, Garcia-Manero G, Ravandi F, Borthakur G, Garris R, Gachimova E, DiNardo C, Pemmaraju N, Cortes J, Kantarjian H, Jabbour E. Phase II study of hyper-CMAD with liposomal vincristine as frontline therapy for patients with acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo R, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen J, Wang Z, Ma W, Lee H, Orlowski R, Sarbassov D, Neelapu S, McDonnell T, Miranda R, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. First-in-class Anti-tumor Agent ONC201 Induces Apoptosis in Hematological Malignancies with Wild Type and Mutant p53. Clinical Lymphoma, Myeloma and Leukemia 15(2), 2015. PMID: None.
Pemmaraju N, Kantarjian HM, O’Brien S, Borthakur G, Ravandi F, Verstovsek S, Daver NG, Garcia-Manero G, DiNardo CD, Skinner J, Konopleva M, Pierce S, Jabbour E, Cortes JE. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Blood 124(21):4565, 2014. PMID: None.
Borthakur G, Nagler A, Ofran Y, Rowe J, Altman J, Frankfurt O, Tallman MS, Avivi I, Peled A, Pereg Y, Foley-Comer A, Russovsky L, Aharon A, McQueen T, Pemmaraju N, Bueso-Ramso CE, Cortes JE, Andreeff M. BL-804, a peptidic CXCR4 antagonist, induces leukemia cell death and specific leukemia cell mobilization in relapsed/refractory acute myeloid leukemia patients in an ongiong phase IIa clinical trial. Blood 124(21):950, 2014. PMID: None.
Borthakur G, Kantarjian H, O'Brien S, Garcia-Manero G, Jabbour E, Daver N, Kadia TM, Gborogen R, Konopleva M, Andreeff M, Ravandi F, Cortes J. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood 124(21):388, 2014. PMID: None.
DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Wei Y, Wierda W, Bueso-Ramos CE, Patel KP, Cortes JE, Ravandi F, Kantarjian H, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21):164, 2014. PMID: None.
Randhawa JK, Kantarjian HM, Borthakur G, Thompson PA, Konopleva M, Daver N, Pemmaraju N, Jabbour E, Kadia TM, Estrov Z, Ramachandran A, Paradela J, Andreeff M, Levis M, Ravandi F, Cortes JE. Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. Blood 124(21):389, 2014. PMID: None.
Jabbour E, Sasaki K, Daver N, Pemmaraju N, Jain N, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Faderl S, O’Brien S, Cortes J, Kantarjian H, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood 124(21):534, 2014. PMID: None.
Jabbour E, O’Brien S, Thomas DA, Sasaki K, Garcia-Manero G, Ravandi F, Borthakur G, York S, Garris R, Cortes JE, Kantarjian HM. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (≥60 years) with Acute Lymphoblastic Leukemia (ALL). Blood 124(21):794, 2014. PMID: None.
Piya S, Ruvolo VR, Ruvolo PP, Davis RE, Wang Z, McQueen T, Schober WD, Andreeff M, Borthakur G. Ablation of Autophagy-Related E Ligase Atg7 Primes Acute Myelogenous Leukemia Cells to Apoptosis, Sensitizes to Chemotherapy and Overcomes Stroma Mediated Protection. Blood 124(21):901, 2014. PMID: None.
Thomas DA, O’Brien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, Estrov Z, Garcia-Manero G, Burger JA, Wierda W, Konopleva M, Andreeff M, Kornblau SM, Verstovsek S, Borthakur G, Kadia T, Garris G, Pemmaraju N, Daver N, Jain N, Cortes JE, Kantarjian HM. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood 124(21):940, 2014. PMID: None.
Badar T, Kantarjian HM, Borthakur G, Garcia-Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Ravandi F, Cortes JE. Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade. Blood 124(21):949, 2014. PMID: None.
Shetty AV, Ravandi F, Alapati B, Borthakur G, Garcia-Manero G, Kadia TM, Wierda W, Estrov Z, Pierce S, O’Brien S, Kantarjian HM, Cortes JE. Survivorship in APL- Outcomes of Acute Promyelocytic Leukemia (APL) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years. Blood 124(21):954, 2014. PMID: None.
Kornblau SM, Hu CW, Qiu Y, Yoo SY, Nguyen TT, Kadia T, Borthakur G, Coombes K, Qutub AA. Heatshock Protein (HSP) Family Expression Is Dichotomous and Prognostic in Acute Myelogenous Leukemia (AML). Blood 124(21):1026, 2014. PMID: None.
Ravandi F, Jeffrey JL, Thomas DA, O’Brien S, Jabbour E, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Kadia T, Jain N, Wang SA, Kebriaei P, Champlin RE, Estrov Z, Cortes JE, Kantarjian HM. Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood 124(21):1079, 2014. PMID: None.
Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Pierce SR, Kantarjian HM, Cortes JE. Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups. Blood 124(21):1801, 2014. PMID: None.
Sasaki K, Jabbour E, Pemmaraju N, Daver NG, Kadia TM, DiNardo CD, Pierce S, Borthakur G, Kantarjian HM, Garcia-Manero G. Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). Blood 124(21):1922, 2014. PMID: None.
Duque AD, Cabrero M, Ravandi F, Pemmaraju N, Borthakur G, Kantarjian HM, Cortes JE, Kadia TM, Daver NG, Jabbour E, Garcia-Manero G, Sasaki K. Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. Blood 124(21):1924, 2014. PMID: None.
Randhawa JK, Jabbar KJ, Kadia T, Borthakur G, Pemmaraju N, Daver N, Kantarjian HM, Cortes JE, Hearn K, Bueso-Ramos CE, Garcia-Manero G. Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate- (Int-)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation. Blood 124(21):1930, 2014. PMID: None.
Sasaki K, Jabbour E, Kantarjian HM, Cortes JE, Garcia-Manero G, Borthakur G, Pierce SR, Pemmaraju N, O’Brien S, Ravandi F. Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. Blood 124(21):2273, 2014. PMID: None.
George B, Jabbour E, Cabrero M, Jain N, Daver N, Ravandi F, Borthakur G, Bohannan Z, Cortes JE, Keating M, O’Brien S, Kantarjian HM, Garcia-Manero G. Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents. Blood 124(21):2278, 2014. PMID: None.
Jabbour E, Kantarjian HM, Thomas DA, Sasaki K, Ravandi F, Cortes JE, Pemmaraju N, Kadia T, Garris R, Garcia-Manero G, Borthakur G, Wierda WG, O’Brien S. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood 124(21):2289, 2014. PMID: None.
Hoang T, Qiao W, Cortes JE, Patel P, Ravandi F, Kadia TM, Brandt M, Luthra R, Kantarjian HM, Borthakur G. Quantitative Assessment of Translocation Transcript Ratio Predicts for Relapse Free Survival Among Patients with Core Binding Factor Acute Myeloid Leukemia. Blood 124(21):2354, 2014. PMID: None.
Oran B, Champlin RE, Cortes JE, de Lima M, Wang X, H-C C, Ravandi F, Ciurea SO, Kantarjian HM, Borthakur G. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation. Blood 124(21):2531, 2014. PMID: None.
Daver N, Kantarjian HM, O’Brien S, Jabbour E, Pierce S, Lim M, Borthakur G, Pemmaraju N, Konopleva M, DiNardo CD, Ravandi F, Garcia-Manero G, Cortes JE. Frequency and Impact of Molecular Response’s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood 124(21):3156, 2014. PMID: None.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Daver N, Verstovsek S. Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF). Blood 124(21):3186, 2014. PMID: None.
Navada SC, Garcia-Manero G, Wilhelm F, Hearn K, Odchimar-Reissig R, Demakos EP, Alvarado Y, Daver N, DiNardo CD, Konopleva M, Borthakur G, Azarnia N, Silverman LR. A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Blood 124(21):3252, 2014. PMID: None.
Borthakur G, Foran JM, Wang ES, Rakkar A, Hager S, Frey NV, Andreeff M, Garcia-Manero G, Kadia TM, Carter BZ, Minderman H, Russell L, Tibes R. A Phase b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis. Blood 124(21):3263, 2014. PMID: None.
Garcia-Manero G, Huang X, Cabrero M, DiNardo CD, Pemmaraju N, Daver NG, Borthakur G, Wierda WG, Kadia T, Alvarado Y, Cortes JE, Jain N, Ravandi F, Jabbour E, Brandt M, Sneed T, Sukholutsky V, Pierce S, Bohannan Z, Kantarjian HM. A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. Blood 124(21):3277, 2014. PMID: None.
Kadia T, Borthakur G, Ferrajoli A, Daver N, Jabbour E, Pemmaraju N, Verstovsek S, Burger JA, Wierda WG, Konopleva M, DiNardo CD, Jain N, Brandt M, Tuttle C, Wang X, Ravandi F, Garcia-Manero G, Cortes JE, Kantarjian HM. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood 124(21):3671, 2014. PMID: None.
Duque AD, Randhawa J, Kantarjian HM, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Gandhi V, Borthakur G, Cortes JE. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML. Blood 124(21):3731, 2014. PMID: None.
Jain P, Kantarjian HM, Jabbour E, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau SM, Ravandi F, O’Brien S, Cortes JE. Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 124(21):4535, 2014. PMID: None.
Sasaki K, Rodriguez-Rivera II, Kantarjian HM, O’Brien S, Jabbour E, Borthakur G, Ravandi F, Burke MJ, Zweidler-McKay PA, Cortes JE. Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Blood 124(21):4538, 2014. PMID: None.
George B, Lori W, Shi Q, Badar T, O’Brien S, Jabbour E, Garcia-Manero G, Jain N, Ravandi F, Borthakur G, Wierda W, Cleeland CS, Kantarjian HM, Cortes JE. Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase. Blood 124(21):4548, 2014. PMID: None.
Badar T, Thompson PA, George B, Daver N, Borthakur G, Cortes JE, Konopleva M, Kadia TM, Bohannan Z, Pierce S, Jabbour E, Ravandi F, Kantarjian HM, Patel KP, Luthra R, Sukholutsky V, Garcia-Manero G. Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications. Blood 124(21):4631, 2014. PMID: None.
Jabbour E, Sasaki K, Daver N, Pemmaraju N, DiNardo CD, Kadia T, Miller D, Sukholutsky V, Huang X, Borthakur G, Estrov Z, Kantarjian HM, Garcia-Manero G. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate--Risk Myelodysplastic Syndromes (MDS). Blood 124(21):4640, 2014. PMID: None.
Jabbour E, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Gail RJ, Daver NG, Pemmaraju N, Kadia T, DiNardo CD, Wang X, Nogueras-Gonzalez G, Borthakur G, Estrov Z, Kantarjian HM, Garcia-Manero G. Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. Blood 124(21):4641, 2014. PMID: None.
Patel P, Routbort M, Noguera-Gonzalez G, Kantarjian HM, Jabbour E, Borthakur G, DiNardo CD, Estrov Z, Daver NG, Wierda WG, Jain N, O’Brien S, Konopleva M, Cortes JE, Pemmaraju N, Alvarado Y, Bueso-Ramos CE, Luthra R, Singh R, Pierce S, Medeiros LJ, Bohannan Z, Huang X, Garcia-Manero G. Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 45 Patients with MDS: Impact on Clinical Outcomes. Blood 124(21):4658, 2014. PMID: None.
Cabrero M, Jabbour E, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia T, Pemmaraju N, Kantarjian HM, Garcia-Manero G. Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. Blood 124(21):4664, 2014. PMID: None.
Cabrero M, Garcia-Manero G, Sasaki K, Daver N, Borthakur G, DiNardo CD, Cortes J, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia TM, Pemmaraju N, Oran B, Champlin RE, Kantarjian H, Jabbour E. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood 124(21):4666, 2014. PMID: None.
Andreeff M, Borthakur G, Zeng Z, Kelly MA, R-Y W, McQueen TJ, Qiu Y, Mak D, Burger JA, Daver NG, Pemmaraju N, Kadia TM, Jabbour E, Pierce S, Ravandi F, Garcia-Manero G, O'Brien SM, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. J Clin Oncol 32(15S), 2014. PMID: None.
Shetty A, Bueso-Ramos CE, Cortes JE, Borthakur G, Pierce S, Kadia TM, Daver NG, Thomas DA, Kantarjian HM, Ravandi F. Outcomes of patients (pts) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with bone marrow necrosis (BMN) at initial diagnosis. J Clin Oncol 32(15S), 2014. PMID: None.
Baljevic M, Kantarjian HM, Jyothsna D, Thomas DA, Rytting ME, Borthakur G, Burger JA, Ravandi F, Jabbour E, Konopleva M, Pierce S, Brandt M, O'Brien SM, Cortes JE. Central nervous system relapse in adults with acute lymphoblastic leukemia. J Clin Oncol 32(15S), 2014. PMID: None.
Shetty A, Cortes JE, Ravandi F, Kadia TM, Garcia-Manero G, Pemmaraju N, Pierce S, Kantarjian HM, Borthakur G. Hyperdiploidy in AML: Outcomes of acute myelogenous leukemia (AML) patients (pts) with a hyperdiploid karyotype. J Clin Oncol 32(15S), 2014. PMID: None.
Ohanian M, Kantarjian HM, Rozovski U, Loghavi S, Huh Y, Abruzzo L, Garcia-Manero G, Ravandi F, Borthakur G, Stingo F, Hu P, Nguyen MH, Fox PS, Medeiros LJ, Estrov Z, Bueso-Ramos CE, Cortes JE. Clinical significance of MYC expression in acute myeloid leukemia. J Clin Oncol 32(15S), 2014. PMID: None.
Takahashi K, Kantarjian HM, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, Dinardo CD, Jabbour E, Konopleva M, Andreeff M, Cortes JE. Propensity score matched comparison of intermediate-intensity chemotherapy induction versus intensive chemotherapy induction in elderly patients (age >= 60) with acute myeloid leukemia (AML). J Clin Oncology 32(15S), 2014. PMID: None.
Daver NG, Kantarjian HM, Pierce S, Brandt M, Dinardo CD, Pemmaraju N, Vaughan K, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Cortes JE, Craig A, Ravandi F. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). J Clin Oncol 32(15S), 2014. PMID: None.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Daver NG, Verstovsek S. Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase. J Clin Oncol 32(15S), 2014. PMID: None.
Jabbour E, O'Brien SM, Jain N, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, York S, Garris R, Cortes JE, Kantarjian HM. Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL). J Clin Oncol 32(15S), 2014. PMID: None.
Kadia TM, Cortes JE, Borthakur G, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Ravandi F, Pemmaraju N, Daver NG, Konopleva M, Wang X, Kantarjian HM. Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML. J Clin Oncol 32(15S), 2014. PMID: None.
O'Brien SM, Jabbour E, Thomas DA, Ravandi F, Cortes JE, Pemmaraju N, Kadia TM, Garris R, Jeanis V, Garcia-Manero G, Borthakur G, Wierda WG, Kantarjian HM. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). J Clin Oncol 32(15S), 2014. PMID: None.
Berlier W, Aguera K, Gallix F, Gay F, Borthakur G, Godfrin Y. Potential of asparagine depletion for the treatment of bladder cancer and other urological tumors. Proc Am Assoc Cancer Res 2014 Annual Meeting, 2014. PMID: None.
Daver N, Kantarjian HM, Garcia-Manero G, Pemmaraju N, Kadia T, DiNardo C, Jain N, Borthakur G, Cortes J, Adam C, Ravandi F. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Proc Am Assoc Cancer Res 2014 Annual Meeting, 2014. PMID: None.
Jain N, Keating MJ, Burger JA, Ferrajoli A, Borthakur G, Koller C, Verstovsek S, O'Brien S, Wierda WG. A Phase II Trial Of Eltrombopag For Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia. Blood 122(21), 2013. PMID: None.
Jain P, Kantarjian HM, Romo CG, Quintas-Cardama A, Jabbour E, Cardenas-Turanzas M, Pierce S, Liboon MJ, Gachimova E, Kadia TM, Borthakur G, Ravandi F, O'Brien S, Cortes JE. Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution. Blood 122(21), 2013. PMID: None.
Strati P, Kantarjian HM, Nazha A, Borthakur G, Daver NG, Kadia TM, Estrov Z, Garcia-Manero G, Rajkhowa T, Ravandi F, Durand M, Levis M, Cortes JE. Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 122(21), 2013. PMID: None.
Nazha A, Kantarjian HM, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia TM, Ferrajoli A, Konopleva M, Borthakur G, Burger JA, Feliu J, Faderl SH. Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients. Blood 122(21), 2013. PMID: None.
Konopleva M, Handisides DR, Richie MA, Benito JM, Borthakur G, Jabbour EJ, Faderl SH, Cortes JE, Kroll S, Andreeff M, Kantarjian HM, Thomas DA. A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias. Blood 122(21), 2013. PMID: None.
Wang AC, McCue D, Ravand F, Borthakur G, Thomas DA, Faderl S, Wierda WG, Cortes JE. Outcomes Of Repeated Administration Of Rasburicase In Recurrent Cycles For Patients With Leukemia. Blood 122(21), 2013. PMID: None.
Badar T, Mattiuzzi G, Kantarjian HM, Ravandi F, Daver NG, Garcia-Manero G, Kadia TM, Jabbour EJ, Borthakur G, Cortes JE. Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine. Blood 122(21), 2013. PMID: None.
Shetty A, Kantarjian HM, Champlin RE, Borthakur G, Badar T, Garcia-Manero G, Andersson BS, Oran B, Ciurea SO, Konopleva M, Andreeff M, Kornblau SM, Wierda WG, Pierce S, Ravandi F, Cortes JE. Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood 122(21), 2013. PMID: None.
Williams LA, Ault PS, Kantarjian HM, Garcia-Manero G, Quintas-Cardama A, Borthakur G, Faderl SH, Jabbour EJ, Cleeland CS, Cortes JE. Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 122(21), 2013. PMID: None.
Nazha A, Kantarjian HM, Jabbour E, DiNardo CD, Borthakur G, MD, Daver NG, Faderl SH, Ning J, Qiao W, Ravandi F, Kadia TM, Pierce SR, Cortes JE, Garcia-Manero G. Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. Blood 122(21), 2013. PMID: None.
Garcia-Manero G, Kadia TM, Daver N, Jabbour J, Jain N, Cortes JE, Estrov Z, Borthakur G, Dong XQ, Kumar VJ, Kantarjian HM. A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS). Blood 122(21), 2013. PMID: None.
Benjamini O, Kantarjian HM, O'Brien S, Thomas DA, Ravandi F, Jain P, Pierce S, Borthakur G, Kadia TM, Jabbour E, Estrov Z, Luthra R, Cortes JE. Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML. Blood 122(21), 2013. PMID: None.
Jain P, Kantarjian HM, Romo CG, Luthra R, Quintas-Cardama A, Jabbour E, Kadia TM, Borthakur G Cardenas-Turanzas M, Pierce S, Ravandi F, O'Brien S, Cortes JE. BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center. Blood 122(21), 2013. PMID: None.
Chae YK, Kantarjian HM, Baljevic M, Quintás-Cardama A, Borthakur G, Kadia TM, O'Brien S, Romo CG, Pierce SR, Jabbour E, Cortes JE. Adverse Prognosis Of Extramedullary Disease In Patients With Chronic Myeloid Leukemia (CML) In The Tyrosine Kinase Inhibitor (TKI) Era: a Cohort Study Of 283 Blastic Phase CML Patients. Blood 122(21), 2013. PMID: None.
Kadia TM, Daver N, Virani F, Jabbour E, Pierce S, Pemmaraju N, Quintas-Cardama A, Borthakur G, O'Brien S, Kantarjian HM, Cortes JE. Incidence, Clinical Characteristics, and Prognostic Significance Of Chromosome 3q Abnormalities In Patients With CML Blast Phase. Blood 122(21), 2013. PMID: None.
DiNardo CD, Kantarjian HM, Ravandi F, Konopleva M, Kadia TM, Borthakur G, Daver NG, Durand M, Rivera S, Quintás-Cardama A, Garcia-Manero G, Cortes JE. A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS. Blood 122(21), 2013. PMID: None.
Ravandi F, Othus M, Faderl SH, Stirewalt DL, Pierce SR, Borthakur G, Godwin J, Anderson JE, Petersdorf S, Cortes JE, Ostronoff F, Pogosova-Agadijanyan E, Appelbaum FR, Kantarjian HM, Estey EH. Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report. Blood 122(21), 2013. PMID: None.
Takahashi K, Jabbour E, Ravandi F, Borthakur G, Cortes JE, Kadia TM, O'Brien S, Thomas DA, Faderl S, Bass J, Wierda WG, Daver N, DiNardo CD, Pierce S, Brandt M, Kantarjian HM, Garcia-Manero G. A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. Blood 122(21), 2013. PMID: None.
Ohanian M, Kantarjian HM, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, O'Brien S, Quintas-Cardama A, Somer BG, Tari A, Verstovsek S, Wierda WG, Cortes JE. Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood 122(21), 2013. PMID: None.
Jabbour E, Kantarjian H, Thomas DA, Ravandi F, Cortes JE, Faderl SH, Pemmaraju N, Kadia TM, Garris R, Prescott H, Garcia-Manero G, Borthakur G, Wierda WG, O'Brien S. Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood 122(21), 2013. PMID: None.
Shah SS, Kantarjian HM, Ravandi F, O'Brien S, Garcia-Manero G, Andreeff M, Marina Konopleva M, Jabbour E, Pierce SR, Borthakur G, Cortes JE. Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy. Blood 122(21), 2013. PMID: None.
Baljevic M, Kantarjian HM, Thomas DA, Rytting M, Dasarathula J, Borthakur G, Burger JA, Ravandi F, Jabbour E, Konopleva M, Pierce S, Brandt M, O'Brien S, Cortes JE. Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement. Blood 122(21), 2013. PMID: None.
Ruvolo PP, R-Y W, Ruvolo VR, Jacamo R, McQueen T, Borthakur G, Qiu Y, Coombes KR, Zhang N, Shpall EJ, Champlin RE, Garzon R, Marcucci G, Croce CM, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation Of GSK3β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. Blood 122(21), 2013. PMID: None.
Daver NG, Naqvi K, Kadia TM, DiNardo CD, Ravandi F, Nazha A, Borthakur G, Pemmaraju N, Brandt M, O'Brien S, Garcia-Manero G, Pierce SR, Jabbour E, Cortes JE, Kantarjian HM. Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age. Blood 122(21), 2013. PMID: None.
Nazha A, Garcia-Manero G, Kantarjian HM, Ravandi F, Borthakur G, Kadia TM, Jabbour E, Pemmaraju N, Daver NG, DiNardo CD, Miller D, Faderl SH. Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. Blood 122(21), 2013. PMID: None.
Sasaki K, Kantarjian HM, Jabbour E, Quintas-Cardama A, Pierce S, Borthakur G, Kadia TM, Pemmaraju N, Ferrajoli A, O'Brien S, Cortes JE. Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction. Blood 122(21), 2013. PMID: None.
Yilmaz M, Kantarjian HM, Quintas-Cardama A, O'Brien S, Burger JA, Ferrajoli A, Borthakur GRavandi F, Pierce S, Jabbour E, Cortes JE. Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI). Blood 122(21), 2013. PMID: None.
Cortes JE, Borthakur G, Pemmaraju N, Daver N, Quintas-Cardama A, Ravandi F, Gachimova E, Estrov Z, Jabbour J, O'Brien S, Kantarjian HM. Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP). Blood 122(21), 2013. PMID: None.
Pan R, Debose L, Benito JM, Golfman LS, Zweidler-McKay PA, Han L, Harutyunyan KG, Mu H, Ruvolo VR, Park E, Muschen M, Leverson J, Borthakur G, Kantarjian HM, Ruvolo PP, Andreeff M, Konopleva M. BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia. Blood 122(21), 2013. PMID: None.
Nazha A, Kantarjian HM, Ravandi F, Xuelin H, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TP, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brandt M, Faderl SH. Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 122(21), 2013. PMID: None.
Jain N, O'Brien S, Thomas DA, Jabbour E, Faderl S, Ravandi F, Borthakur G, York S, Garris R, Cortes JE, Kantarjian HM. Inotuzumab Ozogamicin In Combination With Low-Intensity Chemotherapy (Mini-hyper-CVD) As Frontline Therapy For Older Patients (≥60 years) With Acute Lymphoblastic Leukemia (ALL). Blood 122(21), 2013. PMID: None.
Rytting ME, Thomas DA, O'Brien S, Schroeder K, Garris R, Cortes JE, Ravandi F, Pemmaraju N, Daver N, Faderl SH, Franklin ARK, Borthakur G, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL). Blood 122(21), 2013. PMID: None.
Kornblau SM, Hu CW, Yoo SY, Qiu Y, Zhang N, Borthakur G, Daver NG, Qutub AA, Coombes KR. Classification Of Acute Myelogenous Leukemia (AML) Based On Functionally Related Proteins Groups. Blood 122(21), 2013. PMID: None.
Kantarjian HM, Jabbour E, Yee K, Kropf P, O'Connell C, Stock W, Tibes R, Rizzieri D, Walsh K, Griffiths EA, Roboz GJ, Savona M, Ervin T, Podoltsev NA, Pemmaraju N, Daver N, Garcia-Manero G, Borthakur G, Wierda WG, Ravandi F, Cortes JE, Brandwein JM, Odenike O, Feldman EJ, Chung W, Naim S, Choy G, Taverna P, Hao Y, Dimitrov G, Azab M, J-P I. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). Blood 122(21), 2013. PMID: None.
Takahashi K, Garcia-Manero G, Cortes J, Ravandi F, Faderl S, O'Brien S, Kantarjian HM, Borthakur G. Fludarabine and Cytarabine Based Induction Therapy Is Associated With High Response Rate and Durable Remission With Low Treatment Related Mortality In Elderly Patients With Core-Binding Factor AML (CBF-AML). Blood 122(21), 2013. PMID: None.
Borthakur G, Verstovsek S, Jabbour E, Matthews J, Kadia TM, Daver N, Kantarjian HM, Cortes JE. Eltrombopag For The Management Of Thrombocytopenia Associated With Tyrosine Kinase Therapy In Patients With Chronic Myeloid Leukemia and Myelofibrosis. Blood 122(21), 2013. PMID: None.
Borthakur G, Cortes JE, Ravandi F, Gonzalez GN, Luthra R, Jabbour E, Garcia-Manero G, Kadia TM, Bass J, Brandt M, Kantarjian HM. Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia. Blood 122(21), 2013. PMID: None.
Zhang W, Borthakur G, Gao C, Chen Y, Lan YS, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M. Study Of Activity Of E6201, a Dual FLT3 and MEK Inhibitor, In Acute Myelogenous Leukemia With FLT3 Or RAS Mutation. Blood 122(21), 2013. PMID: None.
Konopleva MY, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Ruvolo P, Huang X, Kadia T, Feliu J, Burger JA, Andreeff M, Liu W, Kornblau SM, Baggerly K, Estey E, Hagop Kantarjian H. Phase II study of the oral AKT inhibitor, MK-2206, for acute myeloid leukemia (AML) in second relapse. Proc Am Assoc Cancer Res 2013 Annual Meeting, 2013. PMID: None.
Borthakur G, Duvvuri S, Lan Y, Ruvolo V, Ruvolo P, Qiu Y, Konopleva M, Kornblau S, Andreeff M. Targeting autophagy-related E1 ligase Atg7 increases chemosensitivity in acute myelogenous leukemia cells and overcomes stroma mediated resistance. Proc Am Assoc Cancer Res 2013 Annual Meeting, 2013. PMID: None.
Pemmaraju N, Kantarjian HM, Jabbour EJ, Quintás-Cardama A, Borthakur G, Burton EM, Dellasala SE, Pierce SA, Kornblau SM, Verstovsek S, O'Brien S, Cortes JE. Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI). Blood 120(21), 2012. PMID: None.
Nazha A, Ravandi F, Kantarjian HM, Huang X, Choi S, Garcia-Manero G, Jabbour EJ, Borthakur G, Kadia TM, Konopleva MK, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Estrov Z, Daver NG, Pemmaraju N, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 120(21), 2012. PMID: None.
Nazha A, Kantarjian HM, Cortes JE, Faderl S, Pierce SA, Daver NG, Pemmaraju N, Ravandi F, Borthakur G, Kadia TM, Quintas-Cardama A, Garcia-Manero G. Outcome of Patients with Myelodysplastic Syndrome (MDS) with Bone Marrow (BM) Blasts Between 10 to 30% Treated with Hypomethylating Agents Versus Intensive Chemotherapy. Blood 120(21), 2012. PMID: None.
Ravandi F, Kadia TM, Borthakur G, Wierda WG, Goldberg SL, Wetzler M, Venugopal P, Seiter K, Chiao J, Kantarjian HM. Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood 120(21), 2012. PMID: None.
Takahashi K, Kantarjian HM, Abruzzo LV, Borthakur G, Garcia-Manero G, O'Brien S, Faderl S, Luthra R, Wierda WG, Ferrajoli A, Pierce SA, Ravandi F, Cortes JE. Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis. Blood 120(21), 2012. PMID: None.
Kazmi SM, Kantarjian HM, Tran KM, Cortes JE, Ravandi F, Borthakur G, Jabbour EJ, Faderl S, Garcia-Manero G, Kadia TM, Daver N, Pierce SA, Nazha A, Quintas-Cardama A, Pemmaraju N. Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia. Blood 120(21), 2012. PMID: None.
Pemmaraju N, Kantarjian HM, Tran KM, Kazmi SM, Kadia TM, Borthakur G, Verstovsek S, O'Brien S, Garcia-Manero G, Estrov Z, Faderl S, Ravandi F, Pierce SA, Cortes JE, Quintas-Cardama A. Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML). Blood 120(21), 2012. PMID: None.
Faderl S, Garcia-Manero G, Ravandi F, Cortes JE, Estrov Z, Borthakur G, O'Brien S, Kadia TM, Konopleva M, Daver N, Brandt M, Schroeder H, Kantarjian HM. A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily x 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood 120(21), 2012. PMID: None.
Quintás-Cardama A, Kantarjian HM, Ravandi F, Foudray C, Pemmaraju N, Kadia TM, Borthakur G, Daver NG, Faderl S, Jabbour E, Cortes JE, Garcia-Manero G. Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. Blood 120(21), 2012. PMID: None.
Ravandi F, Patel KP, Luthra R, Pierce SA, Borthakur G, Jabbour EJ, Kadia TM, Pemmaraju N, Daver N, Konopleva M, Faderl S, Garcia-Manero G, Cortes JE, Kantarjian HM. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors). Blood 120(21), 2012. PMID: None.
Jain P, Kantarjian HM, Faderl S, Patel KP, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia TM, Daver NG, Nazha A, Luthra R, Pierce SA, Cortes JE, Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. Blood 120(21), 2012. PMID: None.
Nazha A, Kantarjian HM, Jain P, Jabbour EJ, Quintás-Cardama A, Luthra R, Abruzzo LV, Borthakur G, Ravandi F, Pierce SA, O'Brien S, Cortes JE. Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood 120(21), 2012. PMID: None.
Strati P, Kantarjian HM, Thomas DA, O'Brien SM, Jabbour EJ, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes JE. Hypercvad Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia. Blood 120(21), 2012. PMID: None.
Romo CG, Kantarjian HM, Luthra R, Quintás-Cardama A, Jabbour EJ, Borthakur G, Kadia TM, Ravandi F, Pemmaraju N, Pierce SA, O'Brien S, Cortes JE. Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts. Blood 120(21), 2012. PMID: None.
Benjamini O, Kantarjian HM, Rios MB, Jabbour E, O'Brien S, Jain P, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintás-Cardama A, Cortes JE. Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience. Blood 120(21), 2012. PMID: None.
Kwang Chae Y, Kantarjian HM, Romo CG, Whitaker C, Jabbour EJ, O'Brien S, Borthakur G, Ravandi F, Thomas DA, Pierce SA, Quintás-Cardama A, Cortes JE. Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Blood 120(21), 2012. PMID: None.
Takahashi K, Pemmaraju N, Beran M, Quintás-Cardama A, Cortes JE, Ravandi F, Faderl S, Verstovsek S, Kadia TM, Borthakur G, Jabbour EJ, Daver N, Estrov Z, Pierce SA, Garcia-Manero G. Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). Blood 120(21), 2012. PMID: None.
Takahashi K, Jabbour EJ, Wang X, Ghanem H, Pemmaraju N, Ravandi F, Cortes JE, Faderl S, Kadia TM, Borthakur G, Wierda WG, Pierce SA, Estrov Z, Kantarjian HM, Garcia-Manero G. Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. Blood 120(21), 2012. PMID: None.
Yilmaz M, Kantarjian HM, Jabbour EJ, O'Brien SM, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger JA, Pierce SA, Quintás-Cardama A, Cortes JE. The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution. Blood 120(21), 2012. PMID: None.
Daver N, Kantarjian HM, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, O'Brien S, Ferrajoli A, Verstovsek S, Kadia TM, Jabbour EJ, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce SA, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood 120(21), 2012. PMID: None.
Cortes JE, Kantarjian HM, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis MJ. Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status. Blood 120(21), 2012. PMID: None.
Kadia TM, Cortes JE, Thomas D, Ravandi F, Pemmaraju N, Daver N, Quintás-Cardama A, Baccus M, Garris R, Jabbour EJ, Kantarjian HM, Borthakur G. A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL). Blood 120(21), 2012. PMID: None.
Jabbour EJ, Kantarjian HM, Cameron Y, Ravandi F, Cortes JE, Garcia-Manero G, Ghanem H, Kadia TM, Faderl S, O'Brien S, Mathisen MS, Brandt M, Pemmaraju N, Thomas DA, Bass J, Borthakur G. Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen. Blood 120(21), 2012. PMID: None.
Andreeff M, Zeng Z, Kelly MA, Wang R, McQueen T, Duvvuri S, Nowshad G, Borthakur G, Burger JA, Kadia TM, Jabbour E, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients. Blood 120(21), 2012. PMID: None.
Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Roland W, Olin R, Raza A, Giagounidis A, Ottmann O, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman J, Wu Y, Liu Y, Schramek D, Zhu J, Wissel P, Kantarjian H. Phase I/II trial of the MEK1/2 inhibitor trametinib (GSK1120212) in relapsed/refractory myeloid malignancies: Evidence of activity in patients with RAS mutation-positive disease. Blood 120(21), 2012. PMID: None.
Nazha A, Kantarjian HM, Borthakur G, Garcia-Manero G, Kadia TM, Faderl S, Estrov Z, Jabbour E, Quintas-Cardama A, Ravandi F, Cortes JE. A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 120(21), 2012. PMID: None.
Mathisen MS, Kantarjian HM, Jabbour EJ, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintas-Cardama A. Infectious Complications in Patients with Relapsed Acute Myeloid Leukemia (AML) Receiving Clofarabine Versus Fludarabine-Containing Salvage Chemotherapy Regimens. Blood 120(21), 2012. PMID: None.
Tran KM, Kantarjian HM, Kazmi SM, Quintás-Cardama A, Cortes JE, Estrov Z, Ohanian M, Kadia TM, Borthakur G, Ravandi F, Pemmaraju N. Cytogenetic and Molecular Characterization of Genitourinary Extramedullary Disease in Acute Myeloid Leukemia. Blood 120(21), 2012. PMID: None.
Pemmaraju N, Kantarjian HM, O'Brien S, Kadia TM, Cortes JE, Borthakur G, Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Quintas-Cardama A, Jabbour EJ, Koller CA, Dellasala SE, Pierce SA, Burton EM, Verstovsek S. Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. Blood 120(21), 2012. PMID: None.
Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Kadia TM, Ravandi F, Andreeff M, Cortes JE, Hoberman K, Szarek M, Rowinsky E, Bergstein I, Kantarjian HM, Frankel AE. SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. Blood 120(21), 2012. PMID: None.
Arana Yi CY, Cortes J, Faderl S, Garcia-Manero G, Konopleva M, Estrov Z, O'Brien S, Borthakur G, Levis MJ, Thomas DA, Pierce SA, Brandt M, Pratz KW, Luthra R, Andreeff M, Kantarjian HM, Ravandi F. Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. Blood 120(21), 2012. PMID: None.
Ravandi F, Alattar ML, Levis MJ, Garcia-Manero G, Richie MA, Daver NG, Faderl S, Andreeff M, Borthakur G, Burger JA, Kadia TM, Grunwald MR, Dellasala SE, Cortes JE, Kantarjian HM. Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood 120(21), 2012. PMID: None.
Falchi L, Kantarjian HM, Quintas-Cardama A, O'Brien S, Jabbour EJ, Ravandi F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia. Blood 120(21), 2012. PMID: None.
Ghanem H, Kantarjian HM, Ravandi F, Cortes JE, Pemmaraju N, Faderl S, Dellasala SE, O'Brien SM, Burger JA, Borthakur G, Kadia TM, Quintás-Cardama A, Brandt M, Pierce SA, Garcia-Manero G, Jabbour EJ. Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP). Blood 120(21), 2012. PMID: None.
Arana Yi CY, Kantarjian HM, Garcia-Manero G, Wierda WG, Borthakur G, Quintas-Cardama A, Konopleva M, Faderl S, Pierce SA, Andreeff M, Ravandi F, Cortes JE. Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies. Blood 120(21), 2012. PMID: None.
Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Borthakur G, Burger JA, Verstovsek S, Ferrajoli A, Wierda WG, Kornblau SM, Andreeff M, Garris R, Wang SA, Estrov Z, Cortes JE, O'Brien S. Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. Blood 120(21), 2012. PMID: None.
Jabbour EJ, Daver NG, Dong XQ, Kadia TM, O'Brien S, Cortes JE, Ravandi F, Pemmaraju N, Ghanem H, Faderl S, Borthakur G, Kantarjian HM, Garcia-Manero G. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. Blood 120(21), 2012. PMID: None.
Benton CB, Qiu P, Ravandi F, Kantarjian HM, Garcia-Manero G, Pierce SA, Borthakur G, Konopleva M, Cortes JE, Andreeff M, Quintás-Cardama A. Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy. Blood 120(21), 2012. PMID: None.
Kornblau SM, Pierce A, Meyer S, Ravandi F, Borthakur G, Coombes KR, Zhang N, Whetton A. Transglutaminase2 Expression in Acute Myeloid Leukemia: Association with Adhesion Molecule Expression and Leukemic Blast Motility. Blood 120(21), 2012. PMID: None.
Alattar ML, Kantarjian HM, Cortes JE, Kadia TM, Borthakur G, Ohanian M, Ravandi F, Garcia-Manero G, Quintas-Cardamas A, Jabbour E, Daver N, Pierce SA, Brandt M, Faderl S, Pemmaraju N. Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 120(21), 2012. PMID: None.
Strati P, Kantarjian HM, Cortes JE, Ravandi F, Pemmaraju N, Garcia-Manero G, Kadia TM, Jabbour EJ, Nazha A, Borthakur G, Faderl S, Quintás-Cardama A, Daver NG. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. Blood 120(21), 2012. PMID: None.
Jain P, Kantarjian HM, Thomas DA, Ravandi F, Kadia TM, Burger JA, Borthakur G, Cortes JE, Daver N, Jabbour EJ, Koller CA, Konopleva M, Pemmaraju N, Kelly MA, Garris R, O'Brien S, Faderl S. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). Blood 120(21), 2012. PMID: None.
Jain P, Kantarjian HM, Nazha A, Jabbour E, Quintás-Cardama A, Benjamini O, Pierce SA, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, O'Brien S, Cortes JE. Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib). Blood 120(21), 2012. PMID: None.
Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour EJ, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Ferrajoli A, Kadia TM, O'Brien S, Cortes JE. The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP). Blood 120(21), 2012. PMID: None.
Ruvolo P, Zeng Z, Ruvolo V, Borthakur G, Kornblau S, Andreeff M, Konopleva M. The AKT inhibitor MK-2206 promotes apoptosis in acute myeloid leukemia cells. Proc Am Assoc Cancer Res 2012 Annual Meeting, 2012. PMID: None.
Borthakur G, Duvvuri S, Tsao T, Zhang W, Ruvolo V, Lu H, Kojima K, Konopleva M, Andreeff M. Insulin-like growth factor 1 receptor (IGF1R) inhibitor BMS754807 is active against FLT3-ITD mutated acute myelogenous leukemia and activity is p53 dependent. Proc Am Assoc Cancer Res 2012 Annual Meeting, 2012. PMID: None.
Daver N, Kantarjian H, Garcia-Manero G, Borthakur G, Ravandi F, Kadia T, Estrov Z, Konopleva M, Faderl S, Cortes J. AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood 118(21), 2011. PMID: None.
Quintás-Cardama A, Kantarjian H, Borthakur G, Estrov Z, Cortes J, Verstovsek S. Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis. Blood 118(21), 2011. PMID: None.
Verstovsek S, Estrov Z, Cortes J, Thomas D, Borthakur G, Kadia T, Jabbour E, Pierce S, Kantarjian H. The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study. Blood 118(21), 2011. PMID: None.
Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Godley L, Gabrail N, Berdeja J, Nadeem A, Stein K, Noble Y, Kassalow L, Kantarjian H. Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes. Blood 118(21), 2011. PMID: None.
Jabbour E, Kantarjian H, Wang X, Abruzzo L, Cornelison A, O'Brien S, Ravandi F, Kadia T, Borthakur G, Estrov Z, Cortes J, Garcia-Manero G. Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS). Blood 118(21), 2011. PMID: None.
Koller P, Kantarjian H, Koller C, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Estrov Z, Quintas-Cardama A, Cortes J. Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI) Who Have a History of Prior Malignancies. Blood 118(21), 2011. PMID: None.
Malik A, Kantarjian H, Quintas-Cardama A, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Thomas D, Burton E, Jabbour E, Cortes J. Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome. Blood 118(21), 2011. PMID: None.
Naqvi K, Kantarjian H, Luthra R, Jabbour E, O'Brien S, Burton E, Verstovsek S, Ravandi F, Wierda W, Borthakur G, Quintas-Cardama A, Cortes J. Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP). Blood 118(21), 2011. PMID: None.
Ohanian M, Kantarjian H, Quintas-Cardama A, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Trinh L, Ferrajoli A, Jabbour E, Kadia T, Cortes J. Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP). Blood 118(21), 2011. PMID: None.
Pemmaraju N, Kantarjian H, Tanaka M, O'Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy. Blood 118(21), 2011. PMID: None.
Cortes J, Garcia-Manero G, Ravandi F, Andreeff M, Borthakur G, Jabbour E, Konopleva M, O'Brien S, Quintas-Cardama A, Verstovsek S, Wierda W, Kantarjian H. Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood 118(21), 2011. PMID: None.
Ravandi F, Faderl S, Cortes J, Garcia-Manero G, Jabbour E, Boone P, Kadia T, Borthakur G, Wierda W, Wetzler M, Venugopal P, Chiao J, Kantarjian H. Phase 1/2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML. Blood 118(21), 2011. PMID: None.
Daver N, Kantarjian H, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. Blood 118(21), 2011. PMID: None.
Takahashi K, Kantarjian H, Pemmaraju N, Borthakur G, Faderl S, Garcia-Manero G, Andreeff M, Pierce S, Ravandi F, Cortes J. FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations. Blood 118(21), 2011. PMID: None.
Quintás-Cardama A, Kantarjian H, Garcia-Manero G, Ravandi F, Brandt M, Pierce S, Borthakur G, Cortes J. Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia. Blood 118(21), 2011. PMID: None.
Gushiken F, Vo Y, Xiao L, Kadia T, Cortes J, Pemmaraju N, Pierce S, Kantarjian H, Borthakur G. Coagulation Profile As Prognostic Indicator in Acute Myeloid Leukemia. Blood 118(21), 2011. PMID: None.
Ravandi F, Faderl S, Pierce S, Garcia-Manero G, Brandt M, Shan J, Kadia T, Borthakur G, Estrov Z, O'Brien S, Cortes J, Kantarjian H. Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse. Blood 118(21), 2011. PMID: None.
Nazha A, Cortes J, Faderl S, Pierce S, Garcia-Manero G, O'Brien S, Ferrajoli A, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia. Blood 118(21), 2011. PMID: None.
Zhang W, Konopleva M, Jacamo R, Borthakur G, Chen W, Cortes J, Ravandi F, Andreeff M. Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML. Blood 118(21), 2011. PMID: None.
Shoukier M, Kantarjian H, Jabbour E, Quintas-Cardama A, Estrov Z, Kadia T, Borthakur G, Garcia-Manero G, Kornblau S, Burton E, O'Brien S, Cortes J. Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts). Blood 118(21), 2011. PMID: None.
Lee H, Cortes J, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios M, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Kantarjian H. Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introduction of Imatinib Therapy - A Single Institution Historical Experience. Blood 118(21), 2011. PMID: None.
Garcia-Manero G, Daver N, Borthakur G, Konopleva M, Ravandi F, Wierda W, Estrov Z, Faderl S, Kadia T, Rey K, Cheung C, Kantarjian H. Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood 118(21), 2011. PMID: None.
Quintás-Cardama A, Kantarjian H, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Brandt M, Borthakur G, Keating M, Freireich E, Cortes J. Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center. Blood 118(21), 2011. PMID: None.
Liu-Dumlao T, O'Brien S, Cortes J, Thomas D, Faderl S, Jabbour E, Koller C, Garris R, Kebriaei P, Champlin R, Borthakur G, Ferrajoli A, Kantarjian H, Ravandi F. Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB). Blood 118(21), 2011. PMID: None.
Kadia T, Ravandi F, Borthakur G, Jabbour E, Pierce S, Garcia-Manero G, Faderl S, Cortes J, Kantarjian H. Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder. Blood 118(21), 2011. PMID: None.
Borthakur G, Andreeff M, Coombes K, Qiu Y, Duvvuri S, Zhang N, Ruvolo V, Konopleva M, Garcia-Manero G, Ruvolo P, Cortes J, Kantarjian H, Kornblau S. High Expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukemia--Time to Target Autophagy to Improve Therapy Outcomes?. Blood 118(21), 2011. PMID: None.
Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce P, Kantarjian H, Garcia-Manero G. Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome. Blood 118(21), 2011. PMID: None.
Pemmaraju N, Kantarjian H, Luthra R, O'Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP). Blood 118(21), 2011. PMID: None.
Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Brandt M, Pierce S, Borthakur G, Cortes J. Early Clearance of Peripheral Blood Blasts but Not White Blood Cells Is a Powerful Prognostic marker for complete Response and Overall Survival in Patients with Acute Myeloid Leukemia (AML) receiving Induction Chemotherapy. Blood 118(21), 2011. PMID: None.
Nazha A, Ravandi F, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Andreeff M, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 118(21), 2011. PMID: None.
Quintás-Cardama A, Kantarjian H, Garcia-Manero G, Brandt M, Faderl S, Pierce S, Borthakur G, Ravandi F, Cortes J. Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The M.D. Anderson Cancer Center Experience. Blood 118(21), 2011. PMID: None.
Boumber Y, Issa J, Jorgensen J, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). Blood 118(21), 2011. PMID: None.
Rytting M, Thomas D, Jabbour E, Franklin A, Borthakur G, Faderl S, Schroeder K, Ravandi F, Garris R, O'Brien S, Kantarjian H. Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Modified Augmented Berlin-Frankfurt-Muenster (ABFM) Therapy. Blood 118(21), 2011. PMID: None.
Thomas D, Kantarjian H, Jorgensen J, Faderl S, Jabbour E, Wierda W, Ravandi F, Verstovsek S, Garcia-Manero G, Koller C, Burger J, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau S, Andreeff M, Garris R, Cortes J, O'Brien S. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. Blood 118(21), 2011. PMID: None.
Konopleva M, Borthakur G, Thall P, Coveler A, Ravandi F, Jabbour E, Nguyen H, Benito J, Gu Y, Wilson W, Melink T, Kantarjian H, Gutheil J, Estey E. Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection. Blood 118(21), 2011. PMID: None.
Lee H, O'Brien S, Kantarjian H, Ravandi F, Faderl S, Koller C, Konopleva M, Verstovsek S, Kadia T, Garcia-Manero G, Borthakur G, Wierda W, Burger J, Thomas D, Cortes J. Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy. Blood 118(21), 2011. PMID: None.
Lee H, Kantarjian H, Thomas D, Faderl S, Koller C, Ferrajoli A, Jabbour E, Garris R, Kebriaei P, Champlin R, Borthakur G, Wierda W, Burger J, Cortes J, O'Brien S, Ravandi F. Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood 118(21), 2011. PMID: None.
Nazha A, Bhatt V, Nogueras-Gonzalez G, Kadia T, Cortes J, Daver N, Garcia-Manero G, Kantarjian H, Borthakur G. Prognostic Implication of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype (MK) in Patients with Acute Myeloid Leukemia (AML) and Complex Cytogenetics. Blood 118(21), 2011. PMID: None.
Quintás-Cardama A, Kantarjian H, Garcia-Manero G, Ravandi F, Brandt M, Faderl S, Pierce S, Borthakur G, Cortes J. Impact of Epigenetic Therapy Versus Conventional Chemotherapy on Survival of Elderly Patients with Acute Myeloid Leukemia. Blood 118(21), 2011. PMID: None.
Alvarado Y, Kantarjian H, Ravandi F, Luthra R, Borthakur G, Garcia-Manero G, Faderl S, Konopleva M, Estrov Z, Andreeff M, Cortes J. FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations. Blood 118(21), 2011. PMID: None.
Mathisen M, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes J, Quintas-Cardama A. Clofarabine Does Not Impact Negatively the Outcomes of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Stem Cell Transplantation and Is Not Associated with Higher Liver Toxicity Rates Compared with Standard Chemotherapy. Blood 118(21), 2011. PMID: None.
Ravandi F, Thomas D, O'Brien S, Garris R, Faderl S, Shan J, Borthakur G, Burger J, Ferrajoli A, Kebriaei P, Champlin R, Estrov Z, Wang S, Jorgensen J, Luthra R, Cortes J, Kantarjian H. Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy. Blood 118(21), 2011. PMID: None.
Garcia-Manero G, Tambaro F, Bekele N, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia T, Konopleva M, Faderl S, Cortes J, Brandt M, Hu Y, McCue D, Newsome W, Pierce S, deLima M, Kantarjian H. Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). Blood 118(21), 2011. PMID: None.
Alattar M, Kantarjian H, Jabbour E, Quintas-Cardama A, Burton E, Borthakur G, Verstovsek S, Wierda W, Konopleva M, Burger J, O'Brien S, Cortes J. Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP). Blood 118(21), 2011. PMID: None.
Garcia-Manero G, Estey E, Jabbour E, Borthakur G, Kadia T, Naqvi K, Levine R, Estrov Z, Quintas-Cardama A, Konopleva M, Faderl S, Tanaka M, Yang H, Ravandi F, Wierda W, Cortes J, Boone P, Kantarjian H. Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. Blood 118(21), 2011. PMID: None.
Quintás-Cardama A, Kantarjian H, Luthra R, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Garcia-Manero G, Faderl S, Konopleva M, Wierda W, Burton E, Cortes J. Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP). Blood 118(21), 2011. PMID: None.
Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia TM, Borthakur G, Wierda WG, Chiao JH, Kantarjian H. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 29(15), 2011. PMID: None.
Borthakur G, Popplewell L, Kirschbaum M, Foran J, Kadia T, Jabbour E, Boyiadzis M, Verma A, Walter R, Wissel P, Xu L, Bauman J, Zhu J, Mazdumar J, Baccus M, Connor J, Cortes J, Kantarjian H. Phase I/II trial of the MEK1/2 inhibitor GSK1120212 in patients with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. J Clin Oncol 29(15), 2011. PMID: None.
Quintas-Cardama A, Cortes JE, Jabbour E, O'Brien SM, Garcia-Manero G, Shan J, Ravandi F, Faderl S, Kadia TM, Borthakur G, Kantarjian H. Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. J Clin Oncol 29(15), 2011. PMID: None.
Ghanem H, Kantarjian H, Garcia-Manero G, Ravandi F, Faderl S, Cortes JE, Reyes A, O'Brien SM, Borthakur G, Kadia TM, Burger KA, Konopleva M, Jabbour E. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). J Clin Oncol 29(15), 2011. PMID: None.
Al-Ameri A, Thomas DA, Ravandi F, O'Brien SM, Kantarjian H, Borthakur G, Kadia TM, Kelly M, Garris R, Faderl S. Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL). J Clin Oncol 29(15), 2011. PMID: None.
Konopleva M, Hogge D, Rizzieri D, Cirrito T, Liu J, Kornblau S, Grable M, Hwang I, Borthakur G, Mankin A, Bivins C, Garcia-Manero G, Kadia T, Harris D, Ravandi F, Andreeff M, Cortes J, Niecestro R, Bergstein I, Kantarjian H, Frankel A. Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood 116, 2010. PMID: None.
Jabbour E, Kantarjian H, Parikh S, Thomas D, Kadia T, Garcia-Manero G, Borthakur G, Pierce S, Brandt M, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide for the treatment of patients with myelofibrosis. Blood 114(22), 2009. PMID: None.
Tong W, Kadia T, Borthakur G, Jabbour E, Pierce S, Shan J, Cortes-Franco J, Ravandi F, Wierda W, Thomas D, Kantarjian H, Garcia-Manero G. Prognostic factors and survival in patients with hypocellular myelodysplastic syndrome: development of a disease specific prognostic score. Blood 114(22), 2009. PMID: None.
Al-Kali A, Jones D, Cortes J, Faderl S, Ao X, Garcia-Manero G, Borthakur G, Konopleva M, Brandt M, Andreeff M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin and cytarabine in patients with newly diagnosed FLT3-mutant acute myeloid leukemia. Blood 114(22), 2009. PMID: None.
Kim H, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Garcia-Manero G. A prognostic model of therapy-related myelodysplastic syndrome. Blood 114(22), 2009. PMID: None.
Mesa R, Kantarjian H, Tefferi A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas D, Cortes-Franco J, Borthakur G, Pardanani A, Estrov Z, Verstovsek S. Validation of the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial. Blood 114(22), 2009. PMID: None.
Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes J, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian H. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Blood 114(22), 2009. PMID: None.
Kadia T, Kornblau S, Kantarjian H, Faderl S, Jones D, Garcia-Manero G, Borthakur G, Koller C, Verstovsek S, Pierce S, Cortes J, Ravandi F. Clinical characterization and proteomic consequences of mutated ras in acute myeloid leukemia. Blood 114(22), 2009. PMID: None.
Garcia-Manero G, Couriel D, Tambaro F, Gabrail N, Nadeem A, Kadia T, Jabbour E, Borthakur G, Faderl S, Newsome W, Yang H, Chen K, Stein K, Kantarjian H. A phase II randomized Bayesian study of very low dose subcutaneous decitabine administered daily or weekly times three in patients with lower risk myelodysplastic syndrome. Blood 114(22), 2009. PMID: None.
Ayoubi M, Thomas D, Kantarjian H, O'Brien S, Ravandi F, Garcia-Manero G, Verstovsek S, Rytting M, Borthakur G, Kadia T, Kornblau S, Andreeff M, Feliu J, Faderl S. Augmented hyper-CVAD in adult ALL salvage therapy: the MDACC experience of hyper-CVAD using dose-intense vincristine, dexamethasone and pegaspargase. Blood 114(22), 2009. PMID: None.
Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, DeLima M, Pierce S, Brandt M, Borthakur G, Ferrajoli A, Wierda W, Koller C, Kantarjian H. Characteristics and outcome of patients with acute myeloid leukemia refractory to one cycle of high dose cytarabine-based induction chemotherapy. Blood 114(22), 2009. PMID: None.
Ravandi F, Kantarjian H, Thomas D, Faderl S, Jones D, Koller C, Dara S, Garris R, Kebriaei P, Champlin R, Borthakur G, Wierda W, Burger J, Cortes J, O'Brien S. Phase II study of combination of the hypercvad regimen with dasatinib in the front line therapy of patients with philadelphia chromosome positive acute lymphoblastic leukemia. Blood 114(22), 2009. PMID: None.
Pemmaraju N, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Parikh S, Konopleva M, Kornblau S, Andreeff M, O'Brien S, Cortes J. FLT3 inhibitor therapy for patients with myelodysplastic syndromes and acute myeloid leukemia: impact on survival according to FLT3 status. Blood 114(22), 2009. PMID: None.
Konopleva M, Benito J, Shi Y, Konoplev S, Kornblau S, Frolova O, Zweidler-McKay P, Qiu Y, Wilson W, Campana D, Jacamo R, Lu H, Fang W, Borthakur G, Bueso-Ramos C, Kantarjian H, Thomas D, Andreeff M. Therapeutic targeting of the hypoxic microenvironment in acute lymphocytic leukemia. Blood 114(22), 2009. PMID: None.
Garcia-Manero G, Khoury H, Borthakur G, Ravandi F, Kadia T, Estrov Z, Jabbour E, Foudray M, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Freeman B, Simmons H, Ptaszynski M, Kantarjian H. A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias. Blood 114(22), 2009. PMID: None.
Kornblau S, Singh N, Ziu Y, Chen W, Faderl S, Borthakur G, Konopleva M, Zhang N, Kevin C. Highly phosphorylated FOX03A is an adverse prognostic factor in acute myeloid leukemia. Blood 114(22), 2009. PMID: None.
Al-Kali A, Kantarjian H, Shan J, Wierda W, Borthakur G, Estrov Z, Verstovsek S, O'Brien S, Cortes J. Current leukemia free survival after tyrosine kinase inhibitor for chronic myeloid leukemia: a new method that accounts for restoring response with sequential TKI. Blood 114(22), 2009. PMID: None.
Al-Ameri A, Kantarjian H, Borthakur G, Bahceci E, Szatrowski T, Damokosh A, Cortes J. Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase. Blood 114(22), 2009. PMID: None.
Mattiuzzi G, Cortes J, McCue D, Bekele B, Xiao L, Borthakur G, Kantarjian H. Palonosetron given daily for up to 5 days is significantly better than ondansetron in the prevention of delayed CINV in patients with acute myelogenous leukemia. Blood 114(22), 2009. PMID: None.
Al-Ameri A, Kantarjian H, Burton E, O'Brien S, Ravandi F, Borthakur G, Walker B, Rios M, Cortes J. Low risk of infectious events in patients with chronic myeloid leukemia in chronic phase treated with dasatinib. Blood 114(22), 2009. PMID: None.
Thomas D, Kantarjian H, Faderl S, Wierda W, Cortes J, Burger J, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau S, Andreeff M, Garris R, Keating M, O'Brien S. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome for patients with de novo philadelphia negative precursor B-cell acute lymphoblastic leukemia. Blood 114(22), 2009. PMID: None.
Cortes J, Foran J, Ghirdaladze D, DeVetten M, Zodelava M, Holman P, Levis M, Kantarjian H, Borthakur G, James J, Zarringkar P, Gunawardane R, Armstrong R, Padre N, Wierenga W, Corringham R, Trikha M. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase inhibitor, in a first-in-human phase 1 AML study. Blood 114(22), 2009. PMID: None.
Garcia-Manero G, Tambaro F, Bekele B, Jabbour E, Ravandi F, Yang H, Borthakur G, Kadia T, Cortes J, Faderl S, Konopleva M, Pierce S, Burger J, Estrov Z, O'Brien S, Thomas D, Newsome W, Kantarjian H. Phase II study of vorinostat in combination with idarubicin and cytarabine as front line therapy in acute myelogenous leukemia or higher risk myelodysplastic syndrome. Blood 114(22), 2009. PMID: None.
Borthakur G, Garcia-Manero G, Estrov Z, Konopleva M, Burger J, Thomas D, Kadia T, Williams B, George S, Kantarjian H. Phase 2 study of decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome--outcome in previously untreated patients. Blood 114(22), 2009. PMID: None.
Borthakur G, Faderl S, Verstovsek S, Jones D, Gandhi V, Estrov Z, O'Brien S, Ravandi F, Bass J, Brandt M, Kantarjian H. Clinical and molecular response in core binding factor acute myelogenous leukemia with fludarabine, cytarabine, G-CSF and gemtuzumab ozogamicin. Blood 114(22), 2009. PMID: None.
Chen Y, Cortes J, Lin E, Ravandi F, Faderl S, Kadia T, Kantarjian H, Borthakur G. Outcomes of salvage treatment in patients with acute myeloid leukemia with FLT3 mutations. Blood 114(22), 2009. PMID: None.
Santos F, Schlette E, Kantarjian H, Sargent R, Garcia-Manero G, Verstovsek S, Kadia T, Jabbour E, Pierce S, Borthakur G. Myelodysplastic syndrome with myelofibrosis: experience of a single-institution with 139 patients. Blood 114(22), 2009. PMID: None.
Borthakur G, Duvvuri S, Samudio I, Kojima K, Konopleva M, Andreeff M. Synergistic activation of p53 family of proteins by the combination of Nutlin 3a and SAHA in acute myelogenous leukemia. Blood 114(22), 2009. PMID: None.
Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios M, Cortes J. Predictive factors for response and outcome in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 114(22), 2009. PMID: None.
Cortes J, Borthakur G, O'Brien S, Jones D, Jabbour E, Ravandi F, Koller C, Walker B, Shan J, Kantarjian H. Efficacy of dasatinib in patients with previously untreated chronic myelogenous leukemia in early chronic phase. Blood 114(22), 2009. PMID: None.
Kantarjian H, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, w S, Coutre S, Borthakur G, Chiao J. A randomized phase 2 study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse. Blood 114(22), 2009. PMID: None.
Parikh S, Kantarjian H, Ravandi F, Borthakur G, Faderl S, Verma A, a F, Estrov Z, Pierce S, Cortes J. Incidence, clinical features and outcome of patients with differentiation syndrome in acute promyelocytic leukemia treated with all-trans retinoic acid alone versus ATRA plus idarubicin versus ATRA plus arsenic trioxide. Blood 114(22), 2009. PMID: None.
Ravandi F, Kantarjian H, Cortes J, Thomas D, Faderl S, Jones D, Jabbour E, Koller C, Dara S, Garris R, Kebriaei P, Borthakur G, Ferrajoli A, O'Brien S. Combination of the hypercvad regimen with dasatinib is effective in patients with relapsed philadelphia chromosome positive acute lymphoblastic leukemia and lymphoid blast phase chronic myeloid leukemia. Blood 114(22), 2009. PMID: None.
Cortes J, O'Brien S, Jones D, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Efficacy of nilotinib in patients with newly diagnosed, previously untreated Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Blood 114(22), 2009. PMID: None.
Kadia T, Estrov Z, Ravandi F, Koller C, Borthakur G, Jabbour E, Faderl S, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Long term followup and patterns of failure in patients with acute myeloid leukemia and high risk myelodysplastic syndrome treated on studies combining a hypomethylating agent and the histone deacetylase inhibitor valproic acid. Blood 114(22), 2009. PMID: None.
Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia (AML) in adolescents and young adults (AYA): the M.D. Anderson Cancer Center experience. J Clin Oncol 27(15s):368s, 2009. PMID: None.
Raza A, Galili N, Borthakur G, Carter TH, Claxton DF, Erba HP, DeAngelo DJ, Berger MS, Schimmer A. A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol 27(15s):165s, 2009. PMID: None.
Borthakur G, Faderl S, Ravandi F, Padmanabhan S, Stock W, Wu K, Li J, Curt G, Tallman M, Minden M. Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML). J Clin Oncol 27(15s):166s, 2009. PMID: None.
Mesa RA, Kantarjian H, Tefferi A, Cheville A, Pardanani A, Levy R, Erickson-Viitanen S, Thomas D, Cortes J, Borthakur G, Verstovsek S. Functional assessment of performance status in patients with myelofibrosis (MF): utility and feasibility of the 6-minute walk test (6MWT). J Clin Oncol 27(15s):376s, 2009. PMID: None.
Verma D, Kantarjian H, Jones D, Borthakur G, Garcia-Manero G, Thomas DA, Verstovsek S, Rios M, Cortes J. Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: analysis of characteristics, outcomes, and prognostic significance. J Clin Oncol 27(15s):363s, 2009. PMID: None.
Estrov Z, Cortes J, Borthakur G, Faderl S, Garcia-Manero G, Ravandi F, Khoury J, Ptaszynski M, Kantarjian H. A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias. J Clin Oncol 27(15s):361s, 2009. PMID: None.
Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Borthakur G, Chiao J, Kantarjian H. A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. J Clin Oncol 27(15s):361s, 2009. PMID: None.
Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM. Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol 27(15s):360s, 2009. PMID: None.
Santos FP, Qiao W, Cortes JE, Jones D, Ravandi F, Verma D, Kantarjian H, Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. J Clin Oncol 27(15s):359s, 2009. PMID: None.
Thomas D, Kantarjian H, Faderl S, Wierda W, Ferrajoli A, Burger J, Cortes J, Koller C, Borthakur G, Estrov Z, Konopleva M, Ravandi F, Garcia-Manero G, O'Brien S. Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia or lymphoblastic lymphoma. Blood 112(11), 2008. PMID: None.
Tong W, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Wierda W, Kornblau S, Borthakur G, Garcia-Manero G, Burton E, Rios M, Cortes J. Imatinib frontline therapy is safe and effective in patients with chronic myeloid leukemia with liver and /or renal dysfunction. Blood 112(11), 2008. PMID: None.
Verma D, Kantarjian H, Rios M, O'Brien S, Ault P, Burton E, Estrov Z, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors for chronic myeloid leukemia and other hematologic malignancies. Blood 112(11), 2008. PMID: None.
Velev N, Cortes J, Champlin R, Kantarjian H, Rondon G, Giralt S, Borthakur G, deLima M. Stem cell transplant for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Blood 112(11), 2008. PMID: None.
Quintas-Cardama A, Kantarjian H, Borthakur G, Faderl S, Garcia-Manero G, Wierda W, Burton E, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations during tyrosine kinase inhibitor therapy. Blood 112(11), 2008. PMID: None.
Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Verstovsek S, Wierda W, Shan J, Cortes J. Prognostic impact of deletions of derivative chromosome 9 on patients with chronic myelogenous leukemia in chronic phase treated with nilotinib or dasatinib. Blood 112(11), 2008. PMID: None.
Borthakur G, Tam C, Kantarjian H, Lin E, Cortes J, O'Brien S, Koller C, Pierce S, Keating M. Chromosome 17 abnormalities are associated with worse overall and relapse free survival in patients with acute myelogenous leukemia and poor-risk cytogenetics. Blood 112(11), 2008. PMID: None.
Issa JP, Castoro R, Ravandi-Kashani F, Faderl S, Huang X, Estey E, Borthakur G, Morris G, Garcia-Manero G, Kantarjian H. Randomized phase II study of combined epigenetic therapy: decitabine vs decitabine and valproic acid in MDS and AML. Blood 112(11), 2008. PMID: None.
Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Estrov Z, Thomas D, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian H. Oral and intravenous clofarabine for patients with myelodysplastic syndrome. Blood 112(11), 2008. PMID: None.
Borthakur G, deLima M, Kantarjian H, Xiao L, dePadua Silva L, Garcia-Manero G, Giralt S, Ravandi-Kashani F, Pierce S, Champlin R. Stem cell transplantation in remission improves survival in acute myelogenous leukemia associated with FLT3 mutations. Blood 112(11), 2008. PMID: None.
Borthakur G, Beran M, Liu J, Verma D, Dong X, Rondon G, Champlin R, Kantarjian H, Popat U. Outcomes in patients with chronic myelomonocytic leukemia: analysis of 279 patients. Blood 112(11), 2008. PMID: None.
Batty N, Kantarjian H, Borthakur G, Ravandi F, O'Brien S, Estrov Z, Shan J, Verstovsek S, Cortes J. Patients with chronic myeloid leukemia with variant Philadelphia chromosome translocations have a similar outcome as those with classic Ph when treated with imatinib or 2nd generation TKI. Blood 112(11), 2008. PMID: None.
Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia in adolescents and young adults: the M. D. Anderson Cancer Center experience. Blood 112(11), 2008. PMID: None.
O'Brien S, Thomas D, Ravandi-Kashani F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian H. Outcome of adults with acute lymphocytic leukemia with second salvage therapy. Blood 112(11), 2008. PMID: None.
Kornblau S, Qiu Y, Graber D, Chen W, Melendez J, Konopleva M, Faderl S, Andreeff M, Borthakur G, Yao H, Coombes K. Protein expression in acute myelogenous leukemia stem cells compared to bulk AML cells using reverse phase proteins arrays. Blood 112(11), 2008. PMID: None.
Faderl S, Borthakur G, Ravandi F, Huang X, Beran M, Ferrajoli A, Koller C, Thomas D, Verstovsek S, Kwari M, Kantarjian H. Results of a randomized phase 2 study of clofarabine plus cytarabine vs clofarabine plus idarubicin vs clofarabine, idarubicin, plus cytarabine as salvage therapy in acute myeloid leukemia. Blood 112(11), 2008. PMID: None.
Santos F, Faderl S, Garcia-Manero G, Koller C, Beran M, Borthakur G, Bueso-Ramos C, Keating M, Cortes J, Kantarjian H, Ravandi F. Acute erythroleukemia: an analysis of 108 patients treated with cytarabine-containing regimens at the M.D. Anderson Cancer Center. Blood 112(11), 2008. PMID: None.
Garg R, Garcia-Manero G, Faderl S, Cortes J, Koller C, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of thymoglobulin, cyclosporine and G-CSF for initial treatment of aplastic anemia and low risk myelodysplastic syndrome. Blood 112(11), 2008. PMID: None.
Dayyani F, Conley A, Pierce S, Strom S, Stevenson W, Borthakur G, Kantarjian H, Garcia-Manero G. Disease-related mortality in patients with lower-risk myelodysplastic syndrome. Blood 112(11), 2008. PMID: None.
Borthakur G, Estrov Z, Garcia-Manero G, Williams B, Wathen J, Konopleva M, Burger J, Ferrajoli A, George S, Kantarjian H. Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood 112(11), 2008. PMID: None.
Fava C, Blamble D, O'Brien S, Garcia-Manero G, Pierce S, Kantarjian H, Borthakur G. Outcome of first salvage therapy in core binding factor associated acute myelogenous leukemia is less than optimal. Blood 112(11), 2008. PMID: None.
Efebera Y, Kantarjian H, Andersson B, Pierce S, DePadua Silva L, Ravandi F, Giralt S, Borthakur G, Champlin R, DeLima M. Allogeneic hematopoietic stem cell transplant versus conventional chemotherapy in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome attaining complete remission post induction chemotherapy: a retrospective case control study. Blood 112(11), 2008. PMID: None.
Ravandi F, Cortes J, Faderl S, Garcia-Manero G, O'Brien S, Borthakur G, Pierce S, Brandt M, Lang M, Zhang W, Luthra R, Jones D, Levis M, Konopleva M, Andreeff M, Kantarjian H. Combination of sorafenib, idarubicin and cytarabine has a high response rate in patients with newly diagnosed acute myeloid leukemia younger than 65 years. Blood 112(11), 2008. PMID: None.
Schimmer A, Estey E, Borthakur G, Carter B, Schiller G, Tallman M, Altman J, Karp J, Kassis J, Jacob C, Morris S, Jolivet J, Andreeff M. Phase 1/2 trial of the XIAP antisense oligonucleotide (AEG35156) in combination with idarubicin and cytarabine in patients with relapsed/refractory AML. Blood 112(11), 2008. PMID: None.
Quintas-Cardama A, Kantarjian H, Thomas D, Cortes J, Ravandi F, Faderl S, Garcia-Manero G, Borthakur G, Bell N, Byrne C, Verstovsek S. Combined therapy with lenalidomide and prednisone renders durable clinical, histopathological, and molecular responses in patients with myelofibrosis. Blood 112(11), 2008. PMID: None.
Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Cortes J, Richie M, Borthakur G, Verstovsek S. Pegylated interferon-ALFA-2A therapy renders high clinical and molecular response rates in patients with essential thrombocythemia and polycythemia VERA. Blood 112(11), 2008. PMID: None.
Cortes J, Mauro M, O'Brien S, Borthakur G, Wierda W, Matloub Y, Sinha R, Liu D, Kantarjian H. The vast majority of CML-CP patients treated with dasatinib (70 mg BID) who progress after long-term follow-up (24 mo) remain in chronic-phase. Blood 112(11), 2008. PMID: None.
Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: How does it relate to the original lenalidomide experience in MDS?. Blood 112(11), 2008. PMID: None.
Cortes J, O'Brien S, Ault P, Borthakur G, Jabbour E, Bradley-Garelik B, Debreczeni K, Yand D, Liu D, Kantarjian H. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 112(11), 2008. PMID: None.
Cortes J, O'Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G, Garcia-Manero G, Letvak L, Kantarjian H. Efficacy of nilotinib (formerly AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Blood 112(11), 2008. PMID: None.
Ravandi F, Thomas D, Kantarjian H, Faderl S, Koller C, Dara S, Garris R, Kebriaei P, Borthakur G, Wierda W, Burger J, Cortes J, O'Brien S. Phase II study of combination of hyperCVAD with dasatinib in frontline therapy of patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 112(11), 2008. PMID: None.
Carter G, Mak D, Morris S, Borthakur G, Estey E, Byrd A, Konopleva M, Kantarjian H, Andreeff M. Pharmacodynamic study phase 1/2 trial of the XIAP antisense oligonucleotide (AEG35156) in combination with chemotherapy in patients with relapsed/refractory AML. Blood 112(11), 2008. PMID: None.
Cortes J, O'Brien S, Borthakur G, Jones D, Ravandi F, Koller C, Mesina O, Ferrrajoli A, Shan J, Kantarjian H. Efficacy of dasatinib in patients with previously untreated chronic myelogenous leukemia in early chronic phase. Blood 112(11), 2008. PMID: None.
Borthakur G, Faderl S, Verstovsek S, Jones D, Estrov Z, O'Brien S, Bass J, Kantarjian H. Molecular response in core binding factor acute myelogenous leukemia with fludarbine, cytarabine, G-CSF and gemtuzumab ozogamicin. Blood 112(11), 2008. PMID: None.
Delmonte J, Kantarjian H, Estey E, Ravandi F, Borthakur G, Burger J, Pierce S, Cortes J. Single center experience with Philadelphia chromosome-positive acute myeloid leukemia. Blood 110(11):1027a, 2007. PMID: None.
Delmonte J, Kantarjian H, Ravandi F, Borthakur G, Giles F, Abruzzo L, Pierce S, Cortes J. Myelodysplastic syndromes and acute myeloid leukemia with t(6;9)(p23;q34). Blood 110(11):1026a, 2007. PMID: None.
Jain N, Kantarjian H, Fava C, Thomas D, Burger J, Borthakur G, Pate O, Cortes J. Imatinib dose can be safely reduced after complete cytogenetic response in patients with chronic myeloid leukemia in early chronic phase treated with high-dose imatinib. Blood 110(11):316a, 2007. PMID: None.
Kantarjian H, Quintas-Cardama A, O'Brien S, Ravandi F, Borthakur G, Liu D, Chen T, Cortes J. Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib. Blood 110(11):314A, 2007. PMID: None.
Jabbour E, Kantarjian H, Atallah E, Borthakur G, Wierda W, Faderl S, Kornblau S, Cortes J. Impact of imatinib mesylate dose escalation on resistance and sub-opitmal responses to standard-dose therapy in patients with chronic myeloid leukemia. Blood 110(11):313a, 2007. PMID: None.
Kornblau S, Qiu Y, Palla S, Zhihong Z, Chen W, Borthakur G, Coombes K, Konopleva M. Patterns and prognostic impact of P13K-AKT pathway activation, regulation and downstream activity in AML using reverse phase proteins arrays. Blood 110(11):706a, 2007. PMID: None.
Ravandi F, Lancet J, Giles F, Plunkett W, Williams B, Burton M, Faderl S, Estrov Z, Borthakur G, Akinsanmi L, Kantarjian H. Phase I study of triciribine phosphate monohydrate, a specific inhibitor of AKt phosphorylation, in adult patients with advanced hematologic malignancies. Blood 110(11):278a, 2007. PMID: None.
Borthakur G, Kantarjian H, O'Brien S, Ravandi F, Koller C, Estrov Z, Torma R, Issa JP. Report of a phase 1/2 study of 5-azacitidine and cytarabine in patients with relapsed, refractory acute myelogenous leukemia. Blood 110(11):277a, 2007. PMID: None.
Borthakur G, Kantarjian H, Garcia-Manero G, Pierce S, Estey E. Salvage therapy with standard dose cytarabine is appropriate for patients with acute myelogenous leukemia refractory to front-line therapy with hypomethylating agents. Blood 110(11):164b, 2007. PMID: None.
Rytting M, Thomas D, Kantarjian H, Cortes J, Borthakur G, Wierda W, Nunez C, Kornblau S, Ravandi F, Wells R, Brenda M, Anna F, O'Brien S. Adaptation of augmented Berlin-Frankfurt-Munster Therapy in adolescents and young adults with acute lymphoblastic leukemia. Blood 110(11):153 b, 2007. PMID: None.
Faderl S, Thomas DA, Gandhi V, Borthakur G, Huang X, Plunkett W, Burger J, Cortes J, O'Brien S, Ravandi F, Bretz J, Kwari M, Kantarjian H. Phase I/II study of clofarabine plus cyclophosphamide in adults with relapsed and refractory acute lymphoblastic leukemia. Blood 110(11):152b, 2007. PMID: None.
Ravandi F, Foran J, Verstovsek S, Cortes J, Wierda W, Boone P, Borthakur G, Sweeney T, Kantarjian. A phase I trial of AT9283, a multi-targeted kinase inhibitor, in patients with refractory hematological malignancies. Blood 110(11):275a, 2007. PMID: None.
Delmonte J, Kantarjian H, Andreeff M, Faderl S, Wright J, Zhang W, Konopleva M, Verstovsek S, Borthakur G, Ravandi F, Cortes J. Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 110(11):272a, 2007. PMID: None.
Tam C, Kantarjian H, Borthakur G, Wierda W, Ravandi F, O'Brien S, Shan J, Cortes. The time to cytogenetic response determines survival in CML patients receiving second-line tyrosine kinase inhibitors, and allows early identification of pts destined to fail therapy. Blood 110(11):573a, 2007. PMID: None.
Quintas-Cardama A, Tefferi A, Thomas D, Cortes J, Ravandi F, Faderl S, Garcia-Manero G, Borthakur G, Bell N, Byrne C, Kantarjian H, Verstovsek S. Phase II study of lenalidomide and prednisone for patients with myelofibrosis. Blood 110(11):1037a, 2007. PMID: None.
Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Cortes J, Richie M, Borthakur G, Verstovsek S. Pegylated interferon-alfa-2a for essential thrombocythemia and polycythemia vera: an update of an ongoing phase II study. Blood 110(11):1036a, 2007. PMID: None.
Alvarado Y, Kantarjian H, Verma D, Mattiuzzi G, Aribi A, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoiesis-stimulating agents in patients with chronic myeloid leukemia treated with imatinib. Blood 110(11):869a, 2007. PMID: None.
Tam C, Thomas DA, Ravandi F, Richardson C, Borthakur G, Burger J, Estey E, Kantarjian H, Verstovsek S. Phase II evaluation of sunitinib malate, a multi-targeted inhibitor of receptor tyrosine kinases, in patients with myelofibrosis. Blood 110(11):1039a, 2007. PMID: None.
Quintas-Cardama A, Kantarjian H, Ravandi F, Burger J, Borthakur G, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Blood 110(11):869a, 2007. PMID: None.
Faderl S, Thomas D, Ravandi F, Garcia-Manero G, Beran M, Rytting M, Koller C, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, O'Brien S, Vu K, Kwari M, Bretz J, Kantarjian H. Intensification of hyper-CVAD with L-Asparaginase, vincristine and dexamethasone has activity in adult patients with relapsed/refractory acute lymphoblastic leukemia. Blood 110(11):149b, 2007. PMID: None.
Jabbour E, Kantarjian H, Shan J, O'Brien S, Wierda W, Ravandi F, Borthakur G, Kornblau S, Walker B, Rios M, Cortes J. Prognostic significance of prior best response to imatinib in patients with chronic myeloid leukemia in chronic phase treated with second generation tyrosine kinase inhibitors. Blood 110(11):577a, 2007. PMID: None.
Jabbour E, Kantarjian H, Jones D, Tam C, Koller C, Borthakur G, Wierda W, Cortes J. Event-free survival in patients with chronic myeloid leukemia treated with 2nd generation tyrosine kinase inhibitors after imatinib failure is dependent on the invitro sensitivity of BCR-ABL kinase domain mutations. Blood 110(11):577a, 2007. PMID: None.
Alvarado Y, Kantarjian H, Faderl S, Burger J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of suboptimal response to Imatinib, as defined by the European LeukemiaNet, in long-term outcome for patients with chronic phase chronic myeloid leukemia. Blood 110(11):573a, 2007. PMID: None.
Borthakur G, Ravandi F, O'Brien S, Beran M, Williams B, Goldsweig H, Giles F. Phase I study of S-trans, trans-farnesylthiosalicylic acid, a novel oral Ras inhibitor, in patients with refractory hematologic malignancies. Blood 110(11):478a, 2007. PMID: None.
Verma D, Kantarjian H, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for patients with chronic myeloid leukemia with clonal evolution treated with 2nd generation tyrosine kinase inhibitors after imatinib failure. Blood 110(11):866a, 2007. PMID: None.
Ravandi F, Issa JP, Faderl S, Garcia-Manero G, Hood M, Jorgensen J, Lee M, O'Brien S, Estey E, Borthakur G, Ferrajoli A, Verstovsek S, Cortes J, Kantarjian H. Randomized study of decitabine versus observation or continued cytotoxic chemotherapy in patients with intermediate and poor risk acute myeloid leukemia in first or subsequent complete remission. Blood 110(11):841a, 2007. PMID: None.
Jain N, Mattiuzzi G, Cortes J, Cassat J, Garcia-Manero G, Ravandi-Kashani F, Pierce S, Borthakur G, O'Brien S, Kantarjian H. Benefit of anti-infectious prophylaxis in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome receiving frontline "targeted therapy". Blood 110(11):841a, 2007. PMID: None.
Borthakur G, Jain N, Kantarjian H, Lin E, Ravandi F, Pierce S, Estey E. Survival is poorer in patients with secondary core binding factor acute myelogenous leukemia compared with de novo core binding factor leukemia. Blood 110(11):840a, 2007. PMID: None.
Mattiuzzi G, Cortes J, Cassat J, Blamble D, Bekele BN, Beran M, Borthakur G, Ravandi F, Burger J, Kantarjian H. An interim analysis of phase II, open randomized comparative trial: alternate or multiple-day dosing of palonosetron is effective and safe in the prevention of chemotherapy induced nausea and vomiting in patients with leukemia receiving high dose ara-c. Blood 110(11):835a, 2007. PMID: None.
Ravandi F, Thomas D, Kantarjian H, Faderl S, Koller C, Brown D, Garris R, Borthakur G, Burger J, Kebriaei P, Jorgensen J, Jones D, Cortes J, O'Brien S. Phase II study of combination of the hyperCVAD regimen with dasatinib in patients with Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia and lymphoid blast phase chronic myeloid leukemia. Blood 110(11):828a, 2007. PMID: None.
Kadia T, Kantarjian H, Verstovsek S, Newman B, Garcia-Manero G, Borthakur G. Treatment of myelodysplastic syndrome with cytokine immunotherapy for low-risk MDS. Blood 110(11):438a, 2007. PMID: None.
Borthakur G, Garcia-Manero G, Faderl S, Estrov Z, Verstovsek S, Hood M, Kantarjian H. Lenalidomide in high-risk myelodysplastic syndrome and acute myelogenous leukemia associated with chromosome 5 abnormalities. Blood 110(11):437a, 2007. PMID: None.
Faderl S, Garcia-Manero G, Gandhi V, Ravandi F, Borthakur G, Thomas D, Ferrajoli A, Estrov Z, Plunkett W, Byrd A, Kwari M, Kantarjian H. Results of an exploratory study of oral and intravenous clofarabine in patients with myelodysplastic syndrome. Blood 110(11):436a, 2007. PMID: None.
Cortes J, O'Brien S, Jones D, Koller C, Borthakur G, Nicaise C, Henderson L, Ferrajoli A, Kantarjian H. Efficacy of dasatinib in patients with previously untreated chronic myelogenous leukemia in early chronic phase. Blood 110(11):17a, 2007. PMID: None.
Cortes J, O'Brien S, Jabbour E, Ferrajoli A, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Thomas M, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Blood 110(11):17a, 2007. PMID: None.
Schimmer A, Brandwein J, O'Brien S, Kantarjian H, Cheson B, Minden M, Yee K, Schuh A, Gupta V, Viallet J, Borthakur G. A phase I trial of the small molecule Pan-Bcl-2 family inhibitor obatoclax mesylate administered by continuous infusion for up to four days to patients with hematological malignancies. Blood 110(11):272a, 2007. PMID: None.
Quintas-Cardama A, Kantarjian H, Andreeff M, Faderl S, Wright J, Zhang W, Konopleva M, Verstovsek S, Borthakur G, Cortes J. Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients with refractory/relapsed acute myelogenous leukemia. Proc ASCO 25(18S):361s, 2007. PMID: None.
Yanada M, Huang X, O'Brien S, Garcia-Manero G, Ravandi F, Borthakur G, Issa J, Giles F, Kantarjian H, Estey E. Effect of hematologic improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukemia or high-risk myelodysplastic syndrome. Proc ASCO 25(18S):371s, 2007. PMID: None.
Estey E, Thall P, Wang X, Borthakur G, Ravandi-Kashani F. Effect of delaying therapy in newly diagnosed AML. Proc ASCO 25(18s):362s, 2007. PMID: None.
Kadia TM, Borthakur G, Wierda W, Ravandi F, Faderl S, Newsome W, Zwiebel J, Egorin M, Garcia-Manero G. A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia. Proc ASCO 25(18S):363s, 2007. PMID: None.
Atallah EL, Kantarjian H, O'Brien S, Jones D, Borthakur G, Nicaise C, Cortes J. Use of dasatinib in patients with previously untreated chronic myelogenous leukemia in chronic phase. Proc ASCO 25(18S):358s, 2007. PMID: None.
Borthakur G, Ravandi-Kashani F, O'Brien S, Williams B, Giles F. Phase I study of s-trans, trans-farnesylthiosalicyclic acid (FTS), a novel oral Ras inhibitor, in patients with refractory hematologic malignancies. Proc ASCO 25(18S):374s, 2007. PMID: None.
Ravandi-Kashani F, Kantarjian H, Faderl S, Verstovsek S, Koller C, Odinga S, Wierda W, Borthakur G, Giles F, O'Brien S, Keating M. Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms. Blood 108(11):330b, 2006. PMID: None.
Kornblau SM, Jackson CE, Worthing A, Faderl S, Beran M, Fayad L, Ravandi-Kashani F, Borthakur G, Gale R, Verstovsek S. A phase I trial of a novel organic arsenic S-dimethylarsino-glutathione (Z10-101) in hematological malignancies. Proc ASCO 24(18S):664s, 2006. PMID: None.
Borthakur G, O'brien S, Ravandi-Kashani F, Giles F, Schimmer A, Viallet J, Kantarjian H. A phase I trial of the small molecule pan-Bcl-2 family inhibitor obatoclax mesylate (GX15-070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia. Blood 108(11):750a, 2006. PMID: None.
Samudio I, Dietrich M, Corn P, Yang D, Borthakur G. Novel small molecule MDM2 inhibitor MI-63 induces p53-dependent apoptosis in AML cell lines. Blood 108(11):733a, 2006. PMID: None.
Jabbour E, Kantarjian H, Jones D, Giles F, Borthakur G, O'Brien S, Cortes J. Clinical characteristics and outcome of patients with T3151 mutation after imatinib failure. Blood 108(11):621a, 2006. PMID: None.
Cortes J, O'Brien S, Jones D, Borthakur G, Giles F, Nicaise C, Kantarjian H. Dasatinib (SPRYCEL) in patients with previously untreated chronic myelogenous leukemia in chronic phase. Blood 108(11):613a, 2006. PMID: None.
Borthakur G, Kantarjian H, Wang X, Giles F, Cortes J, Pierce S, Estey E. Induction therapy with fludarabine, ara-C and G-CSF results in improved event free survival in core binding factor leukemia. Blood 108(11):567a, 2006. PMID: None.
Giles F, Freedman S, Xiao A, Borthakur G, Garcia-Manero G, Wierda W, Kornblau S, O'Brien S, Bergstron D, Rissieri D. MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease and in Philadelphia-positive ALL. Blood 108(11):556a, 2006. PMID: None.
Giles F, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Pierce S, Jabbour E, Cortes J, Kantarjian H. Comorbidity scoring using the hematopoetic cell transplantation comorbidity index is predictive of early death rate and event free survival in patients over 60 years of age receiving induction therapy for acute myeloid leukemia. Blood 108(11):559a, 2006. PMID: None.
Stock W, Undevia S, Faderl S, Odenike T, Ravandi F, Rich E, Verstovsek S, Godley L, Bennett D, Borthakur G, Wierda W, Artz A, Larson R, Ramirez J, Ratain M, Giles F. Phase I study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative in patients with refractory hematological malignancies. Blood 108(11):552a, 2006. PMID: None.
Quintas-Cardama A, Kantarjian H, Giles F, Cortes J, Richie M, Borthakur G, Verstovsek S. Treatment with pegylated interferon-alfa-2A (PEG-IFN-)-2A:PEGASYS) for patients with essential thrombocythemia and polycythemia vera. Blood 108(11):307b, 2006. PMID: None.
Faderl S, Ferrajoli A, Ravandi F, Verstovsek S, Wierda W, Borthakur G, Thomas DA, Cortes J, Kornblau S, Estrov Z, Andreeff M, Beran M, Giles F, Huang X, Kwari M, Kantarjian H. Clofarabine plus anthracycline combinations in acute myeloid leukemia salvage. Blood 108(11):51a, 2006. PMID: None.
Burger J, Borthakur G, Pierce S, Kantarjian H, Estey E. Reproducibility of diagnosis in patients with myelodysplastic syndrome. Proc ASCO 24(18s):664s, 2006. PMID: None.
Borthakur G, O'Brien S, Wierda W, Thomas D, Cortes J, Kantarjian H, Lerner S, Keating M. Immune anemias in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy. Proc ASCO 24(18s):361, 2006. PMID: None.
Jabbour E, Giles F, Cortes J, O'Brien S, Ravandi F, Borthakur G, Garcia-Manero G, Letvak L, Salvado A, Kantarjian H. Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia. Proc ASCO 24(18s):358s, 2006. PMID: None.
Estrov Z, O'Brien S, Giles F, Garcia-Manero G, Borthakur G, Ravandi F, Sams I, Nicaise C, Kantarjian H. Dasatinib (BMS354825), a dual SrcAbl inhibitor, is active in Philadelphia chromosome-positive chronic myelogenous leukemia following treatment failure with imatinib mesylate and AMN107. Proc ASCO 24(18S):344s, 2006. PMID: None.
Verstovsek S, Kantarjian H, Cortes J, Ravandi-Kashani F, Borthakur G, Nicaise C, Sams I, Giles F, Tefferi A. Dasatinib (SPRYCEL) therapy for patients with systemic mastocytosis. Blood 108(11):1036a, 2006. PMID: None.
Jabbour E, O'Brien S, Ravandi F, Cortes J, Borthakur G, Verstovsek S, Garcia-Manero G, Giles F, Zanoria L, Davisson J, Issa J, Kantarjian H. Decitabine induces high response rates in patients with chronic myelomonocytic leukemia. Blood 108(11):750a, 2006. PMID: None.
Atallah E, Kantarjian H, de Lima M, Borthakur G, Wierda W, Champlin R, Cortes J. The role of dasatnib in patients with Philadelphia positive acute lymphocytic leukemia and chronic myeloid leukemia relapsing after stem cell transplantation. Blood 108(11):209b, 2006. PMID: None.
Ravandi-Kashani F, Estrov Z, Ferrajoli A, Borthakur G, Beran M, Pierce S, Koller C, Cortes J, Faderl S, Kantarjian H. Phase II study of thymoglobulin, cyclosporine, and G-CSF for the initial treatment of aplastic anemia and low risk myelodysplastic syndrome. Blood 108(11):292b, 2006. PMID: None.
Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O'brien S, Verstovsek S, Garcia-Manero G, Newman B, Giles F, Issa JP, Kantarjian H. Decitabine induces responses in patients with myelodysplastic syndrome after failure of azacitidine therapy. Blood 108(11):157a, 2006. PMID: None.
Zeng Z, Konopleva M, Nowak B, Plunkett W, Borthakur G, Estey E, Champlin R, Bridger G, Andreef M. Disruption of leukemia/stroma cell interactions by CSCR4 antagonist AMD3465 enhances chemotherapy-induced apoptosis in AML. Blood 106(11):142a, 2005. PMID: None.
Borthakur G, Kantarjian H, Estey E, Verstovsek S, Garcia-Manero G, Cortes J. Study of intravenous homoharringtonine in the treatment of myelodysplastic syndrome. Blood 106(11):305b, 2005. PMID: None.
Faderl S, Thomas DA, Garcia-Manero G, Ravandi F, Beran M, Rytting M, Koller C, Verstovsek S, Borthakur G, Andreef M, Kornblau S, Vu K, Jarmon R, Kantarjian H. Augmented hyper-CVAD in acute lymphoblastic leukemia: the MDACC experience with intensified L-Asparaginase and vincristine in adult ALL salvage. Blood 106(11):523a, 2005. PMID: None.
Borthakur G, Kantarjian H, Verstovsek S, O'brien S, Giles F, Koller C, Rios MB, Cortes JE. Imatinib mesylate therapy for patients with polycythemia vera. Blood 104(11):428a, 2004. PMID: None.
Borthakur G, Matijevic-Aleksic N, Wu KK. CD40L induced COX2 expression in THP-1 cells and HUVEC involves p52/NFKB-2. Blood 102(11):77b, 2003. PMID: None.
Borthakur G, Cortes JE, Estey EH. Incidence and outcome of secondary MDS at MD Anderson Cancer Center 1965-2002. Blood 102(11):331b, 2003. PMID: None.
Borthakur G, Estey EH, Kantarjian H, Koller CA, Giles F, Garcia-Manero G, Cortes J. A randomized trial of interferon-alpha and granulocyte macrophage colony stimulating factor versus interferon and cytarabine versus idarubicin and cytarabine for maintenance therapy in acute myelogenous leukemia, refractory anemia with excess of blasts, refractory anemia with excess of blasts in transformation in first complete remission. Blood 100(11), 2002. PMID: None.
Shrimpton CN, Thaggard JA, Borthakur G, Cruz MA, Lopez JA. Role for lipid rafts in GP1b-mediated platelet function: potential for regulation by nitric oxide. Blood 98, 2001. PMID: None.
Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, KPruthi R, Tefferi A. Hemostatic gene polymorphisms and the prevalence of thrombohemorrhagic complications in polycythemia vera and essential thrombocythemia. Blood 98, 2001. PMID: None.

Book Chapters

Borthakur G, O'Brien S. Treatment of Chronic Lymphocytic Leukemia and Related Disorders. In: Neoplastic Diseases of the Blood. 5th. Springer Science, 103-119, 2013.
Borthakur G, Estey EE. Therapy of acute myelogenous leukemia in adults. In: Cancer Treat Res. None. None, 257-71, 2010.
Borthakur G, Bueso-Ramos C, O'Brien S. Chronic Lymphocytic Leukemia and Associated Disorders. In: MD Anderson Manual of Medical Oncology. None. McGraw-Hill Medical Publishing Division, 39-55, 2006.
Jabbour E, Borthakur G, Bueso-Ramos C, Kantarjian H, Faderl S. Acute Lymphoblastic Leukemia. In: MD Anderson Manual of Medical Oncology. None. McGraw-Hill Medical Publishing Division, 3-17, 2006.

Letters to the Editor

Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver N, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. American Journal of Hematology 99: 1434-1436, 2024.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. American Journal of Hematology 99: 792-796, 2024.
Sheikh IN, AlQahtani S, Yin CC, McCall D, Cuglievan B, Ragoonanan D, Connors JS, Gibson A, Nunez C, Roth M, Ohanian M, Borthakur G, Garcia MB. KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine. Pediatric Blood and Cancer 71: e30898, 2024.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer Journal 13: 148, 2023.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. American Journal of Hematology 98: E281-E284, 2023.
Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leukemia Research 127: 107044, 2023.
Abbas HA, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour E, Konopleva M, Short NJ, DiNardo C, Daver N, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Advances 7: 828-831, 2023.
Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. American Journal of Hematology 98: E53-E56, 2023.
Qiao W, Young E, Feng C, Liu S, Jin J, Noor L, Rojas Hernandez CM, Borthakur G, Gorlova O, Afshar-Kharghan V. Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia. Exp Hematol Oncol 11: 58, 2022.
Venugopal S, Borthakur G, Daver N, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv 6: 5546-5549, 2022.
Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res 119: 106884, 2022.
Roboz GJ, Yee K, Verma A, Borthakur G, de la Fuente Burguera A, Sanz G, Mohammad HP, Kruger RG, Karpinich NO, Ferron-Brady G, Acusta A, Del Buono H, Collingwood T, Ballas M, Dhar A, Wei AH. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Lymphoma 63: 463-467, 2022.
Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J 12: 23, 2022.
Yilmaz M, Daver N, Borthakur G, Kadia T, DiNardo C, Kanagal-Shamanna R, Loghavi S, Oran B, Popat UR, Pierce S, Jabbour E, Short NJ, Issa G, Ohanian M, Konopleva M, Patel K, Kantarjian H, Ravandi F. FLT3 inhibitor based induction and allogeneic stem cell transplant in CR1 improves outcomes in patients with newly diagnosed AML with very low FLT3 allelic burden. Am J Hematol 96: E275-E279, 2021.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106: 894-898, 2021.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients. Blood Cancer J 11: 60, 2021.
Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11: 52, 2021.
Ustun C, Morgan EA, Ritz EM, Vestergaard H, Pullarkat S, Kluin PM, Ohgami R, Baughn LB, Kim Y, Ku NK, Czuchlewski D, Boe Møller M, Schiefer AI, Mrózek K, Horny HP, George TI, Kielsgaard Kristensen T, Beck T, Nathan S, Arana Yi C, Yeung C, Pullarkat V, Gotlib J, Akin C, Kohlschmidt J, Salhotra A, Soma L, Chen D, Han SY, Cho C, Sperr W, Broesby-Olsen S, Linden MA, Dolan M, Hoermann G, Hornick JL, Bloomfield C, Nakamura R, Joachim Deeg H, Litzow MR, Borthakur G, Weisdorf D, Huls G, Perales MA, Valent P, Marcucci G. Core-binding factor acute myeloid leukemia with inv(16). International Journal of Laboratory Hematology 43: e19-e25, 2021.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood cancer journal 11: 25, 2021.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American journal of hematology 96: E50-E53, 2021.
Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 93: 1263-5, 2008.
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Relapse and death during first remission in acute myeloid leukemia. Haematologica 93: 633-634, 2008.

Less

Grant & Contract Support

Title:	A first-in-human (FIH), phase 1, multicenter, open-label, dose escalation and expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally administered GLB-001 in patients with relapsed or refractory acute myeloid leukemia (R/R AML) or relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS)
Funding Source:	GluBio Theraputics Inc
Role:	PI

Title:	A Phase 1b/2a Trial of the Anti-IL1RAP Antibody Nadunolimab in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI

Title:	A phase 1b/2a trial of the anti-IL1RAP antibody nadunolimab in patients with myelodysplastic syndrome and acute myelogenous leukemia
Funding Source:	NIH/NCI
Role:	PI

Title:	Phase 1 Evaluation of the Safety and Pharmacokinetics of First-in-class N-myristoylation Inhibitor, PCLX-001, in Patients with Relapsed/Refractory Acute Myeloid
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I

Title:	2021-0522: A Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects with Acute Myeloid Leukemia
Funding Source:	Intellia Therapeutics
Role:	PI

Title:	2021-0431 A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-cell Malignancies
Funding Source:	Nkarta Therapeutics
Role:	PI

Title:	NO TITLE PROVIDED
Funding Source:	CYCLACEL PHARMACEUTICALS INC
Role:	PI

Title:	2021-0230 SY-1425 in Combination with Venetoclax and Azacitidine in Adult Patients with RARA-positive, Previously Untreated AML Who Are Ineligible for Standard Induction Therapy
Funding Source:	Syros Pharmaceuticals
Role:	PI

Title:	2020-0227 A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer (ACR NK) Cell Therapy, in Subjects with Hematological Malignancies or Dysplasias
Funding Source:	Nkarta Therapeutics
Role:	PI

Title:	2020-1061:TWT-202: Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a single agent or in Combination
Funding Source:	Treadwell Therapeutics, Inc
Role:	PI

Title:	2020-0207 A PHASE 1/2 OPEN-LABEL CLINICAL TRIAL OF TC-110 T CELLS IN ADULTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL) OR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Funding Source:	TCR2 Therapeutics
Role:	PI

Title:	2019-1080 A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Acute Myeloid Leukemia
Funding Source:	Astex Pharmaceuticals, Inc
Role:	PI

Title:	2020-0433 A Phase 1b, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 (LSD-1 Inhibitor) in Combination with Venetoclax and Azacitidine in Treatment-Naïve Subjects with Acute Myeloid Leukemia (AML) who are Not Eligible for Intensive Induction Chemotherapy
Funding Source:	Celgene
Role:	PI

Title:	2019-0263 A Phase 1b Study of SEL120 in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Funding Source:	Ryvu Therapeutics S.A. (formerly Selvita S.A.)
Role:	PI

Title:	PA 18-0102 Study of pre-clinical activity of SEL120 in T-ALL
Funding Source:	Ryvu Therapeutics S. A. (formerly Selvita S. A.)
Role:	PI

Title:	2019-0122 Phase 1B study of PTC299 in relapsed/refractory acute leukemias
Funding Source:	PTC Therapeutics, Inc
Role:	PI

Title:	2018-1019 A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancies
Funding Source:	MedImmune, Inc
Role:	PI

Title:	2018-0905 A Phase 1 Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Funding Source:	Mundipharma Research
Role:	PI

Title:	2018-0634 A Phase I/II study to investigate the safety and clinical activity of GSK3326595 and other agents in subjects with myelodysplastic syndrome and acute myeloid leukemia
Funding Source:	GlaxoSmithKline
Role:	PI

Title:	2018-0319 A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy
Funding Source:	AstraZeneca
Role:	PI

Title:	PA18-0102 Pre-clinical studies with PTC299 and combinations in acute myelogenous leukemia
Funding Source:	PTC Therapeutics, Inc
Role:	PI

Title:	2019-0241 A Phase I Combination Study of CYC065 and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Funding Source:	Cyclacel, Inc
Role:	PI

Title:	2018-0549 A Phase I Pharmacologic Study of CYC140, a Polo-like Kinase 1 Inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes
Funding Source:	Cyclacel, Inc
Role:	PI

Title:	Targeting apical autophagy kinase ULK1 to eliminate stem/progenitor cell (LSC) in acute myelogenous leukemia (AML)
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Title:	Perturbation of autophagy to eliminate Leukemia Stem Cells (LSCs) in Acute Myelogenous Leukemia (AML)
Funding Source:	When Everyone Survives Foundation
Role:	Other Significant Contributor

Title:	Negative regulators of p53 in AML – from oncogenic mechanisms to therapeutic candidates
Funding Source:	Sanford Burnham Prebys
Role:	Co-I

Title:	Targeting T-Acute Lymphoblastic Leukemia Initiating Cell (LIC) and Its Microenvironment with BRD4 and BET Family Proteolysis Targeting Chimera (PROTAC)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Title:	Induction of mitochondrial protein folding stress by the first-in-class imipridone ONC201: Correlative studies in Phase1/2 clinical trial of ONC201
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Targeted Therapy of T-ALL in PI3K and Notch Pathways
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I

Title:	Targeting T-ALL Leukemia Initiating Cell and Its Microenvironment with BET Family Protein Degraders
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Title:	BRD4 Protein Targeting Chimera as Therapeutic Option in T-ALL
Funding Source:	MDACC Institutional Research Grant
Role:	PI

Title:	Concomitant Targeting of Stroma and Leukemia to Overcome Resistance in Acute Myeloid Leukemia Associated with FLT3 Mutations
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Title:	P53 Activation as Treatment Strategy for Acute Myelogenous Leukemia
Funding Source:	Ladies Leukemia League
Role:	PI

Title:	Concomitant Targeting of Stroma and Leukemia to Overcome Resistance in Acute Myeloid Leukemia (AML)
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Title:	The Therapy of AML Core D: Administration and Clinical Trials
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Concomitant Targeting of Leukemia and Stroma to Improve Outcome in FLT3 Internal Tandem Duplication Acute Myelogenous Leukemia
Funding Source:	MDACC Institutional Research Grant
Role:	PI

Title:	Concomitant Targeting of Leukemia and Stroma to Improve Outcome in FLT3 Internal Tandem Duplication Acute Myelogenous Leukemia
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Title:	Concomitant Targeting of Leukemia and Stroma to Improve Outcome in FLT3 Internal Tandem Duplication Acute Myelogenous Leukemia
Funding Source:	MDACC Institutional Research Grant
Role:	PI

Title:	Concomitant Targeting of Leukemia and Stroma to Improve Outcome in FLT3 Internal Tandem Duplication Acute Myelogenous Leukemia
Funding Source:	MDACC R. Lee Clark Fellowship
Role:	PI

Title:	The Therapy of AML Core A: Clinical Trials Core
Funding Source:	NIH/NCI
Role:	Co-I

Title:	Autophagy inhibition as therapeutic strategy for therapy of acute myelogenous leukemia
Funding Source:	MDACC Institutional Research Grant
Role:	PI

Title:	Phase 2 Study of E6201, a dual MEK1 and FLT3 inhibitor in patients with relapsed/refractory acute myelogenous leukemia with RAS and/or FLT3 mutation
Funding Source:	CTNeT
Role:	PI

Title:	Autophagy inhibition as therapeutic strategy for therapy of acute myelogenous leukemia
Funding Source:	Mike Hogg Fund
Role:	PI

Title:	Red blood cell encapsulated L-asparaginase therapy of patients with asparagine synthetase deficient acute myeloid leukemia
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator-MDACC

Title:	Capitalizing on Vulnerabilities in the PI3K/Akt Signaling Pathway in Cancer Project 4: Targeting AKT signaling in acute myelogenous leukemia (AML)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Project Leader

Title:	Biomarkers of response/resistance to Mitogen activated protein kinase inhibitor in acute myelogenous leukemia
Funding Source:	UTHSC-CCTS
Role:	PI

Title:	Regulation of p53 Activation in Adult ALL: Biology and Therapeutic Consequences
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Title:	Phase I/II Trial of ABT263 and AZD6244: Inhibition of BCl-2 and Mitogen Activated Protein Kinase Pathway to Overcome Resistance in Acute Myelogenous Leukemia
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Title:	Synergistic Activation of p53 and Related Pathways as Treatment Strategy
Funding Source:	MDACC Institutional Research Grant
Role:	Postdoctoral Fellow

Title:	P53 Activation as Treatment Strategy for Acute Myelogenous Leukemia
Funding Source:	Leukemia Research Foundation
Role:	PI

Title:	P53 Activation as Treatment Strategy for Acute Myelogenous Leukemia
Funding Source:	Ladies Leukemia League
Role:	PI

Title:	Strategy to Disrupt Stroma Leukemia Interaction for Leukemia Response
Funding Source:	NIH/NCI
Role:	PI

Title:	Mitochondrial Dynamics in Resistant Acute Myelogenous Leukemia Stem/Progenitor Cells and Its Modulation with ERK Inhibition
Funding Source:	MDACC IRG
Role:	PI

Title:	2021-1056: An Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects with Advanced Malignancies
Funding Source:	BioTheryX
Role:	PI

Title:	Evaluate Combinatorial Strategies employing ERK inhibitionin in Vivo and Molecular Mechanisms Arising from Inhibition of ERK
Funding Source:	Astex Pharmaceuticals, Inc
Role:	PI

Title:	2020-1120 A PHASE I/IIA, MULTI-CENTRE, TOLERABILITY, PK AND PRELIMINARY EFFICACY OF CB-103ADVANCED OR METASTATIC SOLID TUMOURS AND HAEMATOLOGICAL MALIGNANCIES CHARACTERISED BY ALTERATIONS OF THE NOTCH SIGNALLING PATHWAY
Funding Source:	Cellestia Biotech AG
Role:	PI

Title:	Defining Single-cell DNA Methylation Landscapes in MDS and tAML
Funding Source:	Institutional Research Grant
Role:	Co-I

Title:	Study of Pre-clinical Activity of IAP Inhibitor in T- Acute Lymphoblastic (T-ALL)
Funding Source:	Astex Pharmaceuticals, Inc
Role:	PI

Title:	Study of Pre-clinical Activity of IAP Inhibitor in T- Acute Lymphoblastic (T-ALL)
Funding Source:	Astex Pharmaceuticals, Inc
Role:	PI

Title:	2019-0511 A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Funding Source:	BioTheryX, Inc
Role:	PI

Title:	Targeting the Osteogenic Niche in the AML Bone Marrow Microenvironment Using ALK 2 Inhibitor TP-0184
Funding Source:	Tolero Pharmaceuticals, Inc
Role:	Co-I

Title:	Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
Funding Source:	Food and Drug Administration (FDA)
Role:	Co-I

Title:	Pre-clinical studies of differentiation induction and apoptosis in acute myelogenous leukemia
Funding Source:	MedImmune, Inc
Role:	PI

Title:	2016-0889 An Open-label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome
Funding Source:	Janssen Scientific Affairs, LLC
Role:	PI

Title:	BRD4 Protein Targeting Chimera (PROTAC) as Therapeutic Option in T Acute Lymphoblastic Leukemia
Funding Source:	MDACC Institutional Research Grant
Role:	PI

Title:	PA16-0956: Study of Expression of IL1RAP in Leukemia Samples
Funding Source:	Cantargia AB
Role:	Co-PI

Title:	2016-0556 A phase 1/2, open-label, dose-escalation/dose-expansion, safety and tolerability study of INCB059872 in subjects with advanced malignancies
Funding Source:	Incyte Corporation
Role:	PI

Title:	2016-1114 An open-label, multicenter Phase I study to characterize the safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose of BAY1251152 in patients with advanced hematological malignancies
Funding Source:	Bayer Healthcare AG
Role:	PI

Title:	2017-0092: A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in combination with Low Dose Cytarabine in Subjects with Newly-diagnosed Acute Myeloid Leukemia
Funding Source:	Bristol-Myers Squibb
Role:	PI

Title:	2016-0401 A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2879552 given orally in subjects with relapsed/refractory acute myeloid leukemia
Funding Source:	GlaxoSmithKline
Role:	PI

Title:	NO TITLE PROVIDED
Funding Source:	NIH/NCI
Role:	Co-PI

Title:	2016-0199: A Phase IB Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Hematologic Malignancies
Funding Source:	Merck, Inc
Role:	PI

Title:	2015-1129: A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)
Funding Source:	Agensys, Inc
Role:	PI

Title:	Anti-leukemic effect of BRD4 Proteolysis Targeting Chimera (PROTAC); ARV-825 and ARV-771 in preclinical model of disseminated acute myelogenous leukemia in mouse
Funding Source:	Arvinas, Inc
Role:	PI

Title:	2015-0665: Phase 1 A/B Study of LY2606368 in Combination with Cytarabine and Fludarabine in Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
Funding Source:	Eli Lilly and Company
Role:	PI

Title:	Concomitant targeting of stroma and leukemia to overcome resistance in acute myeloid leukemia associated with FLT3 mutations
Funding Source:	Children's Leukemia Research Association, Inc
Role:	PI

Title:	2015-0020: A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-cell Lymphoblastic Leukemia (T-ALL) or T-cell Lymphoblastic Lymphoma(T-LBL) Patients
Funding Source:	Eli Lilly and Company
Role:	PI

Title:	2015-0054 Phase 1 Open-label, dose-escalation, safety and tolerability study of INCB054329 in subjects with advanced malignancies
Funding Source:	Incyte Corporation
Role:	Co-PI

Title:	2014-0959: A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects with Advanced Cancer
Funding Source:	AbbVie, Inc
Role:	Co-PI

Title:	2014-0731: Phase I/II Study of Oral ONC201 in Patients with Relapsed or Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes
Funding Source:	Oncoceutics, Inc
Role:	PI

Title:	2021-0285 Phase IA/B Combination Study of ADI-PEG 20, Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Funding Source:	Polaris
Role:	PI

Title:	2014-0777: A Phase 1/2a, Study of E6201 for the Treatment of Advanced Hematologic Malignancies with FLT3 Mutation, Including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Funding Source:	Strategia Therapeutics
Role:	PI

Title:	2014-0399: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk MDS or CML
Funding Source:	TetraLogic Pharmaceuticals
Role:	PI

Title:	2013-0527: A phase I/II open-label,dose escalation study to investigate the safety,PK, PD & clinical activity of GSK525762 in subjects with relapsed,refractory hematologic malignancies
Funding Source:	GlaxoSmithKline
Role:	PI

Title:	2013-0141: A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination with 5-azacitidine in Subjects with MDS who are Refractory or have Relapsed to 5-azacitidine Therapy
Funding Source:	TetraLogic Pharmaceuticals
Role:	PI

Title:	2012-1097: A Phase 1/2, Multicenter, Open-label Study Designed to Evaluate Safety and Efficacy Profile of Repeated Escalating Doses of BL-8040 in Adult Subjects with Relapsed Acute Myeloid Leukemia
Funding Source:	Bioline
Role:	PI

Title:	2009-0570: A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes
Funding Source:	Eisai
Role:	PI

Title:	LS2012-36679: Study of activity of E6201, a dual FLT3 and MEK inhibitor, in acute myelogenous leukemia with FLT or RAS mutation
Funding Source:	Eisai
Role:	PI

Title:	2011-0838: Phase 2 Study of LY2090314 in Patients with Acute Leukemia
Funding Source:	Eli Lilly and Company
Role:	PI

Title:	2011-0319: Eltrombopag for the management of thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia (CML)
Funding Source:	Novartis
Role:	PI

Title:	2010-0805: Phase 1 Open-Label Dose-Escalating Study Evaluating the Safety and Preliminary Efficacy of TXA127 in Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia
Funding Source:	US Biotest
Role:	PI

Title:	2010-0933: 'Phase I Study of CA-18C3 in Subjects with Advanced Hematologic Malignancies
Funding Source:	XBiotech USA
Role:	Principal Investigator-MDACC

Title:	2009-0518: An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
Funding Source:	Aegera
Role:	Principal Investigator-MDACC

Title:	2009-0239: An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias
Funding Source:	Glaxo Smith Kline
Role:	Principal Investigator-MDACC

Title:	2008-0267: Phase II study of MOAD in ALL salvage
Funding Source:	Enzon
Role:	PI

Title:	Leukemia SPORE; Project 3: P53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia
Funding Source:	NIH/NCI
Role:	Co-I

Title:	2008-0288: A Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Funding Source:	MGI
Role:	PI

Title:	P53 activation as treatment strategy for acute myelogenous leukemia
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	PI

Title:	Correlative study portion for CS2007-21914: An Open-label, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity and Maximum Tolerated Dose of OPB-31121 in Subjects with Advanced Leukemias or Myelodysplastic Syndromes
Funding Source:	Otsuka
Role:	PI

Title:	2008-0065: A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previously Untreated Acute Myeloid Leukemia (AML) SG033-0003
Funding Source:	Seattle Genetics
Role:	Principal Investigator-MDACC

Title:	2008-0037: A multicenter, open-label, 2-stage, phase II study of single-agent obatoclax mesylate administered for 3 consecutive days every 2 weeks to older patients with previously untreated acute myeloid leukemia (AML)
Funding Source:	GeminX
Role:	Principal Investigator-MDACC

Title:	Therapy of AML (overall) Project 4:Clinical Trials in AML
Funding Source:	NIH/NCI
Role:	Co-I

Title:	2007-0488 "An Open-label, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity and Maximum Tolerated Dose of OPB-31121 in Subjects with Advanced Leukemias or Myelodysplastic Syndromes"
Funding Source:	Otsuka
Role:	PI

Title:	2006-1089: A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes at First Relapse with Complete Remission Duration < 1 Year
Funding Source:	Sanofi
Role:	PI

Title:	2006-0796: A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide
Funding Source:	Amgen
Role:	PI

Title:	2006-0688: A Multi-Center, Open-Label, Phase II Study of Obatoclax Mesylate (GX15-070MS) in Patients with Previously-Untreated Myelodysplastic Syndromes (MDS) with Anemia and/or Thrombocytopenia
Funding Source:	GeminX
Role:	Principal Investigator-MDACC

Title:	2006-0657: Phase II Study of Lenalidomide and Darbepoetin alfa in Myelodysplastic Syndrome (Low to Intermediate-1 Risk Category)
Funding Source:	Celgene
Role:	PI

Title:	2006-0293: A Phase II Study of Lenalidomide in patients with Higher Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) with 5q deletion Cytogenetic Abnormalities
Funding Source:	Celgene
Role:	PI

Title:	2006-0201: A phase I open-label study of S-trans, trans-farnesylthiosalicylic acid(FTS) administered on days 1 to 21 of a 28 day cycle in patients with advanced hematologic malignancies
Funding Source:	Concordia
Role:	Principal Investigator-MDACC

Title:	2005-0690: Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Hematologic Malignancies
Funding Source:	Children's Hospital Los Angeles
Role:	PI

Title:	New Approaches to the Biology and Treatment of MDS; Project 1: New Therapeutic Strategies in High-risk MDS
Funding Source:	NIH/NCI
Role:	Co-I

Title:	CPRIT IIRACT 2024 (Maiti)/Armored Allogeneic CD70 CAR-γδ T Cell for Acute Myeloid Leukemia with Relapsed/Refractory or Measurable Residual Disease
Funding Source:	NIH/NCI
Role:	OSC

Title:	A Phase 1B/2A trial of combination of ASTX727 with ASTX029 in Acute Myeloid Leukemia
Funding Source:	Aztex Pharmaceuticals
Role:	PI

Title:	Phase 1 Study of N-Myristoylation Inhibitor PCLX-001 for Acute Myeloid Leukemia
Funding Source:	NIH/NCI
Role:	Co-I

Title:	2021-0659 A Phase 1/1B Open-Label, DoseEscalation and Dose-Expansion Study of APVO436 In Patients With Relapsed or Refractory AML Or High-Grade MDS
Funding Source:	Aptevo
Role:	PI

Title:	Unraveling the role of microRNAs in the pathogenesis of T-cell acute lymphoblastic lymphoma/leukemia
Funding Source:	MDACC IRG
Role:	Co-I

Title:	Decision aid to facilitate chemotherapy decision making in older adults with acute myeloid leukemia Character Count
Funding Source:	The University of Nebraska Medical Center
Role:	Collaborator

Title:	Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203
Funding Source:	Food and Drug Administration (FDA)
Role:	Co-I

CV information above last modified January 16, 2025

Gautam Borthakur, M.D.

About Dr. Borthakur

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Gautam Borthakur, M.D.

About Dr. Borthakur

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer